Proprietary  Name,Active Ingredient/Moiety,Applicant,NDA/BLA,Application Number(1),Application Number(2),Application Number(3),Dosage Form(1),Route of Administration(1),Dosage Form(2),Route of Administration(2),Dosage Form(3),Route of Administration(3),FDA Receipt Date,FDA Approval Date,Approval Year,Abbreviated Indication(s),Approved Use(s),Review Designation,Orphan Drug Designation,Accelerated Approval,Breakthrough Therapy Designation,Fast Track Designation,Qualified Infectious Disease Product,Issued a Priority Review Voucher,Redeemed a Priority Review Voucher,Notes,receipt_date,approval_date,review_time_days,log_review_time_days,therapeutic_area,classification_confidence,classification_method,review_type_simplified,therapeutic_area_factor,review_type_factor,regulatory_era_factor,review_time_days_response,log_review_time_days_response
Lupron,leuprolide acetate,TAP Pharmaceuticals,NDA,19010,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1983,4/9/1985,1985,palliative treatment of advanced prostatic cancer,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-28,1985-04-09,468,6.148468295917647,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,468,6.148468295917647
Seldane,terfenadine,Merrell-Dow,NDA,18949,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/1/1983,5/8/1985,1985,"indicated for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-01,1985-05-08,799,6.683360945766275,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,799,6.683360945766275
Ridaura,auranofin,SmithKline & French,NDA,18689,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/5/1981,5/24/1985,1985,"indicated in the management of adults with active, classical, or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-10-05,1985-05-24,1327,7.190676034332207,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1327,7.190676034332207
Marinol,dronabinol,Unimed,NDA,18651,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/25/1981,5/31/1985,1985,treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatment,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-06-25,1985-05-31,1436,7.269616749608169,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,1436,7.269616749608169
Fortaz,ceftazidime,Glaxo,NDA,50578,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/23/1983,7/19/1985,1985,"treatment of patients with following infections caused by susceptible strains of designated organisms: lower respiratory infections including pneumonia, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecological infections, intra-abdominal infections including peritonitis, central nervous system infections including meningitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-05-23,1985-07-19,788,6.669498089857879,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,788,6.669498089857879
Hexabrix,"ioxaglate meglumine, ioxaglate sodium",Mallinckrodt,NDA,18905,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/19/1982,7/26/1985,1985,"indicated for cerebral angiography, peripheral arteriography, selective visceral arteriography and selective coronary arteriography with or without left ventriculography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-11-19,1985-07-26,980,6.887552571664617,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,980,6.887552571664617
Baros Effervescent,"tartaric acid, sodium bicarbonate",Mallinckrodt,NDA,18509,NA,NA,"Granule, Effervescent",Oral,NA,NA,NA,NA,6/9/1980,8/7/1985,1985,indictated for double-contrast radiographic imaging of the upper gastrointestinal tract,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-06-09,1985-08-07,1885,7.541683099882111,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1885,7.541683099882111
Sulcosyn,sulconazole nitrate,Syntex,NDA,18738,NA,NA,Solution,Topical,NA,NA,NA,NA,6/15/1983,8/30/1985,1985,"treatment of tinea cruris tinea corporis caused by Trichophyton mentagrophytes, Epidermophyton floccosum, and Microeporam canis; and for the treatment of tinea versicolor",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-06-15,1985-08-30,807,6.693323668269949,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,807,6.693323668269949
Betoptic,betaxolol hydrochloride,Alcon,NDA,19270,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,5/4/1984,8/30/1985,1985,"indicated in the treatment of patients with chronic open-angle glaucoma, patients with elevated intraocular pressure (ocular hypertensive patients), patients with glaucoma or ocular hypertension who have reactive airway disease, patients with glaucoma or ocular hypertension who are currently on multiple anti-glaucoma therapy",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-04,1985-08-30,483,6.180016653652572,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,483,6.180016653652572
Protropin,somatrem,Genentech,NDA,19107,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/1/1983,10/17/1985,1985,long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-01,1985-10-17,777,6.655440350367647,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,777,6.655440350367647
Moctanin,monooctanoin,Ascot Hospital,NDA,19368,NA,NA,Liquid,"Perfusion, Biliary",NA,NA,NA,NA,9/25/1984,10/29/1985,1985,"indicated as a solubilizing agent for cholesterol (radiolucent) gallstones retained in the biliary tract of patients following cholecystectomy, when other means of reducing cholesterol stones retained in the common bile duct have failed or cannot be undertaken",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-09-25,1985-10-29,399,5.988961416889864,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,399,5.988961416889864
Tambocor,flecainide acetate,Riker,NDA,18830,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/1982,10/31/1985,1985,"treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia; symptomatic nonsustained ventricular tachycardia and frequent premature ventricular complexes",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-21,1985-10-31,1045,6.951772164398911,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1045,6.951772164398911
Cuprid,trientine hydrochloride,Merck Sharp & Dohme,NDA,19194,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/6/1984,11/8/1985,1985,treatment of patients with Wilson's disease who are intolerant of penicillamine,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-06,1985-11-08,672,6.5102583405231496,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,672,6.5102583405231496
Femstat,butoconazole nitrate,Syntex,NDA,19215,NA,NA,Cream,Vaginal,NA,NA,NA,NA,1/23/1984,11/25/1985,1985,indicated for local treatment of vulvovaginal mycotic infections caused by Candida species,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-23,1985-11-25,672,6.5102583405231496,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,672,6.5102583405231496
Primaxin,"cilastatin sodium, imipenem",Merck Sharp & Dohme,NDA,50587,NA,NA,Powder,Intravenous,NA,NA,NA,NA,5/3/1984,11/26/1985,1985,"treatment of patients with the following infections caused by susceptible strains of designated microorganisms in: lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, bacterial septicemia, bone and joint infections, skin and skin structure infections, endocarditis, polymicrobic infections",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-03,1985-11-26,572,6.349138991379798,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,572,6.349138991379798
Betagan,levobunolol hydrochloride,Allergan,NDA,19219,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/19/1984,12/19/1985,1985,has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-19,1985-12-19,700,6.551080335043404,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,700,6.551080335043404
Versed,midazolam hydrochloride,Hoffmann-La Roche,NDA,18654,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1982,12/20/1985,1985,"intramuscularly: for preoperative sedation and to impair memory of peri-operative events;  intravenously: as an agent for conscious sedation prior to short diagnostic or endoscopic procedures either alone or with a narcotic; intravenously: for induction of general anesthesia, before administration of other anesthetic agents",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-15,1985-12-20,1101,7.00397413672268,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1101,7.00397413672268
Suprol,suprofen,Ortho,NDA,18217,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/23/1978,12/24/1985,1985,relief of mild to moderate pain; treatment of primary dysmenorrhea,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1978-10-23,1985-12-24,2619,7.870547844507712,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2619,7.870547844507712
[drug marketed without a proprietary name],indium In 111 oxyquinoline,Amersham,NDA,19044,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/5/1983,12/24/1985,1985,"indicated for radiolabeling autologous leukocytes as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-05,1985-12-24,750,6.620073206530356,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,750,6.620073206530356
Cordarone,amiodarone hydrochloride,Ives,NDA,18972,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/14/1983,12/24/1985,1985,"indicated for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias: recurrent ventricular fibrillation or recurrent hemodynamically unstable ventricular tachycardia, when these have not responded to documented aggregate doses of other available antiarrhythmics or when alternative agents could not be tolerated",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-14,1985-12-24,1016,6.923628628138427,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1016,6.923628628138427
Vasotec,enalapril maleate,Merck Sharp & Dohme,NDA,18998,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/16/1983,12/24/1985,1985,treatment of hypertension,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-16,1985-12-24,830,6.721425700790643,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,830,6.721425700790643
Cesamet,nabilone,Eli Lilly,NDA,18677,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/17/1982,12/26/1985,1985,for use in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-02-17,1985-12-26,1408,7.249925536717988,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Pre-PDUFA,1408,7.249925536717988
Omnipaque,iohexol,Sterling,NDA,18956,NA,NA,Solution,"Injection, Oral, Rectal",NA,NA,NA,NA,3/1/1983,12/26/1985,1985,"indicated for intrathecal administration including angiocardiography, cerebral and peripheral arteriography, digital subtraction angiography, urography, phlebography and lumbar myelography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-01,1985-12-26,1031,6.93828448401696,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1031,6.93828448401696
Temovate,clobetasol propionate,Glaxo,NDA,19322,19323,NA,Cream,Topical,Ointment,Topical,NA,NA,8/30/1984,12/27/1985,1985,short term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-08-30,1985-12-27,484,6.182084906716632,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,484,6.182084906716632
Cefotan,cefotetan disodium,Stuart,NDA,50588,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/20/1984,12/27/1985,1985,"indicated for the treatment of the following infections when caused by susceptible strains of designated organisms: urinary tract infections, lower respiratory infections, skin and skin structure infections; gynecologic infections, intra-abdominal infections, bone and joint infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-20,1985-12-27,707,6.561030665896573,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,707,6.561030665896573
Dormalin,quazepam,Schering,NDA,18708,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/9/1982,12/27/1985,1985,"treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-04-09,1985-12-27,1358,7.213768308118642,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1358,7.213768308118642
Carnitor,L-carnitine,Sigma-Tau,NDA,18948,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/8/1983,12/27/1985,1985,treatment of primary systemic carnitine deficiency,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-02-08,1985-12-27,1053,6.959398512133975,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1053,6.959398512133975
Mexitil,mexiletine hydrochloride,Boehringer Ingelheim Pharmaceuticals,NDA,18873,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/1/1982,12/30/1985,1985,"for the suppression of symptomatic ventricular arrhythmias, including frequent premature ventricular contractions, unifocal or multifocal, couplets and ventricular tachycardia",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-10-01,1985-12-30,1186,7.078341579557671,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1186,7.078341579557671
Wellbutrin,bupropion hydrochloride,Burroughs Wellcome,NDA,18644,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/1981,12/30/1985,1985,"treatment of depression in patients who fail to respond adequately to, or who cannot tolerate, alternative antidepressant treatments",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-12-23,1985-12-30,1468,7.291656209174461,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1468,7.291656209174461
Virazole,ribavirin,Viratek,NDA,18859,NA,NA,For Solution,Inhalation,NA,NA,NA,NA,9/21/1982,12/31/1985,1985,indicated in the treatment of carefully selected hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-09-21,1985-12-31,1197,7.087573705557973,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1197,7.087573705557973
Isovue,iopamidol,Squibb,NDA,18735,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/4/1983,12/31/1985,1985,"indicated for lumbar, thoracic, cervical and total columnar myelography, coronary angiography and ventriculography, peripheral arteriography and ventriculography, peripheral arteriography, cerebral arteriography and CT scanning of the head and body",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-04,1985-12-31,1033,6.940222469119639,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1033,6.940222469119639
Orudis,ketoprofen,Wyeth,NDA,18754,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/16/1982,1/9/1986,1986,treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-03-16,1986-01-09,1395,7.240649694255466,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1395,7.240649694255466
Nix,permethrin,Burroughs Wellcome,NDA,19435,NA,NA,Lotion,Topical,NA,NA,NA,NA,2/28/1985,3/31/1986,1986,single-application treatment of infestation with Pediculus humanus capitis (the head louse) and its nits (eggs),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-28,1986-03-31,396,5.981414211254481,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,396,5.981414211254481
Intron-A,interferon alfa-2b,Schering,BLA,103132,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/1983,6/4/1986,1986,treatment of patients 18 years of age or older with hairy cell leukemia,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-04,1986-06-04,974,6.881411303642535,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,974,6.881411303642535
Roferon-A,interferon alfa-2a,Hoffmann-La Roche,BLA,103145,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/1984,6/4/1986,1986,treatment of patients 18 years of age or older with hairy cell leukemia,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-10-24,1986-06-04,588,6.376726947898627,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,588,6.376726947898627
Orthoclone OKT3,muromonab-CD3,Ortho Pharms,BLA,103135,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/1984,6/19/1986,1986,treatment of acute allograft rejection in renal transplant patients,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103463,1984-03-29,1986-06-19,812,6.699500340161678,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,812,6.699500340161678
Buspar,buspirone hydrochloride,Bristol-Myers,NDA,18731,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/15/1982,9/29/1986,1986,management of anxiety disorders or the short term relief of the symptoms of anxiety,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-15,1986-09-29,1384,7.232733136177615,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1384,7.232733136177615
Tegison,etretinate,Hoffmann-La Roche,NDA,19369,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/19/1984,9/30/1986,1986,"treatment of severe recalcitrant psoriasis, including erythrodermic and generalized pustular types",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-19,1986-09-30,650,6.476972362889683,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,650,6.476972362889683
Pepcid,famotidine,Merck Sharp & Dohme,NDA,19462,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/24/1985,10/15/1986,1986,short term treatment of acute duodenal ulcer; maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer; treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-24,1986-10-15,478,6.169610732491456,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,478,6.169610732491456
Tenex,guanfacine hydrochloride,Robins,NDA,19032,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/14/1983,10/27/1986,1986,indicated in the management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-14,1986-10-27,1139,7.037905963447182,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1139,7.037905963447182
Provocholine,methacholine chloride,Hoffmann-La Roche,NDA,19193,NA,NA,For Solution,Inhalation,NA,NA,NA,NA,12/29/1983,10/31/1986,1986,indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-29,1986-10-31,1037,6.9440872082295275,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1037,6.9440872082295275
Cibacalcin,calcitonin (human),Ciba-Geigy,NDA,18470,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/8/1980,10/31/1986,1986,treatment of symptomatic Paget’s disease of the bone,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-12-08,1986-10-31,2153,7.674617497364363,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,2153,7.674617497364363
Technescan Hida,technetium Tc-99m lidofenin,Merck Sharp & Dohme,NDA,18489,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/6/1980,10/31/1986,1986,indicated as a hepatobiliary imaging agent,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-05-06,1986-10-31,2369,7.7702232041587855,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2369,7.7702232041587855
Noroxin,norfloxacin,Merck Sharp & Dohme,NDA,19384,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/14/1985,10/31/1986,1986,Treatment of adults with complicated and uncomplicated urinary tract infections caused by susceptible strains of microorganisms,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-01-14,1986-10-31,655,6.484635235635252,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,655,6.484635235635252
Lamprene,clofazimine,Ciba-Geigy,NDA,19500,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/1/1985,12/15/1986,1986,"indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-07-01,1986-12-15,532,6.2766434893416445,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,532,6.2766434893416445
Enkaid,encainide hydrochloride,Bristol-Myers,NDA,18981,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/13/1984,12/24/1986,1986,for the treatment of documented life threatening arrhythmias such as sustained ventricular tachycardia; for the treatment of patients with symptomatic nonsustained ventricular tachycardia and frequent premature ventricular complexes,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-13,1986-12-24,1076,6.98100574072173,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1076,6.98100574072173
Atrovent,ipratropium bromide,Boehringer Ingelheim Pharmaceuticals,NDA,19085,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,8/1/1983,12/29/1986,1986,"indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-08-01,1986-12-29,1246,7.1276936993473985,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1246,7.1276936993473985
Alfenta,alfentanil hydrochloride,Janssen,NDA,19353,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/26/1984,12/29/1986,1986,indicated as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbituate/nitrous oxide/oxygen; as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia; as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-26,1986-12-29,733,6.597145701886651,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,733,6.597145701886651
Exirel,pirbuterol acetate,Pfizer,NDA,19009,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,4/21/1983,12/30/1986,1986,"indicated for the relief of acute bronchospasm in patients with chronic reversible obstructive airway disease (extrinsic asthma, intrinsic asthma and chronic bronchitis/emphysema)",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-04-21,1986-12-30,1349,7.207118856207756,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1349,7.207118856207756
Cyklokapron,tranexamic acid,KabiVitrum,NDA,19280,19281,NA,Tablet,Oral,Injectable,Injection,NA,NA,5/9/1984,12/30/1986,1986,indicated in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction,NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-09,1986-12-30,965,6.872128101338986,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,965,6.872128101338986
Brevibloc,esmolol hydrochloride,DuPont,NDA,19386,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/8/1985,12/31/1986,1986,"indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable; also indicated in compensatory sinus tachycardia where, in the physician's judgment the rapid heart rate requires specific intervention",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-01-08,1986-12-31,722,6.582025138892826,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,722,6.582025138892826
Azactam,aztreonam,Squibb,NDA,50580,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1983,12/31/1986,1986,"treatment of the following infections caused by susceptible gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), Lower Respiratory Tract Infections, Septicemia, Skin and Skin Structure Infections, Intra-abdominal Infections, Gynecologic Infections; indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms including abscesses, infections complicating hollow viscous perforations, cutaneous infections and infections of serous surfaces",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-29,1986-12-31,1098,7.001245622069476,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1098,7.001245622069476
Unasyn,"sulbactam sodium, ampicillin sodium",Pfizer,NDA,50608,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/18/1985,12/31/1986,1986,treatment of infections due to susceptible of designated microorganisms for: Lower Respiratory Tract Infections; Skin and Skin Structure Infections; Urinary Tract Infections; Intra-Abdominal Infections; Gynecological Infections,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-18,1986-12-31,622,6.432940092739179,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,622,6.432940092739179
Ocufen,flurbiprofen sodium,Allergan,NDA,19404,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/19/1984,12/31/1986,1986,inhibition of intraoperative miosis,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-19,1986-12-31,742,6.60934924316738,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,742,6.60934924316738
Choletec,technetium Tc-99m mebrofenin,Squibb,NDA,18963,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/4/1983,1/21/1987,1987,indicated as a hepatobiliary imaging agent,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-04,1987-01-21,1419,7.257707677160043,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1419,7.257707677160043
Retrovir,zidovudine,Burroughs Wellcome,NDA,19655,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/2/1986,3/19/1987,1987,for the management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocystis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/inducer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-12-02,1987-03-19,107,4.672828834461906,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,107,4.672828834461906
Elocon,mometasone furoate,Schering,NDA,19543,NA,NA,Ointment,Topical,NA,NA,NA,NA,11/8/1985,4/30/1987,1987,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-11-08,1987-04-30,538,6.2878585601617845,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,538,6.2878585601617845
Hytrin,terazosin hydrochloride,Abbott Laboratories,NDA,19057,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/1983,8/7/1987,1987,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-03,1987-08-07,1404,7.247080584585756,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1404,7.247080584585756
Mevacor,lovastatin,Merck Sharp & Dohme,NDA,19643,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/14/1986,8/31/1987,1987,indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) when the response to diet and other nonpharmacological measures alone has been inadequate,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-11-14,1987-08-31,290,5.66988092298052,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,290,5.66988092298052
Cipro,ciprofloxacin hydrochloride,Miles,NDA,19537,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/25/1986,10/22/1987,1987,"indicated for treatment of infections caused by susceptible strains of designated microorganisms in the conditions listed: lower respiratory, skin and skin structure, bone and joint, and urinary tract infections; infectious diarrhea",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-03-25,1987-10-22,576,6.3561076606958915,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,576,6.3561076606958915
Activase,alteplase,Genentech,BLA,103172,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/1/1986,11/13/1987,1987,"indicated for use in the management of acute myocardial infarction in adults for the lysis of thrombi obstructing coronary arteries, the improvement of ventricular function and reduction of the incidence of congestive heart failure",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-01,1987-11-13,561,6.329720905522696,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,561,6.329720905522696
Novantrone,mitoxantrone hydrochloride,Lederle,NDA,19297,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/24/1984,12/23/1987,1987,"indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults.  This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-24,1987-12-23,1308,7.176254532017144,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Pre-PDUFA,1308,7.176254532017144
Parathar,teriparatide acetate,Rorer,NDA,19498,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/28/1985,12/23/1987,1987,as a diagnostic agent to assist in establishing the diagnosis in patients presenting with evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-28,1987-12-23,908,6.811244378601294,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,908,6.811244378601294
Ucephan,"sodium phenylacetate, sodium benzoate",Kendall McGaw,NDA,19530,NA,NA,Solution,Oral,NA,NA,NA,NA,10/2/1985,12/23/1987,1987,"indicated as adjunctive therapy for the prevention and treatment of hyperammonemia in chronic management of urea cycle enzymopathies involving partial or complete deficiencies of carbamylphosphate synthetase, ornithine transcarbmylase, or argininosuccinate synthetase",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-10-02,1987-12-23,812,6.699500340161678,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,812,6.699500340161678
Rowasa,mesalamine,Reid-Rowell,NDA,19618,NA,NA,Enema,Rectal,NA,NA,NA,NA,6/13/1986,12/24/1987,1987,"treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-06-13,1987-12-24,559,6.326149473155099,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,559,6.326149473155099
Spectamine,iofetamine hydrochloride  I 123,Medi-Physics,NDA,19432,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/12/1985,12/24/1987,1987,evaluation of nonlucunar stroke especially when used within 96 hours of the first onset of neurological deficit,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-12,1987-12-24,1045,6.951772164398911,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1045,6.951772164398911
Prozac,fluoxetine hydrochloride,Eli Lilly,NDA,18936,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/6/1983,12/29/1987,1987,treatment of depression,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-06,1987-12-29,1575,7.362010551259734,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1575,7.362010551259734
Prinivil,lisinopril,Merck Sharp & Dohme,NDA,19558,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/17/1986,12/29/1987,1987,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-04-17,1987-12-29,621,6.431331081933479,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,621,6.431331081933479
Cefmax,cefmenoxime hydrochloride,TAP Pharmaceuticals,NDA,50571,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/28/1983,12/30/1987,1987,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in:  Lower respiratory infections, urinary tract infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-06-28,1987-12-30,1646,7.406103381237015,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1646,7.406103381237015
Levatol,penbutolol sulfate,Eli Lilly,NDA,18976,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1983,12/30/1987,1987,treatment of mild-to-moderate arterial hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-06,1987-12-30,1576,7.362645270417825,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1576,7.362645270417825
Deursil,ursodiol,Gipharmex,NDA,19594,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/24/1986,12/31/1987,1987,"patients with radiolucent, non-calcified, gallbladder stones <20mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease or age",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-24,1987-12-31,675,6.51471269087253,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,675,6.51471269087253
Terazol 7,terconazole,Ortho,NDA,19579,NA,NA,Cream,Vaginal,NA,NA,NA,NA,5/22/1986,12/31/1987,1987,local treatment of vulvovaginal candidiasis (moniliasis),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-22,1987-12-31,588,6.376726947898627,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,588,6.376726947898627
Corotrope,milrinone lactate,Sterling-Winthrop,NDA,19436,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/27/1985,12/31/1987,1987,short-term  intravenous  treatment  of  patients  with  acute  decompensated  heart  failure,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-27,1987-12-31,917,6.821107472256465,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,917,6.821107472256465
Bactroban,mupirocin,Beecham,NDA,50591,NA,NA,Ointment,Topical,NA,NA,NA,NA,3/26/1984,12/31/1987,1987,"indicated for the topical treatment of impetigo due to: Staphylococcus aureus, beta hemolytic Streptococcus, and Streptococcus pyogenes",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-03-26,1987-12-31,1375,7.226209010100671,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1375,7.226209010100671
Iopidine,apraclonidine hydrochloride,Alcon,NDA,19779,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,10/5/1987,12/31/1987,1987,to control or prevent postsurgical elevations in intraocular pressure that occur in patients after argon laser trabeculoplasty or argon laser iridotomy,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-10-05,1987-12-31,87,4.465908118654584,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,87,4.465908118654584
Rimadyl,carprofen,Hoffmann-La Roche,NDA,18550,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/24/1980,12/31/1987,1987,"acute or long-term use for the relief of signs and symptoms of rheumatiod arthritis, osteoarthritis, and acute gouty arthritis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-09-24,1987-12-31,2654,7.883823214892152,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2654,7.8838232148921525
Naftin,naftifine hydrochloride,Herbert Labs,NDA,19599,NA,NA,Cream,Topical,NA,NA,NA,NA,3/18/1986,2/29/1988,1988,indicated for the topical treatment of tinea cruris and tinea corporis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-03-18,1988-02-29,713,6.569481420414296,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,713,6.569481420414296
Axid,nizatidine,Eli Lilly,NDA,19508,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/15/1986,4/12/1988,1988,treatment of active duodenal ulcers for up to six weeks; maintenance therapy of duodenal ulcer patients at a reduced dosage after healing of an active duodenal ulcer,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-15,1988-04-12,698,6.548219102762372,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,698,6.548219102762372
Magnevist,gadopentetate dimeglumine,Berlex,NDA,19596,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/19/1986,6/2/1988,1988,"using magnetic resonance imaging in adult patients, gadopentetate dimeglumine provides contrast enhancement in those intracranial lesions with abnormal vascularity or those thought to cause an abnormal blood brain barrier",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-08-19,1988-06-02,653,6.481577129276431,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,653,6.481577129276431
Voltaren,diclofenac sodium,Ciba,NDA,19201,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,12/20/1983,7/28/1988,1988,"acute and chronic treatment of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-20,1988-07-28,1682,7.427738840532894,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1682,7.427738840532894
Thiola,tiopronin,Mission Pharmacal,NDA,19569,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/8/1986,8/11/1988,1988,"prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-01-08,1988-08-11,946,6.852242569051878,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,946,6.852242569051878
Photoplex,"avobenzone, padimate-O",Herbert Labs,NDA,19459,NA,NA,Lotion,Topical,NA,NA,NA,NA,4/8/1985,9/30/1988,1988,protection from the acute and long-term risks associated with UVA and UVB light exposure,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-08,1988-09-30,1271,7.147559271189454,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1271,7.147559271189454
Sandostatin,octreotide acetate,Sandoz,NDA,19667,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/9/1987,10/21/1988,1988,treatment of chronic and severe diarrhea and flushing episodes associated with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-02-09,1988-10-21,620,6.429719478039138,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,620,6.429719478039138
Cardene,nicardipine hydrochloride,Syntex,NDA,19488,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/20/1985,12/21/1988,1988,management of patients with chronic stable angina (effort-associated angina); management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-11-20,1988-12-21,1127,7.027314514039777,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1127,7.027314514039777
Ethamolin,ethanolamine oleate,Glaxo,NDA,19357,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/14/1984,12/22/1988,1988,"treatment of patients with esophageal varices that have recently bled, to prevent rebleeding",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-09-14,1988-12-22,1560,7.352441100243583,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1560,7.352441100243583
Cytotec,misoprostol,Searle,NDA,19268,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/23/1984,12/27/1988,1988,"prevention of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)- induced gastric ulcers in patients at high risk of complications from a gastric ulcer, e.g., the elderly and patients with concomitant disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-23,1988-12-27,1679,7.425953657077541,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1679,7.425953657077541
Nimotop,nimodipine,Miles,NDA,18869,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/17/1982,12/28/1988,1988,for the improvement of neurological deficits due to spasm following subarachnoid hemorrhage from ruptured congenital intracranial aneurysms in patients who are in good neurological condition post-ictus (e.g. Hunt and Hess Grades I-III),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-09-17,1988-12-28,2294,7.738052297689316,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,2294,7.738052297689316
Cartrol,carteolol hydrochloride,Abbott Laboratories,NDA,19204,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/1984,12/28/1988,1988,management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-10-03,1988-12-28,1547,7.344072850573066,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1547,7.344072850573066
Hismanal,astemizole,Janssen,NDA,19402,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/25/1985,12/29/1988,1988,relief of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-25,1988-12-29,1403,7.246368080102461,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1403,7.246368080102461
Oxistat,oxiconazole nitrate,Glaxo,NDA,19828,NA,NA,Cream,Topical,NA,NA,NA,NA,2/11/1988,12/30/1988,1988,"treatment of tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-02-11,1988-12-30,323,5.777652323222656,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,323,5.777652323222656
Optiray,ioversol,Mallinckrodt,NDA,19710,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/26/1987,12/30/1988,1988,"Optiray-320 for angiography throughout the cardiovascular system including cerebral, coronary, peripheral, visceral and renal arteriography, aortography, and left ventriculography; contrast enhanced CT imaging of the head and body, and I.V. excretory urography. Optiray-240  indicated  for cerebral angiography and venography. Optiray-160 intra-arterial digital subtraction angiography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-06-26,1988-12-30,553,6.315358001522335,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,553,6.315358001522335
Ifex,ifosfamide,Bristol-Myers,NDA,19763,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/10/1987,12/30/1988,1988,"used in combination with certain other approved antineoplastic agents is indicated for third-line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-10,1988-12-30,386,5.955837369464831,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,386,5.955837369464831
Ceretec,technetium Tc-99m exametazime,Amersham,NDA,19829,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/15/1988,12/30/1988,1988,use as an adjunct in the detection of altered regional cerebral perfusion in strokes,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-03-15,1988-12-30,290,5.66988092298052,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,290,5.66988092298052
Mesnex,mesna,Asta,NDA,19884,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,7/6/1988,12/30/1988,1988,prophylactic agent for reducing the incidence of ifosamide-induced hemorrhagic cystitis,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-06,1988-12-30,177,5.176149732573829,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,177,5.176149732573829
Ceradon,cefotiam hydrochloride,Takeda,NDA,50601,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/1985,12/30/1988,1988,"treatment of infections caused by susceptible strains of the designated microorganisms: lower respiratory tract infections, bronchitis, and pneumonia",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-30,1988-12-30,1340,7.200424892944957,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1340,7.200424892944957
Permax,pergolide mesylate,Eli Lilly,NDA,19385,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/13/1985,12/30/1988,1988,as adjunctive treatment to levodopa in the management of the signs and symptoms of Parkinson’s disease,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-09-13,1988-12-30,1204,7.093404625868766,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1204,7.093404625868766
Eulexin,flutamide,Schering,NDA,18554,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/30/1980,1/27/1989,1989,in combination with LHRH agonistic analogs (such as leuprolide acetate) for the treatment of metastatic prostatic carcinoma,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-09-30,1989-01-27,3041,8.019941687677365,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,3041,8.019941687677365
Cefpiramide,cefpiramide sodium,Wyeth-Ayerst,NDA,50633,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/31/1987,1/31/1989,1989,"indicated for the treatment of the following infections when caused by susceptible strains of designated organisms:  lower respiratory infections including pneumonia, skin and skin structure infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-07-31,1989-01-31,550,6.309918278226516,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,550,6.309918278226516
Paraplatin,carboplatin,Bristol-Myers,NDA,19880,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1988,3/3/1989,1989,"palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-06-30,1989-03-03,246,5.5053315359323625,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,246,5.5053315359323625
Suprax,cefixime,Lederle,NDA,50621,50622,NA,Tablet,Oral,Suspension,Oral,NA,NA,6/27/1986,4/28/1989,1989,"indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Uncomplicated Urinary Tract Infections, Otitis Media, Pharyngitis and tonsillitis, Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-06-27,1989-04-28,1036,6.943122422819428,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1036,6.943122422819428
Lariam,mefloquine hydrochloride,Department of the Army,NDA,19578,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/5/1986,5/2/1989,1989,"treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax; also indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum.",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-05,1989-05-02,1182,7.074963197966044,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1182,7.074963197966044
Epogen,epoetin alfa,Amgen,BLA,103234,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/3/1987,6/1/1989,1989,"treatment of anemia associated with chronic renal failure, including patients on dialysis (end-stage renal disease) and patients not on dialysis",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-11-03,1989-06-01,576,6.3561076606958915,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,576,6.3561076606958915
Eldepryl,selegiline hydrochloride,Somerset,NDA,19334,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/23/1984,6/5/1989,1989,indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-07-23,1989-06-05,1778,7.48324441607385,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1778,7.48324441607385
Cytovene,ganciclovir sodium,Syntex,NDA,19661,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1986,6/23/1989,1989,"treatment of CMV retinitis in immunocompromised 
patients, including patients with acquired immunodeficiency syndrome (AIDS)",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-12-29,1989-06-23,907,6.810142450115136,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,907,6.810142450115136
Losec,omeprazole,Merck Sharp & Dohme,NDA,19810,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,7/1/1988,9/14/1989,1989,"short-term treatment (four to eight weeks) of severe erosive esophagitis; short-term treatment of symptomatic gastroesophageal reflux disease (GERD) poorly responsive to customary medical treatment, usually including an adequate course of a histamine H2 receptor antagonist;  long-term treatment of Zollinger-Ellison syndrome",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-01,1989-09-14,440,6.0867747269123065,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,440,6.0867747269123065
Clozaril,clozapine,Sandoz,NDA,19758,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/1/1987,9/26/1989,1989,treatment of severely ill schizophrenic patients who fail to respond to standard drug therapies,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1989-09-26,756,6.628041376179533,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,756,6.628041376179533
Diprivan,propofol,ICI,NDA,19627,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/1/1986,10/2/1989,1989,induction and maintenance of anesthesia,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-08-01,1989-10-02,1158,7.05444965813294,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1158,7.05444965813294
Alferon N,interferon alfa-n3,Interferon Sciences,BLA,103158,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1985,10/10/1989,1989,treatment of condyloma acuminata (genital warts),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-12-16,1989-10-10,1394,7.239932591320469,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1394,7.2399325913204695
Adenocard,adenosine,Medco,NDA,19937,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1988,10/30/1989,1989,"indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-28,1989-10-30,306,5.723585101952381,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,306,5.723585101952381
Eminase,anistreplase,Beecham,BLA,103273,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/8/1988,11/27/1989,1989,"indicated for use in the management of acute myocardial infarction (AMI) in adults, for the lysis of thrombi obstructing coronary arteries, the reduction of infarct size, the improvement of ventricular function following AMI, and the reduction of mortality associated with AMI",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103674,1988-06-08,1989-11-27,537,6.285998094508865,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,537,6.285998094508865
Rythmol,propafenone hydrochloride,Knoll,NDA,19151,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/26/1983,11/27/1989,1989,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician, are life-threatening",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-26,1989-11-27,2224,7.707062655370473,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2224,7.707062655370473
Toradol,ketorolac tromethamine,Syntex,NDA,19698,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/22/1987,11/30/1989,1989,indicated for the short-term management of pain,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-06-22,1989-11-30,892,6.79346613258001,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,892,6.79346613258001
Osmovist,iotrolan,Berlex,NDA,19580,NA,NA,Injectable,Intrathecal,NA,NA,NA,NA,2/10/1986,12/7/1989,1989,"indicated for lumbar, thoracic, cervical, and total columnar myelography, and computerized tomography (CT) of spinal and subarachnoid spaces, in adults",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-10,1989-12-07,1396,7.241366283322318,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1396,7.241366283322318
Oculinum,botulinum toxin type A,Allergan,BLA,103000,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/1985,12/9/1989,1989,"for the treatment of strabismus  in patients 12 years of age and above;
blepharospasm associated with dystonia, including benign essential blepharospasm or [seventh] nerve disorders in patients 12 years of age and above",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-03-28,1989-12-09,1717,7.448333860897476,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1717,7.448333860897476
Zefazone,cefmetazole sodium,Upjohn,NDA,50637,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1987,12/11/1989,1989,"treatment of serious infections caused by susceptible strains of the designated microorganisms in the following diseases: Urinary Tract Infections; Lower Respiratory Tract Infections; Skin and Skin Structure Infections; Intraabdominal Infections; reduce the incidence of certain postoperative infections in patients who undergo caesarean section, abdominal or vaginal hysterectomy, cholecystectomy (high risk patients), and colorectal surgery",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-31,1989-12-11,711,6.566672429803241,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,711,6.566672429803241
Pindac,pinacidil,Eli Lilly,NDA,19456,NA,NA,"Capsule, Extended Release",Oral,NA,NA,NA,NA,7/31/1985,12/28/1989,1989,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-07-31,1989-12-28,1611,7.384610383176974,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1611,7.384610383176974
Anafranil,clomipramine hydrochloride,Ciba-Geigy,NDA,19906,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/16/1989,12/29/1989,1989,"treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM III-R (circa 1989) diagnosis of OCD",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-06-16,1989-12-29,196,5.278114659230517,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,196,5.278114659230517
Zoladex,goserelin acetate,ICI,NDA,19726,NA,NA,Implant,Implantation,NA,NA,NA,NA,8/14/1987,12/29/1989,1989,palliative treatment of advanced carcinoma of the prostate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-08-14,1989-12-29,868,6.7661917146603505,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Pre-PDUFA,868,6.7661917146603505
Dalgan,dezocine,Wyeth-Ayerst,NDA,19082,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/1983,12/29/1989,1989,indicated for the management of pain when the use of an opioid analgesic is appropriate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-07-29,1989-12-29,2345,7.76004068088038,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2345,7.76004068088038
Cardiogen-82,rubidium Rb 82 chloride,Bristol-Myers Squibb,NDA,19414,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1984,12/29/1989,1989,indicated for assessing regional myocardial perfusion in the diagnosis and localization of myocardial infarction,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-28,1989-12-29,1827,7.510430556378006,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1827,7.510430556378006
Betamet,metipranolol hydrochloride,Bausch & Lomb,NDA,19907,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,10/21/1988,12/29/1989,1989,has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or intraocular hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-10-21,1989-12-29,434,6.073044534100405,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,434,6.073044534100405
Ortho Cyclen,"norgestimate, ethinyl estradiol",RW Johnson,NDA,19653,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/24/1987,12/29/1989,1989,prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-03-24,1989-12-29,1011,6.918695219020472,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1011,6.918695219020472
Decabid,indecainide hydrochloride,Eli Lilly,NDA,19693,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,1/5/1988,12/29/1989,1989,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician, are life-threatening",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-01-05,1989-12-29,724,6.584791392385716,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,724,6.584791392385716
Diflucan,fluconazole,Pfizer,NDA,19949,19950,NA,Tablet,Oral,Injectable,Injection,NA,NA,3/2/1989,1/29/1990,1990,"treatment of oropharyngeal and esophageal candidiasis; serious systemic candidal infections, including urinary tract infection, peritonitis, and pneumonia; also indicated for treatment of cryptococcal meningitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-02,1990-01-29,333,5.808142489980444,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,333,5.808142489980444
Synarel,nafarelin acetate,Syntex,NDA,19886,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,11/16/1988,2/13/1990,1990,"management of endometriosis, including pain relief and reduction of endometriotic lesions",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-16,1990-02-13,454,6.118097198041348,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,454,6.118097198041348
Adagen,pegademase bovine,Enzon,BLA,19818,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/13/1988,3/21/1990,1990,indicated for enzyme replacement therapy for adenosine deaminase (ADA) deficiency  in  patients  with  severe  combined  immunodeficiency  disease  (SCID)  who  are  not  suitable  candidates  for  –  or  who  have  failed  –  bone  marrow  transplantation,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1988-01-13,1990-03-21,798,6.682108597449809,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,798,6.682108597449809
TechneScan MAG3,technetium Tc-99m mertiatide,Mallinckrodt,NDA,19882,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/18/1988,6/15/1990,1990,"indicated as a renal imaging agent for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-10-18,1990-06-15,605,6.405228458030842,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,605,6.405228458030842
Ergamisol,levamisole hydrochloride,Janssen,NDA,20035,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/1/1989,6/18/1990,1990,indicated as adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' stage C colon cancer,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-01,1990-06-18,229,5.43372200355424,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,229,5.43372200355424
Ethmozine,moricizine hydrochloride,DuPont,NDA,19753,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/1/1987,6/19/1990,1990,"indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1990-06-19,1022,6.92951677076365,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1022,6.92951677076365
Arduan,pipecuronium bromide,Organon,NDA,19638,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1987,6/26/1990,1990,"indicated as an adjunct to general anesthesia, to provide skeletal muscle relaxation during surgery; can also be used to provide skeletal muscle relaxation for endotracheal intubation",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-29,1990-06-26,910,6.813444599510896,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,910,6.813444599510896
Dipentum,olsalazine sodium,Pharmacia,NDA,19715,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/1/1987,7/31/1990,1990,indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1990-07-31,1064,6.96979066990159,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1064,6.96979066990159
Exosurf,"colfosceril palmitate, cetyl alcohol, tyloxapol",Burroughs Wellcome,NDA,20044,NA,NA,For Suspension,Intratracheal,NA,NA,NA,NA,2/16/1990,8/2/1990,1990,"indicated for prophylactic treatment of infants with birth weight less than 1350 grams who are at risk of developing RDS, prophylactic treatment of infants with birth weight greater than 1350 grams who have evidence of pulmonary immaturity, and rescue treatment of infants who have developed RDS",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-02-16,1990-08-02,167,5.117993812416755,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,167,5.117993812416755
Idamycin,idarubicin hydrochloride,Adria,NDA,50661,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/1989,9/27/1990,1990,in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-08-31,1990-09-27,392,5.971261839790462,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,392,5.971261839790462
Cardura,doxazosin mesylate,Pfizer,NDA,19668,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/11/1987,11/2/1990,1990,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-03-11,1990-11-02,1332,7.194436851100335,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1332,7.194436851100335
Ornidyl,eflornithine hydrochloride,Marion Merrell Dow,NDA,19879,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/2/1988,11/28/1990,1990,treatment of meningoencephalitic stage of Trypanosoma brucei gambiense infection (sleeping sickness),NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-08-02,1990-11-28,848,6.742880635791903,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,848,6.742880635791903
Cutivate,fluticasone propionate,Glaxo,NDA,19957,NA,NA,Ointment,Topical,NA,NA,NA,NA,10/26/1989,12/14/1990,1990,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-10-26,1990-12-14,414,6.025865973825314,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,414,6.025865973825314
Ultravate,halobetasol propionate,Bristol-Myers Squibb,NDA,19968,NA,NA,Ointment,Topical,NA,NA,NA,NA,4/3/1989,12/17/1990,1990,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-04-03,1990-12-17,623,6.434546518787453,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,623,6.434546518787453
Cardiotec,technetium Tc-99m teboroxime,Squibb,NDA,19928,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1988,12/19/1990,1990,"indicated as a myocardial perfusion agent that is useful in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease, using rest and stress techniques",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-23,1990-12-19,726,6.587550014824796,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,726,6.587550014824796
Dynacirc,isradipine,Sandoz,NDA,19546,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/25/1986,12/20/1990,1990,indicated for the management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-04-25,1990-12-20,1700,7.438383530044307,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1700,7.438383530044307
Actimmune,interferon gamma-1b,Genentech,BLA,103348,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1989,12/20/1990,1990,treatment of chronic granulomatous disease,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103836,1989-12-22,1990-12-20,363,5.8944028342648505,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,363,5.8944028342648505
Cardiolite,technetium Tc-99m sestamibi,DuPont,NDA,19785,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/1988,12/21/1990,1990,"indicated as a myocardial perfusion agent that is useful in distinguishing normal from abnormal myocardium, and in the localization of the abnormality, in patients with suspected myocardial infarction",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-12,1990-12-21,739,6.6052979209482015,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,739,6.6052979209482015
Hexalen,altretamine,US Bioscience,NDA,19926,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/19/1988,12/26/1990,1990,palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent based combination,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-19,1990-12-26,737,6.602587892189336,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,737,6.602587892189336
ProSom,estazolam,Abbott Laboratories,NDA,19080,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/1983,12/26/1990,1990,short term treatment of insomnia,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-19,1990-12-26,2564,7.849323818040561,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2564,7.849323818040561
Geref,sermorelin acetate,Serono,NDA,19863,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/5/1988,12/28/1990,1990,for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone (GH),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-05-05,1990-12-28,967,6.874198495453294,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,967,6.874198495453294
Vascor,bepridil hydrochloride,McNeil Laboratories,NDA,19002,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/28/1983,12/28/1990,1990,treatment of chronic stable angina (classic effort-associated angina) in patients failing to respond adequately to other therapy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-28,1990-12-28,2557,7.846589975291186,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,2557,7.846589975291186
Floxin,ofloxacin,RW Johnson,NDA,19735,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/1987,12/28/1990,1990,"treatment for the following infections caused by susceptible strains of designated microorganisms; lower respiratory tract infections (acute bacterial exacerbations of chronic bronchitis and pneumonia); sexually transmitted diseases (acute, uncomplicated urethral and cervical gonorrhea, nongonococcal urethritis and cervicitis, and mixed infections of the urethra and cervix); skin and skin structure infections (mild to moderate skin and skin structure infections); urinary tract infections (uncomplicated cystitis, and complicated urinary tract infections); and prostatitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-22,1990-12-28,1102,7.004881989712859,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1102,7.004881989712859
Rev-Eyes,dapiprazole hydrochloride,Angelini,NDA,19849,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,5/27/1988,12/31/1990,1990,treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasmypatholytic (tropicamide) agents,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-05-27,1990-12-31,948,6.854354502255021,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,948,6.854354502255021
Zofran,ondansetron hydrochloride,Glaxo,NDA,20007,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/12/1989,1/4/1991,1991,prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy including high-dose cisplatin,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-10-12,1991-01-04,449,6.1070228877422545,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,449,6.1070228877422545
Ganite,gallium nitrate,Fujisawa,NDA,19961,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/1989,1/17/1991,1991,for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-20,1991-01-17,668,6.504288173536645,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,668,6.504288173536645
Altace,ramipril,Hoechst-Roussel,NDA,19901,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/7/1988,1/28/1991,1991,for the treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-07,1991-01-28,812,6.699500340161678,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,812,6.699500340161678
Chemet,succimer,McNeil,NDA,19998,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/22/1989,1/30/1991,1991,treatment of lead poisoning in children with blood lead levels above 45 mug/dL,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-08-22,1991-01-30,526,6.26530121273771,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,526,6.26530121273771
Lodine,etodolac,Wyeth-Ayerst,NDA,18922,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/30/1982,1/31/1991,1991,indicated for the treatment of osteoarthritis; management of pain,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-30,1991-01-31,2954,7.990915463091325,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2954,7.9909154630913255
Neupogen,filgrastim,Amgen,BLA,103353,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/5/1990,2/20/1991,1991,"to decrease the incidence of infection, as manifested in febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-01-05,1991-02-20,411,6.018593214496234,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,411,6.018593214496234
Leukine,sargramostim,Immunex,BLA,103362,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/24/1990,3/5/1991,1991,approved for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and reduce the incidence of severe and life-threatening infections and infections resulting in death,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-02-24,1991-03-05,374,5.924255797414532,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,374,5.924255797414532
Nuromax,doxacurium chloride,Burroughs Wellcome,NDA,19946,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/21/1989,3/7/1991,1991,"indicated as an adjunct to general anesthesia, to provide skeletal muscle relaxation during surgery; also be used to provide skeletal muscle relaxation for endotracheal intubation",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-21,1991-03-07,716,6.573680166960646,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,716,6.573680166960646
Ceredase,alglucerase,Genzyme,NDA,20057,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/24/1990,4/5/1991,1991,"indicated for use as long-term enzyme replacement therapy for patients with a confirmed diagnosis of Type 1 Gaucher disease who exhibit signs and symptoms that are severe enough to result in one of the following conditions:  moderate to severe anemia, thrombocytopenia with bleeding tendency, bone disease, significant hepatomegaly or splenomegaly",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-04-24,1991-04-05,346,5.846438775057725,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,346,5.846438775057725
Fludara,fludarabine phosphate,Berlex,NDA,20038,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/1989,4/18/1991,1991,treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to other treatments or whose disease has progressed during treatment with at least one standard alkylating agent-containing regimen,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-24,1991-04-18,510,6.234410725718371,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,510,6.234410725718371
Monopril,fosinopril sodium,Bristol-Myers Squibb,NDA,19915,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/1988,5/16/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-15,1991-05-16,912,6.815639990074331,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,912,6.815639990074331
Lotensin,benazepril hydrochloride,Ciba,NDA,19851,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/6/1988,6/25/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-06,1991-06-25,1084,6.988413181999592,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1084,6.988413181999592
Survanta,beractant,Ross,BLA,20032,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,1/2/1990,7/1/1991,1991,"prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency; treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1990-01-02,1991-07-01,545,6.300785794663244,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,545,6.300785794663244
Plendil,felodipine,Merck Sharp & Dohme,NDA,19834,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,2/26/1988,7/25/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-02-26,1991-07-25,1245,7.126890808898808,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1245,7.126890808898808
Foscavir,foscarnet sodium,Astra,NDA,20068,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/20/1990,9/27/1991,1991,treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-09-20,1991-09-27,372,5.918893854273146,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,372,5.918893854273146
Videx,didanosine,Bristol-Myers Squibb,NDA,20154,20155,20156,"Tablet, Chewable",Oral,Solution,Oral,Solution,Oral,4/2/1991,10/9/1991,1991,adult and pediatric patients over six months of age with advanced HIV infection who are intolerant of zidovudine [AZT] therapy or who have demonstrated significant clinical or immunologic deterioration during zidovudine therapy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1991-04-02,1991-10-09,190,5.247024072160486,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,190,5.247024072160486
Nipent,pentostatin,Parke-Davis,NDA,20122,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/11/1991,10/11/1991,1991,treatment for adult patients with alpha-interferon-refractory hairy cell leukemia,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1991-02-11,1991-10-11,242,5.488937726156687,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,242,5.488937726156687
Aredia,pamidronate disodium,Ciba-Geigy,NDA,20036,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/21/1989,10/31/1991,1991,treatment of hypercalcemia associate with malignancy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-12-21,1991-10-31,679,6.520621127558696,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,679,6.520621127558696
Pravachol,pravastatin sodium,Bristol-Myers Squibb,NDA,19898,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/1989,10/31/1991,1991,as an adjunct to diet for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolemia (Type IIa and IIb) when the response to a diet restricted in saturated fat and cholesterol has not been adequate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-01-31,1991-10-31,1003,6.910750787961936,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1003,6.910750787961936
Ticlid,ticlopidine hydrochloride,Syntex,NDA,19979,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/1989,10/31/1991,1991,"indicated to reduce the risk of thrombotic stroke (fatal 
or nonfatal) in patients who have experienced stroke precursors,
and in patients who have had a completed thrombotic stroke",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-15,1991-10-31,715,6.5722825426940075,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,715,6.5722825426940075
Biaxin,clarithromycin,Abbott Laboratories,NDA,50662,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/1989,10/31/1991,1991,indicated for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below:  pharyngitis/tonsillitis; sinusitis; acute bacterial exacerbations of chronic bronchitis; pneumonia; uncomplicated skin and skin structure infections,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-12-20,1991-10-31,680,6.522092798170152,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,680,6.522092798170152
Zithromax,azithromycin,Pfizer,NDA,50670,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/11/1990,11/1/1991,1991,"indicated for the treatment of individuals 16 years of age and older with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below: acute bacterial exacerbations of chronic obstructive pulmonary disease; pneumonia; streptococcal pharyngitis/tonsillitis, as an alternative to first line therapy in individuals who cannot use first line therapy; uncomplicated skin and skin structure infections; non-gonococal urethritis and cervicitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-04-11,1991-11-01,569,6.343880434126331,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,569,6.343880434126331
Accupril,quinapril hydrochloride,Parke-Davis,NDA,19885,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/26/1989,11/19/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-01-26,1991-11-19,1027,6.934397209928558,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1027,6.934397209928558
Romazicon,flumazenil,Roche,NDA,20073,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/10/1990,12/20/1991,1991,"the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-12-10,1991-12-20,375,5.926926025970411,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,375,5.926926025970411
Zocor,simvastatin,Merck Sharp & Dohme,NDA,19766,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/16/1987,12/23/1991,1991,as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacological measures alone has not been adequate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-10-16,1991-12-23,1529,7.332369205929062,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1529,7.332369205929062
Cefzil,cefprozil,Bristol-Myers Squibb,NDA,50664,50665,NA,Tablet,Oral,Suspension,Oral,NA,NA,3/30/1990,12/23/1991,1991,indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below: pharyngitis/tonsillitis; otitis media; secondary bacterial infection of acute bronchitis and acute bacterial exacerbations of chronic bronchitis; uncomplicated skin and skin structure infections,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-03-30,1991-12-23,633,6.450470422144176,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,633,6.450470422144176
Supprelin,histrelin acetate,Johnson & Johnson,NDA,19836,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/1989,12/24/1991,1991,treatment of central precocious puberty,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-05-22,1991-12-24,946,6.852242569051878,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,946,6.852242569051878
Relafen,nabumetone,SmithKline Beecham,NDA,19583,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/10/1986,12/24/1991,1991,acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-10,1991-12-24,2143,7.669961995473577,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2143,7.669961995473577
Ismo,isosorbide mononitrate,Wyeth,NDA,19091,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1983,12/30/1991,1991,prevention and control of stable angina pectoris due to coronary artery disease,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-30,1991-12-30,2922,7.980023592310645,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2922,7.980023592310645
Zoloft,sertraline hydrochloride,Pfizer,NDA,19839,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/13/1988,12/30/1991,1991,treatment of depression,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-04-13,1991-12-30,1356,7.212294468500341,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1356,7.212294468500341
Lorabid,loracarbef,Eli Lilly,NDA,50667,50668,NA,For Suspension,Oral,Capsule,Oral,NA,NA,8/27/1990,12/31/1991,1991,indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed: Secondary Bacterial Infection of Acute Bronchitis; Acute Bacterial Exacerbations of Chronic Bronchitis; Pneumonia; Acute Otitis Media; Acute Maxillary Sinusitis; Pharyngitis and Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Uncomplicated Urinary Tract Infections; Uncomplicated Pyelonephritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-08-27,1991-12-31,491,6.19644412779452,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,491,6.19644412779452
Penetrex,enoxacin,Warner-Lambert,NDA,19616,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/24/1986,12/31/1991,1991,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the infections listed: urinary tract infections (uncomplicated and complicated), uncomplicated urethritis or endocervicitis due to susceptible strains of Neisseria gonorrhoea, including non-penicillinase- and penicillinase-producing strains",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-10-24,1991-12-31,1894,7.546446273746024,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1894,7.546446273746024
Mivacron,mivacurium chloride,Burroughs Wellcome,NDA,20098,NA,NA,Solution,Intravenous,NA,NA,NA,NA,8/30/1990,1/22/1992,1992,"for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-08-30,1992-01-22,510,6.234410725718371,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,510,6.234410725718371
Omniflox,temafloxacin hydrochloride,Abbott Laboratories,NDA,20043,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/30/1989,1/30/1992,1992,"treatment of adults with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed: Lower Respiratory Tract Infections (acute bacterial exacerbation of chronic bronchitis and pneumonia), uncomplicated skin and skin structure infections, prostatitis, uncomplicated and complicated urinary tract infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-30,1992-01-30,791,6.673297967767654,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,791,6.673297967767654
Maxaquin,lomefloxacin hydrochloride,Searle,NDA,20013,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/31/1990,2/21/1992,1992,indicated  for  the  treatment  of  adults  with  mild  to moderate  infections  caused  by  susceptible  strains  of  the  designated  microorganisms  in  the  conditions listed: complicated and uncomplicated urinary tract infections; acute bacterial exacerbations of chronic bronchitis; indicated pre-operatively to reduce the incidence of urinary tract infections in the early postoperative period in patients undergoing transurethral surgical procedures,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-07-31,1992-02-21,570,6.345636360828596,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,570,6.345636360828596
Proleukin,aldesleukin,Chiron,BLA,103293,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/1/1988,5/5/1992,1992,treatment of adults (>18 years old) with metastatic renal cell carcinoma,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1988-12-01,1992-05-05,1251,7.1316985104669115,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Pre-PDUFA,1251,7.1316985104669115
Proscar,finasteride,Merck Sharp & Dohme,NDA,20180,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/15/1991,6/19/1992,1992,treatment of symptomatic benign prostatic hyperplasia,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-15,1992-06-19,431,6.066108090103747,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,431,6.066108090103747
Hivid,zalcitabine,Roche,NDA,20199,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1991,6/19/1992,1992,indicated for the treatment of adult patients with advanced HIV infection who have demonstrated significant clinical or immunological deterioration,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1991-10-31,1992-06-19,232,5.44673737166631,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,232,5.44673737166631
Vumon,teniposide,Bristol-Myers Squibb,NDA,20119,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/28/1990,7/14/1992,1992,indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1990-09-28,1992-07-14,655,6.484635235635252,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,655,6.484635235635252
Halfan,halofantrine hydrochloride,SmithKline Beecham,NDA,20250,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/7/1992,7/24/1992,1992,treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-07,1992-07-24,199,5.293304824724492,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,199,5.293304824724492
Norvasc,amlodipine besylate,Pfizer,NDA,19787,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/1987,7/31/1992,1992,"treatment of hypertension, alone or in combination with other antihypertensive agents, treatment of chronic stable angina alone or in combination with other antianginal agents, treatment of confirmed or suspected vasospastic angina, as monotherapy or in combination with other antianginal drugs",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-12-23,1992-07-31,1682,7.427738840532894,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1682,7.427738840532894
Zebeta,bisoprolol fumarate,Lederle,NDA,19982,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/1/1989,7/31/1992,1992,management of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-08-01,1992-07-31,1095,6.9985096422506015,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1095,6.9985096422506015
Vantin,cefpodoxime proxetil,Upjohn,NDA,50674,50675,NA,Tablet,Oral,Suspension,Oral,NA,NA,3/29/1991,8/7/1992,1992,"treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed:  Acute, community-acquired pneumonia; acute, uncomplicated urethral and cervical gonorrhea; acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae; uncomplicated skin and skin structure infections; acute otitis media; pharyngitis/tonsillitis; uncomplicated urinary tract infections",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-03-29,1992-08-07,497,6.208590026096629,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,497,6.208590026096629
Actinex,masoprocol,Block,NDA,19940,NA,NA,Cream,Topical,NA,NA,NA,NA,4/10/1989,9/4/1992,1992,topical treatment of actinic (solar) keratoses,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-04-10,1992-09-04,1243,7.1252830915107115,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1243,7.1252830915107115
Sporanox,itraconazole,Janssen,NDA,20083,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/31/1990,9/11/1992,1992,"treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-05-31,1992-09-11,834,6.726233402358747,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,834,6.726233402358747
Suprane,desflurane,Anaquest,NDA,20118,NA,NA,Liquid,Inhalation,NA,NA,NA,NA,1/30/1991,9/18/1992,1992,indicated as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-30,1992-09-18,597,6.391917113392602,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,597,6.391917113392602
Betapace,sotalol hydrochloride,Bristol-Myers Squibb,NDA,19865,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1988,10/30/1992,1992,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1988-06-30,1992-10-30,1583,7.367077059881012,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,1583,7.367077059881012
ProHance,gadoteridol,Squibb,NDA,20131,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/23/1991,11/16/1992,1992,"provides contrast enhancement of the brain, spine, and surrounding tissues resulting in improved visualization of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood-brain barrier",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-23,1992-11-16,663,6.4967749901858625,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,663,6.4967749901858625
Mepron,atovaquone,Burroughs Wellcome,NDA,20259,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/24/1992,11/25/1992,1992,treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-24,1992-11-25,215,5.3706380281276624,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,215,5.3706380281276624
Desogen,"desogestrel, ethinyl estradiol",Organon,NDA,20071,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/31/1990,12/10/1992,1992,prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-12-31,1992-12-10,710,6.565264970035361,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,710,6.565264970035361
Ambien,zolpidem tartrate,Lorex,NDA,19908,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/1989,12/16/1992,1992,short-term treatment of insomnia,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-01-30,1992-12-16,1416,7.255591274253665,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1416,7.255591274253665
Mycobutin,rifabutin,Adria,NDA,50689,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/17/1992,12/23/1992,1992,prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-17,1992-12-23,341,5.831882477283517,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,341,5.831882477283517
Imitrex,sumatriptan succinate,Glaxo,NDA,20080,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,7/2/1990,12/28/1992,1992,acute treatment of migraine attacks with or without aura,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-07-02,1992-12-28,910,6.813444599510896,Other,high,indication_keyword_match,Priority,Other,Priority,Pre-PDUFA,910,6.813444599510896
Indiclor,indium In 111 chloride,Amersham,NDA,19862,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/2/1988,12/29/1992,1992,indicated for radiolabeling of monoclonal antibodies in preparations used for in vivo diagnostic imaging procedures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-05-02,1992-12-29,1702,7.43955930913332,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1702,7.43955930913332
Taxol,paclitaxel,Bristol-Myers Squibb,NDA,20262,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/22/1992,12/29/1992,1992,treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-07-22,1992-12-29,160,5.075173815233827,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Pre-PDUFA,160,5.075173815233827
OncoScint,satumomab pendetide,Cytogen,BLA,103336,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/28/1989,12/29/1992,1992,"indicated for determining the extent and location of extrahepatic malignant disease in the following:
[A] in patients with known colorectal cancer 
[B] in patients with known ovarian cancer",NA,Standard,Yes (indication [B] only),No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103673,1989-09-28,1992-12-29,1188,7.080026499922591,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Pre-PDUFA,1188,7.080026499922591
Paxil,paroxetine hydrochloride,SmithKline Beecham,NDA,20031,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/21/1989,12/29/1992,1992,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-11-21,1992-12-29,1134,7.033506484287697,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,1134,7.033506484287697
Tilade,nedocromil sodium,Fisons,NDA,19660,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,3/3/1987,12/30/1992,1992,indicated for maintenance therapy in the management of patients with mild to moderate bronchial asthma,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-03-03,1992-12-30,2129,7.663407664893479,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,2129,7.663407664893479
Lamisil,terbinafine hydrochloride,Sandoz,NDA,20192,NA,NA,Cream,Topical,NA,NA,NA,NA,7/3/1991,12/30/1992,1992,"treatment of the following dermatologic infections: interdigital tinea pedis, tinea cruris, or tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, or Trichophyton rubrum",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-07-03,1992-12-30,546,6.302618975744905,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,546,6.302618975744905
Manoplax,flosequinan,Boots,NDA,19960,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/1/1990,12/30/1992,1992,management of congestive heart failure in patients not responding adequately to diuretics,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-01,1992-12-30,821,6.710523109452428,Other,high,indication_keyword_match,Standard,Other,Standard,Pre-PDUFA,821,6.710523109452428
Omniscan,gadodiamide,Sterling-Winthrop,NDA,20123,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/12/1990,1/8/1993,1993,intravenous administration with magnetic resonance imaging in adult patients to provide contrast enhancement in those central nervous system lesions with abnormal vascularity or those thought to cause abnormalities in the blood brain barrier,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-12,1993-01-08,819,6.70808408385307,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,819,6.70808408385307
Leustatin,cladribine,Johnson & Johnson,NDA,20229,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1991,2/26/1993,1993,treatment of active hairy cell leukemia,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1993-02-26,423,6.0473721790462776,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,423,6.0473721790462776
Lovenox,enoxaparin sodium,Rhone-Poulenc Rorer,NDA,20164,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/31/1991,3/29/1993,1993,"prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism, following hip replacement surgery",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1993-03-29,454,6.118097198041348,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,454,6.118097198041348
Claritin,loratadine,Schering,NDA,19658,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1986,4/12/1993,1993,for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1986-10-31,1993-04-12,2355,7.764296006450518,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,2355,7.764296006450518
Metastron,strontium 89 chloride,Medi Physics,NDA,20134,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/2/1992,6/18/1993,1993,for the relief of bone pain in patients with painful skeletal metastases,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-10-02,1993-06-18,259,5.556828061699537,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,259,5.556828061699537
Orlaam,levomethadyl acetate hydrochloride,Biometric Res,NDA,20315,NA,NA,Concentrate,Oral,NA,NA,NA,NA,6/21/1993,7/9/1993,1993,indicated for the management of opiate dependence,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-21,1993-07-09,18,2.8903717578961645,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,18,2.8903717578961645
Betaseron,interferon beta-1b,Chiron,BLA,103471,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/18/1992,7/23/1993,1993,for use in ambulatory patients with relapse-remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1992-06-18,1993-07-23,400,5.991464547107982,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,400,5.991464547107982
Felbatol,felbamate,Wallace,NDA,20189,NA,NA,Suspension,Oral,NA,NA,NA,NA,9/30/1991,7/29/1993,1993,"[A] as monotherapy and adjunctive therapy in the treatment of partial seizures with and without generalization in adults with epilepsy
[B] as adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children",NA,Priority,Yes (indication [B] only),No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-30,1993-07-29,668,6.504288173536645,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,668,6.504288173536645
Propulsid,cisapride monohydrate,Janssen,NDA,20210,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/1991,7/29/1993,1993,symptomatic treatment of patients with nocturnal heartburn due to gastroesophageal reflux disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-08-29,1993-07-29,700,6.551080335043404,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,700,6.551080335043404
Imagent GI,perflubron,Alliance,NDA,20091,NA,NA,Liquid,Oral,NA,NA,NA,NA,10/25/1990,8/13/1993,1993,Indicated for use with magnetic resonance imaging to enhance the delineation of the bowel in order to distinguish it from adjacent organs and areas of suspected pathology,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-25,1993-08-13,1023,6.930494765951626,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,1023,6.930494765951626
Demadex,torsemide,Boehringer Mannheim,NDA,20136,20137,NA,Tablet,Oral,Injectable,Injection,NA,NA,2/28/1991,8/23/1993,1993,"treatment of edema associated with congestive heart failure (CHF), renal disease, or hepatic disease; treatment of hypertension",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-02-28,1993-08-23,907,6.810142450115136,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,907,6.810142450115136
Cognex,tacrine hydrochloride,Parke-Davis,NDA,20070,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/4/1990,9/9/1993,1993,treatment of mild to moderate dementia of the Alzheimer's type,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-06-04,1993-09-09,1193,7.084226422097916,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,1193,7.084226422097916
Flumadine,rimantadine hydrochloride,Forest,NDA,19649,19650,NA,Tablet,Oral,Syrup,Oral,NA,NA,11/14/1986,9/17/1993,1993,prophylaxis and treatment of illness caused by various strains of influenza A virus in adults; indicated for prophylaxis against influenza A virus in children,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1986-11-14,1993-09-17,2499,7.823645930834952,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,2499,7.823645930834952
Alomide,lodoxamide tromethamine,Alcon,NDA,20191,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,6/10/1991,9/23/1993,1993,"treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis",NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-10,1993-09-23,836,6.728628613084702,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,836,6.728628613084702
Zosyn,"tazobactam sodium, pipercillin sodium",Lederle,NDA,50684,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/3/1991,10/22/1993,1993,"treatment of moderate to severe infections cased by piperacillin-resistant, piperacillin/tazobactam-susceptible, beta-lactamase producing strains of designated microorganisms in: appendicitis and peritonitis; uncomplicated and complicated skin and skin structures infections; postpartum endometritis or pelvic inflammatory disease; community-acquired pneumonia (moderate severity only)",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-03,1993-10-22,780,6.659293919683638,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,780,6.659293919683638
Livostin,levocabastine hydrochloride,Iolab,NDA,20219,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,9/24/1991,11/10/1993,1993,temporary relief of the signs and symptoms of seasonal allergic conjunctivitis,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-24,1993-11-10,778,6.656726524178391,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,778,6.656726524178391
Neutrexin,trimetrexate glucuronate,US BioScience,NDA,20326,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/1/1993,12/17/1993,1993,"for use with concurrent leucovorin administration is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carnii pneumonia (PCP) in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole (TMP/SMX) therapy or for whom TMP/SMX is contraindicated",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-02-01,1993-12-17,319,5.765191102784844,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,319,5.765191102784844
Effexor,venlafaxine hydrochloride,Wyeth-Ayerst,NDA,20151,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/26/1991,12/28/1993,1993,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-26,1993-12-28,977,6.884486652042782,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,977,6.884486652042782
Kytril,granisetron hydrochloride,SmithKline Beecham,NDA,20239,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/14/1992,12/29/1993,1993,"prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-14,1993-12-29,624,6.436150368369428,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,624,6.436150368369428
Trasylol,aprotinin,Miles,BLA,20304,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/1992,12/29/1993,1993,"prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases
of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1992-11-24,1993-12-29,400,5.991464547107982,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,400,5.991464547107982
Dovonex,calcipotriene,Bristol-Myers,NDA,20273,NA,NA,Ointment,Topical,NA,NA,NA,NA,3/31/1992,12/29/1993,1993,treatment of moderate plaque psoriasis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-31,1993-12-29,638,6.45833828334479,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,638,6.45833828334479
Risperdal,risperidone,Janssen,NDA,20272,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/15/1992,12/29/1993,1993,management of the manifestations of psychotic disorders,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-15,1993-12-29,623,6.434546518787453,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,623,6.434546518787453
Pulmozyme,dornase alfa,Genentech,BLA,103532,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,3/29/1993,12/30/1993,1993,management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-29,1993-12-30,276,5.62040086571715,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,276,5.62040086571715
Neurontin,gabapentin,Parke-Davis,NDA,20235,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1992,12/30/1993,1993,indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-31,1993-12-30,699,6.54965074223381,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,699,6.54965074223381
Aceon,perindopril erbumine,RW Johnson Pharmaceutical Development,NDA,20184,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/28/1991,12/30/1993,1993,treatment of patients with essential hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-28,1993-12-30,916,6.82001636467413,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,916,6.82001636467413
Lipidil,fenofibrate,Fournier,NDA,19304,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/4/1984,12/31/1993,1993,adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1984-06-04,1993-12-31,3497,8.159660737063376,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,3497,8.159660737063376
Lescol,fluvastatin sodium,Sandoz,NDA,20261,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/1992,12/31/1993,1993,as an adjunct to diet in the treatment of elevated total cholesterol (total-C) and LDL-C levels in patients with primary hypercholesteremia (type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures has not been adequate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-31,1993-12-31,640,6.461468176353717,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,640,6.461468176353717
Oncaspar,pegaspargase,Enzon,BLA,103411,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/15/1991,2/1/1994,1994,Treatment of acute lymphocytic leukemia (ALL) in patients who require L-asparaginase in their treatment regimen but have developed hypersensitivity to the native forms of L-asparaginase,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-15,1994-02-01,1113,7.014814351275545,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,1113,7.014814351275545
Serevent,salmeterol xinafoate,Glaxo,NDA,20236,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,12/20/1991,2/4/1994,1994,maintenance treatment of asthma and prevention of bronchospasm in patients 12 years old and above,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-20,1994-02-04,777,6.655440350367647,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,777,6.655440350367647
Rhinocort,budesonide,GH Besselaar,NDA,20233,NA,NA,"Aerosol, Metered",Nasal,NA,NA,NA,NA,12/31/1992,2/14/1994,1994,management of symptoms of seasonal or perennial allergic rhinitis in adults and children and nonallergic perennial rhinitis in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-31,1994-02-14,410,6.016157159698354,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,410,6.016157159698354
Zemuron,rocuronium bromide,Organon,NDA,20214,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/1993,3/17/1994,1994,"indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-29,1994-03-17,261,5.564520407322694,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,261,5.564520407322694
Semprex-D,"acrivastine, pseudoephedrine hydrochloride",Burroughs Wellcome,NDA,19806,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/29/1987,3/25/1994,1994,"indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-12-29,1994-03-25,2278,7.731053144007127,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,2278,7.731053144007127
[drug marketed without a proprietary name],iobenguane sulfate I 131,CIS US,NDA,20084,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/15/1991,3/25/1994,1994,indicated as an adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas and neuroblastomas,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-11-15,1994-03-25,861,6.7580945044277305,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,861,6.7580945044277305
Prograf,tacrolimus,Fujisawa,NDA,50708,50709,NA,Capsule,Oral,Injectable,Injection,NA,NA,7/26/1993,4/8/1994,1994,indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-07-26,1994-04-08,256,5.545177444479562,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,256,5.545177444479562
Cerezyme,imiglucerase,Genzyme,BLA,20367,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/21/1993,5/23/1994,1994,"indicated for long-term enzyme replacement therapy for patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1993-05-21,1994-05-23,367,5.905361848054571,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,367,5.905361848054571
Octreoscan,indium In 111 pentetreotide,Mallinckrodt Medical,NDA,20314,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/23/1992,6/2/1994,1994,for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-10-23,1994-06-02,587,6.375024819828097,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,587,6.375024819828097
Zerit,stavudine,Bristol-Myers Squibb,NDA,20412,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/1993,6/24/1994,1994,indicated for the treatment of adults with advanced HIV infection who are intolerant of approved therapies with proven clinical benefit or who have experienced significant clinical or immunologic deterioration while receiving these therapies or for whom such therapies are contraindicated,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1993-12-28,1994-06-24,178,5.181783550292085,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,178,5.181783550292085
Famvir,famciclovir,SmithKline Beecham,NDA,20363,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1993,6/29/1994,1994,management of acute herpes zoster (shingles),NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-30,1994-06-29,364,5.8971538676367405,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,364,5.8971538676367405
Cystagon,cysteamine bitartrate,Mylan,NDA,20392,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/23/1993,8/15/1994,1994,indicated for the management of nephropathic cystinosis in children and adults,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-23,1994-08-15,265,5.579729825986222,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,265,5.579729825986222
[drug marketed without a proprietary name],fludeoxyglucose F 18,Downstate Clinical Center,NDA,20306,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/19/1993,8/19/1994,1994,indicated in positron emission tomography for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-01-19,1994-08-19,577,6.3578422665081,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,577,6.3578422665081
Neurolite,technetium Tc-99m bicisate,Dupont Merck,NDA,20256,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/6/1992,11/23/1994,1994,indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-06,1994-11-23,992,6.899723107284872,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,992,6.899723107284872
Luvox,fluvoxamine maleate,Solvay,NDA,20243,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1991,12/5/1994,1994,treatment of obsessions and compulsions in patients with obsessive-compulsive disorder,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-30,1994-12-05,1071,6.976348070447749,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1071,6.976348070447749
Trusopt,dorzolamide hydrochloride,Merck,NDA,20408,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/10/1993,12/9/1994,1994,treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-10,1994-12-09,364,5.8971538676367405,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,364,5.8971538676367405
Fragmin,dalteparin sodium,Pharmacia,NDA,20287,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/30/1992,12/22/1994,1994,prophylaxis against deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE) in patients undergoing abdominal surgery who are at risk for thromboembolic complications,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-30,1994-12-22,722,6.582025138892826,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,722,6.582025138892826
ReoPro,abciximab,Centocor,BLA,103575,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1993,12/22/1994,1994,indicated as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) for the prevention of acute cardiac ischemic complications in patients at high risk for abrupt closure of the treated coronary vessel,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-16,1994-12-22,371,5.916202062607435,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,371,5.916202062607435
Serzone,nefazodone hydrochloride,Bristol-Myers,NDA,20152,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1991,12/22/1994,1994,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-06,1994-12-22,1203,7.0925737159746784,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1203,7.0925737159746784
Navelbine,vinorelbine tartrate,Burroughs Wellcome,NDA,20388,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/27/1993,12/23/1994,1994,"as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC)",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-08-27,1994-12-23,483,6.180016653652572,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,483,6.180016653652572
Lamictal,lamotrigine,Burroughs Wellcome,NDA,20241,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/1992,12/27/1994,1994,indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-23,1994-12-27,1009,6.9167150203536085,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,1009,6.9167150203536085
Renormax,spirapril hydrochloride,Sandoz,NDA,20240,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/31/1991,12/29/1994,1994,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1994-12-29,1094,6.9975959829819265,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1094,6.9975959829819265
Vexol,rimexalone,Alcon,NDA,20474,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,6/1/1994,12/30/1994,1994,treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-06-01,1994-12-30,212,5.356586274672012,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,212,5.356586274672012
Sular,nisoldipine,Miles,NDA,20356,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,4/1/1993,2/2/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-04-01,1995-02-02,672,6.5102583405231496,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,672,6.5102583405231496
Ultram,tramadol hydrochloride,RW Johnson,NDA,20281,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/18/1993,3/3/1995,1995,management of moderate to moderately severe pain,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-18,1995-03-03,470,6.152732694704104,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,470,6.152732694704104
Glucophage,metformin hydrochloride,Lipha,NDA,20357,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1993,3/3/1995,1995,indicated as an adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus whose hyperglycemia cannot be satisfactorily managed on diet alone,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-09-29,1995-03-03,520,6.253828811575473,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,520,6.253828811575473
Cozaar,losartan potassium,Merck,NDA,20386,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/3/1993,4/14/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-03,1995-04-14,497,6.208590026096629,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,497,6.208590026096629
Revex,nalmefene hydrochloride,Ohmeda,NDA,20459,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/29/1994,4/17/1995,1995,"indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-04-29,1995-04-17,353,5.8664680569332965,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,353,5.8664680569332965
Univasc,moexipril hydrochloride,Schwarz Pharma,NDA,20312,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/1992,4/19/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-18,1995-04-19,852,6.747586526829315,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,852,6.747586526829315
Cellcept,mycophenolate mofetil,Syntex,NDA,50722,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/10/1994,5/3/1995,1995,prophylaxis of organ rejection in patients receiving allogeneic renal transplants,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-11-10,1995-05-03,174,5.159055299214529,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,174,5.159055299214529
Prevacid,lansoprazole,TAP Holdings,NDA,20406,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,11/15/1993,5/10/1995,1995,short-term treatment (up to four weeks) for healing and symptom relief of active duodenal ulcer; short-term treatment (up to eight weeks) for healing and symptom relief of all grades of erosive esophagitis; long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-15,1995-05-10,541,6.293419278846481,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,541,6.293419278846481
Ultravist,iopromide,Berlex Laboratories,NDA,20220,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/2/1992,5/10/1995,1995,"intra-arterial Ultravist is indicated for intra-arterial digital subtraction angiography, cerebral arteriography, and peripheral arteriography, and coronary arteriography and left ventriculography, visceral angiography, and aortography; intravenous Ultravist is indicated for peripheral venography and for contrast enhanced computed tomographic (CECT) imaging of the head and body, and excretory urography",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-02,1995-05-10,1164,7.059617628291383,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1164,7.059617628291383
Zinecard,dexrazoxane,Pharmacia,NDA,20212,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/10/1992,5/26/1995,1995,"for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300 mg/m2 and who, in their physician's opinion, would benefit from continuing therapy with doxorubicin",NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1992-02-10,1995-05-26,1201,7.0909098220799835,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,1201,7.0909098220799835
Ultane,sevoflurane,Abbott Laboratories,NDA,20478,NA,NA,Liquid,Inhalation,NA,NA,NA,NA,7/11/1994,6/7/1995,1995,induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-07-11,1995-06-07,331,5.802118375377063,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,331,5.802118375377063
Dynabac,dirithromycin,Lilly,NDA,50678,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,4/29/1993,6/19/1995,1995,"treatment of individuals 12 years of age or older with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following specific conditions: acute bacterial exacerbation of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections,",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-04-29,1995-06-19,781,6.660575149839686,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,781,6.660575149839686
Precose,acarbose,Bayer,NDA,20482,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1994,9/6/1995,1995,adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus whose hyperglycemia cannot be managed alone.  It may also be used in combination with a sulfonylurea when diet plus Precose or a sulfonurea do not result in adequate glycemic control,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-06,1995-09-06,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Azelex,azelaic acid,Allergan,NDA,20428,NA,NA,Cream,Topical,NA,NA,NA,NA,2/28/1994,9/13/1995,1995,treatment of mild-to-moderate inflammatory acne vulgaris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-28,1995-09-13,562,6.331501849893691,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,562,6.331501849893691
Coreg,carvedilol,SmithKline Beecham,NDA,20297,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/31/1993,9/14/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-31,1995-09-14,897,6.799055862058796,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,897,6.799055862058796
Flolan,epoprostenol sodium,Burroughs Wellcome,NDA,20444,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1994,9/20/1995,1995,long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension in NYHA Class III and Class IV patients,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-28,1995-09-20,569,6.343880434126331,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,569,6.343880434126331
Eprex,epoetin alfa,Johnson & Johnson,BLA,103310,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1989,9/29/1995,1995,"indicated for the treatment of anemia associated with chronic renal  failure, including patients on dialysis (ESRD) and patients not on dialysis",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103839,1989-02-28,1995-09-29,2404,7.784889295655098,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,2404,7.784889295655098
Fosamax,alendronate sodium,Merck,NDA,20560,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/31/1995,9/29/1995,1995,treatment of osteoporosis in postmenopausal women; treatment of Paget's disease of the bone.,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-31,1995-09-29,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Casodex,bicalutamide,Zeneca,NDA,20498,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/14/1994,10/4/1995,1995,use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer,NA,Standard,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1994-09-14,1995-10-04,385,5.953243334287785,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,385,5.953243334287785
Epivir,lamivudine,Glaxo Wellcome,NDA,20564,20596,NA,Tablet,Oral,Solution,Oral,NA,NA,7/7/1995,11/17/1995,1995,in combination with Retrovir (zidovudine) for the treatment of HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-07-07,1995-11-17,133,4.890349128221754,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,133,4.890349128221754
Amaryl,glimepiride,Hoechst-Roussel,NDA,20496,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/30/1994,11/30/1995,1995,indicated as an adjunct to diet and exercise to lower blood glucose levels in patients with noninsulin-dependent (Type 2) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone; in combination with insulin to lower the blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-08-30,1995-11-30,457,6.124683390894205,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,457,6.124683390894205
Invirase,saquinavir,Roche,NDA,20628,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/31/1995,12/6/1995,1995,in combination with nucleoside analogues for the treatment of advanced HIV infection in selected patients,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-08-31,1995-12-06,97,4.574710978503383,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,97,4.574710978503383
Ethyol,amifostine,US Bioscience,NDA,20221,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/1991,12/8/1995,1995,indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-30,1995-12-08,1530,7.333023014386481,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,1530,7.333023014386481
Zyrtec,cetirizine,Pfizer,NDA,19835,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/1/1988,12/8/1995,1995,"relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-07-01,1995-12-08,2716,7.906915488678587,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,2716,7.906915488678587
Rilutek,riluzole,Rhone-Poulenc,NDA,20599,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/1995,12/12/1995,1995,treatment of patients with amyotrophic lateral sclerosis (ALS),NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-29,1995-12-12,166,5.111987788356544,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,166,5.111987788356544
Cedax,ceftibuten,Schering Plough,NDA,50685,50686,NA,Capsule,Oral,Suspension,Oral,NA,NA,12/20/1991,12/20/1995,1995,"indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following conditions: acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-20,1995-12-20,1461,7.2868764117507,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1461,7.2868764117507
Oxilan,ioxilan,Cook Imaging,NDA,20316,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/4/1992,12/21/1995,1995,"indicated for intra-arterial use in cerebral arteriography, coronary arteriography and left ventriculography, visceral angiography, aortography and peripheral arteriography;  indicated for intravenous use in excretory urography and contrast enhanced computed tomographic imaging of the head and body",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-04,1995-12-21,1112,7.013915474810528,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1112,7.013915474810528
Photofrin,porfimer sodium,QLT Phototherapeutics,NDA,20451,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/13/1994,12/27/1995,1995,"palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1994-04-13,1995-12-27,623,6.434546518787453,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,623,6.434546518787453
Arimidex,anastrozole,Zeneca,NDA,20541,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/29/1995,12/27/1995,1995,treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-29,1995-12-27,273,5.60947179518496,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,273,5.60947179518496
Corvert,ibutilide fumurate,Upjohn,NDA,20491,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/28/1994,12/28/1995,1995,indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-10-28,1995-12-28,426,6.054439346269371,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,426,6.054439346269371
Maxipime,cefepime hydrochloride,Bristol-Myers Squibb,NDA,50679,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/1/1992,1/18/1996,1996,"indicated in the treatment of the following infections when caused by susceptible strains of designated microorganisms: uncomplicated and complicated urinary tract infections, including pyelonephritis; uncomplicated skin and skin structure infections; pneumonia",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-07-01,1996-01-18,1296,7.16703787691222,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1296,7.16703787691222
Myoview,technetium Tc-99m tetrofosmin,Medi Physics,NDA,20372,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/7/1993,2/9/1996,1996,indicated for scientific imaging of the myocardium following separate administrations under exercise and resting conditions to enhance the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-07,1996-02-09,977,6.884486652042782,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,977,6.884486652042782
Norvir,ritonavir,Abbott Laboratories,NDA,20659,20680,NA,Solution,Oral,Capsule,Oral,NA,NA,12/21/1995,3/1/1996,1996,in combination with nucleoside analogues or as monotherapy for the treatment of HIV infection when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-12-21,1996-03-01,71,4.2626798770413155,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,71,4.2626798770413155
Crixivan,indinavir sulfate,Merck,NDA,20685,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1996,3/13/1996,1996,treatment of HIV infection in adults when antiretroviral therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-01-31,1996-03-13,42,3.737669618283368,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,42,3.7376696182833684
Visipaque,iodixanol,Nycomed,NDA,20351,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/5/1993,3/22/1996,1996,"indicated for intra-arterial use in visceral intra-arterial digital subtraction angiography, angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, cerebral arteriography; indicated for intravenous use in contrast enhancement computed tomography imaging of the head and body, excretory urography, and peripheral venography",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-05,1996-03-22,1113,7.014814351275545,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1113,7.014814351275545
Mavik,trandolapril,Knoll,NDA,20528,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1994,4/26/1996,1996,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-04-26,575,6.354370040797351,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,575,6.354370040797351
Buphenyl,sodium phenylbutyrate,Ucyclyd,NDA,20573,NA,NA,Powder,Oral,NA,NA,NA,NA,2/17/1995,4/30/1996,1996,"indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-17,1996-04-30,438,6.082218910376446,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,438,6.082218910376446
Taxotere,docetaxel,Rhone-Poulenc,NDA,20449,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/27/1994,5/14/1996,1996,treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1994-07-27,1996-05-14,657,6.48768401848461,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,657,6.48768401848461
Gemzar,gemcitabine hydrochloride,Lilly,NDA,20509,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/2/1995,5/15/1996,1996,first-line treatment for patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas; also indicated for patients previously treated with 5-fluorouracil,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-02,1996-05-15,468,6.148468295917647,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,468,6.148468295917647
Avonex,interferon beta-1a,Biogen,BLA,103628,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/1995,5/17/1996,1996,indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-22,1996-05-17,361,5.8888779583328805,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,361,5.8888779583328805
Acthrel,corticorelin ovine triflutate,Ferring Pharmaceuticals,BLA,20162,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/19/1991,5/23/1996,1996,indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing’s syndrome,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1991-02-19,1996-05-23,1920,7.560080465021827,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,1920,7.560080465021827
Hycamtin,topotecan hydrochloride,SmithKline Beecham,NDA,20671,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1995,5/28/1996,1996,treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-22,1996-05-28,158,5.062595033026967,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,158,5.062595033026967
Differin,adapalene,Galderma,NDA,20338,20380,NA,Solution,Topical,Gel,Topical,NA,NA,3/26/1993,5/31/1996,1996,indicated for the topical treatment of acne vulgaris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-26,1996-05-31,1162,7.057897937411856,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1162,7.057897937411856
Xalatan,latanoprost,Pharmacia and Upjohn,NDA,20597,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,6/16/1995,6/5/1996,1996,indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and/or ocular hypertension who were intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-16,1996-06-05,355,5.872117789475416,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,355,5.872117789475416
Albenza,albendazole,SmithKline Beecham,NDA,20666,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/1995,6/11/1996,1996,"indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium; also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-11,1996-06-11,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Humalog,lispro insulin,Lilly,BLA,20563,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/14/1995,6/14/1996,1996,treatment of diabetes mellitus in patients requiring insulin,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1995-03-14,1996-06-14,458,6.126869184114185,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,458,6.126869184114185
Camptosar,irinotecan hydrochloride,Pharmacia and Upjohn,NDA,20571,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1995,6/14/1996,1996,treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1996-06-14,169,5.1298987149230735,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,169,5.1298987149230735
Remeron,mirtazapine,Organon,NDA,20415,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/1995,6/14/1996,1996,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-30,1996-06-14,501,6.2166061010848646,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,501,6.2166061010848646
Merrem,meropenem,Zeneca,NDA,50706,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/30/1993,6/21/1996,1996,indicated as single agent therapy for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: complicated intra-abdominal infections (appendicitis and peritonitis); pediatric bacterial meningitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-30,1996-06-21,934,6.839476438228843,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,934,6.839476438228843
Viramune,nevirapine,Boehringer Ingelheim Pharmaceuticals,NDA,20636,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/23/1996,6/21/1996,1996,indicated for use in combination with nucleoside analogues to treat adults with HIV infection who have experienced clinical and/or immunological deterioration,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-02-23,1996-06-21,119,4.77912349311153,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,119,4.77912349311153
Vistide,cidofovir,Gilead Sciences,NDA,20638,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/1995,6/26/1996,1996,treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS),NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-04,1996-06-26,266,5.583496308781699,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,266,5.583496308781699
CEA-Scan,arcitumomab,Immunomedics,BLA,103425,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/15/1991,6/28/1996,1996,for use in conjunction with computerized tomography scans to detect recurrent or metastatic colorectal cancer,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-15,1996-06-28,1901,7.550135342488429,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,1901,7.550135342488429
Myoscint,imciromab pentetate,Centocor,BLA,103634,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/7/1995,7/3/1996,1996,indicated for the preparation of Indium In 111 Imciromab pentetate to be used as a cardiac imaging agent for detecting the presence and/or identifying the location of myocardial injury in patients with suspected myocardial infarction,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-07-07,1996-07-03,362,5.8916442118257715,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,362,5.8916442118257715
Ultiva,remifentanil hydrochloride,Glaxo Wellcome,NDA,20630,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/1995,7/12/1996,1996,"indicated for induction and maintenance of general anesthesia for inpatient and outpatient procedures, and for continuation as an analgesic into the immediate postoperative period under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting; also provides an analgesic component of monitored anesthesia care",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-15,1996-07-12,301,5.707110264748875,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,301,5.707110264748875
Allegra,fexofenadine hydrochloride,Hoechst Marion Roussel,NDA,20625,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/31/1995,7/25/1996,1996,relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-07-31,1996-07-25,360,5.886104031450156,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,360,5.886104031450156
Cerebyx,fosphenytoin sodium,Parke-Davis,NDA,20450,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/23/1995,8/5/1996,1996,"for short-term parenteral administration when other means of phenytoin administration are unavailable, inappropriate or deemed less advantageous, indicated for the following:
[A] control of generalized convulsive status epilepticus
[B] prevention and treatment of seizures occurring during neuorsurgery
[C] as a substitute, short-term, for oral phenytoin",NA,Standard,Yes (indication [A] only),No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-23,1996-08-05,529,6.270988431858299,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,529,6.270988431858299
Verluma,nofetumomab,Boehringer Ingelheim Pharmaceuticals,BLA,103582,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/1994,8/20/1996,1996,"detection of extensive stage disease in patients with biopsy-confirmed, previously untreated, small cell lung cancer",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by  BLA 103769,1994-03-30,1996-08-20,874,6.773080375655535,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,874,6.773080375655535
Ivy Block,bentoquatam,Enviroderm,NDA,20532,NA,NA,Lotion,Topical,NA,NA,NA,NA,9/29/1994,8/26/1996,1996,"indicated as a skin protectant against poison ivy, poison oak, poison sumac",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-08-26,697,6.546785410760524,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,697,6.546785410760524
Feridex,ferumoxides,Advanced Magnetics,NDA,20416,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/7/1994,8/30/1996,1996,"indicated for detection of lesions of the liver and spleen manifested by an alteration in RES distribution, to facilitate visualization and detection of hepatosplenic lesions, including, but not limited to, tumors",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-07,1996-08-30,935,6.840546529288687,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,935,6.840546529288687
Alphagan,brimonidine tartrate,Allergan,NDA,20613,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,9/7/1995,9/6/1996,1996,indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-07,1996-09-06,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
ProAmatine,midodrine hydrochloride,Roberts,NDA,19815,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/1988,9/6/1996,1996,treatment of symptomatic or orthostatic hypotension,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1988-04-28,1996-09-06,3053,8.023879992734878,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,3053,8.023879992734878
Meretek UBT,13 C Urea,Meretek,NDA,20586,NA,NA,For Solution,Oral,NA,NA,NA,NA,5/11/1995,9/17/1996,1996,for the detection of the presence of absence of active Helicobactor pylori infection of the stomach,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-11,1996-09-17,495,6.20455776256869,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,495,6.20455776256869
Nilandron,nilutamide,Roussel UCLAF,NDA,20169,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/7/1994,9/19/1996,1996,in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-03-07,1996-09-19,927,6.831953565565855,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,927,6.831953565565855
Denavir,penciclovir,SmithKline Beecham,NDA,20629,NA,NA,Cream,Topical,NA,NA,NA,NA,10/16/1995,9/24/1996,1996,treatment of recurrent herpes labialis (cold sores) in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-16,1996-09-24,344,5.840641657373398,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,344,5.840641657373398
Naropin,ropivacaine hydrochloride monohydrate,Astra,NDA,20533,NA,NA,Solution,Injection,NA,NA,NA,NA,3/31/1995,9/24/1996,1996,"production of local or regional anesthesia for surgery, for postoperative pain management and for obstetrical procedures",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-31,1996-09-24,543,6.297109319933935,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,543,6.297109319933935
Elmiron,pentosan polysulfate sodium,Baker Norton,NDA,20193,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/19/1991,9/26/1996,1996,indicated for the relief of bladder pain or discomfort associated with interstitial cystitis,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-19,1996-09-26,1926,7.563200592358071,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1926,7.563200592358071
Accolate,zafirlukast,Zeneca,NDA,20547,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/1995,9/26/1996,1996,prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-26,1996-09-26,458,6.126869184114185,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,458,6.126869184114185
Zyprexa,olanzapine,Lilly,NDA,20592,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/22/1995,9/30/1996,1996,treatment of the manifestations of psychotic disorders,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-22,1996-09-30,374,5.924255797414532,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,374,5.924255797414532
Mentax,butenafine hydrochloride,Penederm,NDA,20524,NA,NA,Cream,Topical,NA,NA,NA,NA,4/5/1995,10/18/1996,1996,treatment of interdigital tinea pedis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-04-05,1996-10-18,562,6.331501849893691,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,562,6.331501849893691
Cystadane,betaine anhydrous,Orphan Medical,NDA,20576,NA,NA,For Solution,Oral,NA,NA,NA,NA,10/25/1995,10/25/1996,1996,treatment of homocystinuria to decrease elevated homocysteine blood levels,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-25,1996-10-25,366,5.902633333401366,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,366,5.902633333401366
ProstaScint,capromab pendetide,Cytogen,BLA,103608,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/13/1995,10/28/1996,1996,"indicated for the preparation of lndium In 111 Capromab Pendetide to be used as a diagnostic imaging agent in newly diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation, who are at high risk for pelvic lymph node metastases, and in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-13,1996-10-28,654,6.483107351457199,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,654,6.483107351457199
Retavase,reteplase,Boehringer Mannheim,BLA,103632,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1995,10/30/1996,1996,"indicated in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103786,1995-06-30,1996-10-30,488,6.1903154058531475,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,488,6.1903154058531475
Astelin,azelastine hydrochloride,Wallace Lab,NDA,20114,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,3/26/1991,11/1/1996,1996,"treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 12 years and older",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-03-26,1996-11-01,2047,7.624130585661289,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,2047,7.624130585661289
Stromectol,ivermectin,Merck,NDA,50742,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/1/1996,11/22/1996,1996,indicated for the treatment of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis; also indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-01,1996-11-22,235,5.459585514144159,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,235,5.459585514144159
Aricept,donepezil hydrochloride,Eisai,NDA,20690,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/5/1996,11/25/1996,1996,treatment of mild to moderate dementia of the Alzheimer's type,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-05,1996-11-25,234,5.455321115357702,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,234,5.455321115357702
Zanaflex,tizanidine hydrochloride,Athena Neuroscience,NDA,20397,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/6/1993,11/27/1996,1996,acute and intermittent management of increased muscle tone associated with spasticity,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-06,1996-11-27,1087,6.99117688712121,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1087,6.99117688712121
Gastromark,ferumoxsil,Advanced Magnetics,NDA,20410,NA,NA,Suspension,Oral,NA,NA,NA,NA,11/23/1993,12/6/1996,1996,for oral use with magnetic resonance imaging to enhance the delineation of the bowel to distinguish it from organs and tissues that are adjacent to the upper regions of the gastrointestinal tract,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-23,1996-12-06,1109,7.011213987350367,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1109,7.011213987350367
Zyflo,zileuton,Abbott Laboratories,NDA,20471,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/19/1994,12/9/1996,1996,prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-07-19,1996-12-09,874,6.773080375655535,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,874,6.773080375655535
Aphthasol,amlexanox,Block Drug,NDA,20511,NA,NA,Paste,Oral,NA,NA,NA,NA,4/19/1995,12/17/1996,1996,the treatment of aphthous ulcers in people with normal immune systems,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-04-19,1996-12-17,608,6.410174881966167,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,608,6.410174881966167
Lipitor,atorvastatin calcium,Parke-Davis,NDA,20702,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/1996,12/17/1996,1996,"indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-06-17,1996-12-17,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Patanol,olopatadine hydrochloride,Alcon,NDA,20688,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/29/1996,12/18/1996,1996,For the temporary prevention of itching of the eye due to allergic conjunctivitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-29,1996-12-18,324,5.780743515792329,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,324,5.780743515792329
Glyset,miglitol,Bayer,NDA,20682,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/1995,12/18/1996,1996,indicated as adjunct to diet or diet plus sulfonylurea therapy to improve glycemic control in patients with non-insulin-dependent diabetes mellitus,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-29,1996-12-18,355,5.872117789475416,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,355,5.872117789475416
Monurol,fosfomycin tromethamine,Zambon,NDA,50717,NA,NA,For Solution,Oral,NA,NA,NA,NA,9/29/1994,12/19/1996,1996,treatment of uncomplicated urinary tract infections(acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-12-19,812,6.699500340161678,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,812,6.699500340161678
Zagam,sparfloxacin,Rhone-Poulenc Rorer,NDA,20677,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/1995,12/19/1996,1996,indicated for the treatment of adults with the following infections caused by susceptible strains of designated organisms: community-acquired pneumonia; acute bacterial exacerbations of chronic bronchitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-27,1996-12-19,358,5.8805329864007,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,358,5.8805329864007
Copaxone,glatiramer acetate,Teva,NDA,20622,NA,NA,For Solution,Subcutaneous,NA,NA,NA,NA,10/11/1995,12/20/1996,1996,indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-11,1996-12-20,436,6.077642243349034,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,436,6.077642243349034
Diovan,valsartan,Ciba-Geigy,NDA,20665,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/1995,12/23/1996,1996,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1996-12-23,361,5.8888779583328805,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,361,5.8888779583328805
Dostinex,cabergoline,Pharmacia and Upjohn,NDA,20664,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/1995,12/23/1996,1996,"treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-27,1996-12-23,362,5.8916442118257715,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,362,5.8916442118257715
Orgaran,danaparoid sodium,Organon,NDA,20430,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1994,12/24/1996,1996,indicated for the prophylaxis of post-operative deep venous thrombosis (DVT) which may lead to pulmonary embolism (PE) in patients undergoing elective hip replacement surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1996-12-24,725,6.586171654854675,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,725,6.586171654854675
Topamax,topiramate,RW Johnson,NDA,20505,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1994,12/24/1996,1996,adjunctive therapy for the treatment of adults with partial onset seizures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1996-12-24,725,6.586171654854675,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,725,6.586171654854675
Rezulin,troglitazone,Parke-Davis,NDA,20720,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/1/1996,1/29/1997,1997,indicated for use in Type II diabetes patients whose hyperglycemia is inadequately controlled despite insulin therapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-08-01,1997-01-29,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Aldara,imiquimod,3M,NDA,20723,NA,NA,Cream,Topical,NA,NA,NA,NA,7/26/1996,2/27/1997,1997,treatment of external genital and perianal warts/condyloma acuminata in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-26,1997-02-27,216,5.375278407684165,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,216,5.375278407684165
Skelid,tiludronate disodium,Sanofi Winthrop,NDA,20707,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/28/1996,3/7/1997,1997,treatment of Paget's disease of bone,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-02-28,1997-03-07,373,5.921578419643816,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,373,5.921578419643816
Agrylin,anagrelide hydrochloride,Roberts,NDA,20333,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1996,3/14/1997,1997,treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and ameliorate associated systems,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-31,1997-03-14,408,6.0112671744041615,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,408,6.0112671744041615
Viracept,nelfinavir mesylate,Agouron,NDA,20779,20778,NA,Tablet,Oral,Powder,Oral,NA,NA,12/23/1996,3/14/1997,1997,treatment of HIV infection when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-12-23,1997-03-14,81,4.394449154672439,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,81,4.394449154672439
Quadramet,samarium Sm 153 lexidronam,Cytogen,NDA,20570,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/13/1995,3/28/1997,1997,indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-13,1997-03-28,654,6.483107351457199,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,654,6.483107351457199
Rescriptor,delavirdine mesylate,Pharmacia and Upjohn,NDA,20705,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/15/1996,4/4/1997,1997,treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-07-15,1997-04-04,263,5.572154032177765,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,263,5.572154032177765
Flomax,tamsulosin hydrochloride,Boehringer Ingelheim Pharmaceuticals,NDA,20579,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/15/1996,4/15/1997,1997,indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-15,1997-04-15,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Pytest Kit,14 C Urea,TriMed,NDA,20617,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/22/1995,5/9/1997,1997,indicated for the diagnosis of Helicobacter pylori infection of the stomach,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-22,1997-05-09,718,6.576469569048224,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,718,6.576469569048224
Normiflo,ardeparin sodium,Wyeth-Ayerst,NDA,20227,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1992,5/23/1997,1997,prevention of deep venous thrombosis which may lead to pulmonary embolism following knee replacement surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-16,1997-05-23,1619,7.389563953677635,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1619,7.389563953677635
Fareston,toremifene citrate,Orion,NDA,20497,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/3/1995,5/29/1997,1997,treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or receptor unknown tumors,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-03,1997-05-29,877,6.776506992372183,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,877,6.776506992372183
Tazorac,tazarotene,Allergan,NDA,20600,NA,NA,Gel,Topical,NA,NA,NA,NA,6/19/1995,6/13/1997,1997,indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement and topical treatment of patients with facial acne vulgaris of mild to moderate severity,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-19,1997-06-13,725,6.586171654854675,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,725,6.586171654854675
Posicor,mibefradil dihydrochloride,Roche,NDA,20689,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/11/1996,6/20/1997,1997,treatment of hypertension and chronic stable angina pectoris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-03-11,1997-06-20,466,6.1441856341256456,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,466,6.1441856341256456
Baycol,cerivastatin sodium,Bayer,NDA,20740,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/1996,6/26/1997,1997,indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-06-26,1997-06-26,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Mirapex,pramipexole dihydrochloride,Pharmacia and Upjohn,NDA,20667,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/28/1995,7/1/1997,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1997-07-01,551,6.311734809152915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,551,6.311734809152915
Duract,bromfenac sodium,Wyeth-Ayerst,NDA,20535,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/30/1994,7/15/1997,1997,indicated for the short-term (generally less than 10 days) management of pain,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1997-07-15,928,6.833031732786201,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,928,6.833031732786201
Femara,letrozole,Novartis Pharmaceuticals,NDA,20726,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/25/1996,7/25/1997,1997,indicated for the treatment of advanced breast cancer in postmenopausal women,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-25,1997-07-25,365,5.8998973535824915,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,365,5.8998973535824915
Anzemet,dolasetron mesylate,Hoechst Marion Roussel,NDA,20623,20624,NA,Tablet,Oral,Injectable,Injection,NA,NA,9/29/1995,9/11/1997,1997,prevention of chemotherapy-induced nausea and vomiting; prevention of postoperative nausea and vomiting,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-29,1997-09-11,713,6.569481420414296,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,713,6.569481420414296
Genesa,arbutamine hydrochloride,Gensia,NDA,20420,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/6/1994,9/12/1997,1997,indicated for us as an aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately when used in conjunction with radionuclide myocardial perfusion imaging or echocardiography,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-01-06,1997-09-12,1345,7.20414929203594,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1345,7.20414929203594
Requip,ropinirole hydrochloride,SmithKline Beecham,NDA,20658,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/2/1996,9/19/1997,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-02,1997-09-19,626,6.439350371100098,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,626,6.439350371100098
Corlopam,fenoldopam mesylate,Neurex,NDA,19922,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/1988,9/23/1997,1997,"indicated for the in-hospital, short-term (up to 48 hours) use in the management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-12-12,1997-09-23,3207,8.073091199693154,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,3207,8.073091199693154
Seroquel,quetiapine fumarate,Zeneca,NDA,20639,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/29/1996,9/26/1997,1997,treatment of the manifestations of psychotic disorders,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-29,1997-09-26,424,6.049733455231958,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,424,6.049733455231958
Gabitril,tiagabine hydrochloride,Abbott Laboratories,NDA,20646,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/6/1995,9/30/1997,1997,indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-11-06,1997-09-30,694,6.542471960506805,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,694,6.542471960506805
Avapro,irbesartan,Sanofi,NDA,20757,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/1996,9/30/1997,1997,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-09-26,1997-09-30,369,5.910796644040527,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,369,5.910796644040527
Infergen,interferon alfacon-1,Amgen,BLA,103663,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/11/1996,10/6/1997,1997,treatment of chronic hepatitis C virus (HCV) infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-11,1997-10-06,543,6.297109319933935,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,543,6.297109319933935
Raxar,grepafloxacin hydrochloride,Glaxo Wellcome,NDA,20695,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/8/1996,11/6/1997,1997,"treatment of adults with acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-11-08,1997-11-06,363,5.8944028342648505,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,363,5.8944028342648505
Plavix,clopidogrel bisulfate,Sanofi,NDA,20839,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/1997,11/17/1997,1997,"indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1997-04-28,1997-11-17,203,5.313205979041787,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,203,5.313205979041787
Meridia,sibutramine hydrochloride,Knoll  Pharmacuticals,NDA,20632,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/9/1995,11/22/1997,1997,"indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-08-09,1997-11-22,836,6.728628613084702,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,836,6.728628613084702
Neumega,oprelvekin,Genetics Institute,BLA,103694,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1996,11/25/1997,1997,indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-23,1997-11-25,337,5.820082930352362,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,337,5.820082930352362
Zomig,zolmitriptan,Zeneca,NDA,20768,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/26/1996,11/25/1997,1997,treatment of acute migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-11-26,1997-11-25,364,5.8971538676367405,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,364,5.8971538676367405
Teslascan,mangafodipir trisodium,Nycomed,NDA,20652,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/1995,11/26/1997,1997,"indicated as an adjunct to MRI to enhance the T1-weighted images used in the detection, localization, characterization, and evaluation of lesions of the liver",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-09-15,1997-11-26,803,6.688354713946762,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,803,6.688354713946762
Rituxan,rituximab,Genentech,BLA,103705,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1997,11/26/1997,1997,"treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-02-28,1997-11-26,271,5.602118820879701,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,271,5.602118820879701
Antizol,fomepizole,Orphan Medical,NDA,20696,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/6/1996,12/4/1997,1997,"indicated as an antidote to ethylene glycol (antifreeze) poisoning in patients who have ingested, or are suspected of having ingested ethylene glycol",NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-06,1997-12-04,363,5.8944028342648505,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,363,5.8944028342648505
Omnicef,cefdinir,Parke-Davis,NDA,50739,50749,NA,Capsule,Oral,Suspension,Oral,NA,NA,9/4/1996,12/4/1997,1997,"indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the following conditions:  community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis and uncomplicated skin and skin structure infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-09-04,1997-12-04,456,6.1224928095143865,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,456,6.1224928095143865
Evista,raloxifene hydrochloride,Lilly,NDA,20815,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/9/1997,12/9/1997,1997,prevention of osteoporosis in postmenopausal women,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-09,1997-12-09,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Zenapax,daclizumab,Roche,BLA,103749,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/10/1997,12/10/1997,1997,"indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-06-10,1997-12-10,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Regranex,becaplermin,Johnson & Johnson,BLA,103691,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1996,12/16/1997,1997,"indicated for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-16,1997-12-16,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Trovan,alatrofloxacin mesylate,Pfizer,NDA,20760,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1996,12/18/1997,1997,"indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the following conditions: nosocomial pneumonia, community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute sinusitis, complicated intra-abdominal infections including post-surgical infections, gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections, prophylaxis of infection associated with elective colorectal surgery, vaginal and abdominal hysterectomy, uncomplicated skin and skin structure infection including diabetic foot infections, uncomplicated urinary tract infections, chronic bacterial prostatitis, uncomplicate urethral gonorrhea in males and endocervical and rectal gonorrhea in females, pelvic inflammatory disease",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1997-12-18,353,5.8664680569332965,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,353,5.8664680569332965
Trovan,trovafloxacin mesylate,Pfizer,NDA,20759,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1996,12/18/1997,1997,indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the following conditions:,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1997-12-18,353,5.8664680569332965,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,353,5.8664680569332965
Teveten,eprosartan mesylate,SmithKline Beecham,NDA,20738,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/11/1996,12/22/1997,1997,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-10-11,1997-12-22,437,6.07993319509559,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,437,6.07993319509559
Prandin,repaglinide,Novo Nordisk,NDA,20741,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/1/1997,12/22/1997,1997,"indicated as an adjunct to diet and exercise to lower blood glucose in patients with non-insulin dependent (type 2) diabetes whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone; in combination with metformin to lower blood glucose in patients whose hyperglycemia cannot be controlled satisfactorily by exercise, diet, and either repaglinide or metformin alone",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-07-01,1997-12-22,174,5.159055299214529,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,174,5.159055299214529
Sclerosol,talc,Bryan,NDA,20587,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,8/15/1995,12/24/1997,1997,for the prevention of the recurrence of malignant pleural effusions in symptomatic patients,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1995-08-15,1997-12-24,862,6.759255270663693,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,862,6.759255270663693
Emadine,emedastine difumarate,Alcon,NDA,20706,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,3/26/1996,12/29/1997,1997,for the temporary relief of the signs and symptoms of allergic conjunctivitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-03-26,1997-12-29,643,6.466144724237619,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,643,6.466144724237619
Tasmar,tolcapone,Roche,NDA,20697,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/5/1996,1/29/1998,1998,indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson’s disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-06-05,1998-01-29,603,6.401917196727186,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,603,6.401917196727186
Amerge,naratriptan,Glaxo Wellcome,NDA,20763,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/4/1996,2/10/1998,1998,acute treatment of migraine headache,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-04,1998-02-10,433,6.07073772800249,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,433,6.07073772800249
Singulair,montelukast sodium,Merck,NDA,20829,20830,NA,Tablet,Oral,Tablet,Oral,NA,NA,2/21/1997,2/20/1998,1998,prophylaxis and chronic treatment of asthma in patients 15 years and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-02-21,1998-02-20,364,5.8971538676367405,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,364,5.8971538676367405
Refludan,lepirudin,Hoechst Marion Roussel,NDA,20807,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1996,3/6/1998,1998,anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and thromboembolic disease in order to prevent further thromboembolic complications,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-31,1998-03-06,430,6.063785208687608,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,430,6.063785208687608
Lotemax; Alrex,loteprednol etabonate,Bausch & Lomb,NDA,20583,20841,20803,Suspension,Ophthalmic,Suspension,Ophthalmic,Suspension,Ophthalmic,3/31/1995,3/9/1998,1998,"Lotemax is indicated for treatment of steroid response inflammatory conditions of the palepebral and bulbar conjunctiva, cornea, and anterior segment of the eye; Lotemax is also indicated for treatment of post-operative inflammation following ocular surgery; Alrex is indicated for temporary relief of signs and symptoms of seasonal allergic conjunctivitis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-03-31,1998-03-09,1074,6.97914527506881,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1074,6.97914527506881
Detrol,tolterodine tartrate,Pharmacia and Upjohn,NDA,20771,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/25/1997,3/25/1998,1998,"treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-25,1998-03-25,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Actonel,risedronate sodium,Procter & Gamble,NDA,20835,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/1/1997,3/27/1998,1998,treatment of Paget's disease of the bone,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-01,1998-03-27,360,5.886104031450156,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,360,5.886104031450156
Viagra,sildenafil citrate,Pfizer,NDA,20895,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1997,3/27/1998,1998,treatment of erectile dysfunction,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-29,1998-03-27,179,5.187385805840755,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,179,5.187385805840755
Azopt,brinzolamide,Alcon,NDA,20816,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,1/28/1997,4/1/1998,1998,treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-01-28,1998-04-01,428,6.059123195581797,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,428,6.059123195581797
Sucraid,sacrosidase,Orphan Medical,BLA,20772,NA,NA,Solution,Oral,NA,NA,NA,NA,5/7/1997,4/9/1998,1998,"treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID)",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1997-05-07,1998-04-09,337,5.820082930352362,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,337,5.820082930352362
Zemplar,paricalcitol,Abbott Laboratories,NDA,20819,NA,NA,Solution,Intravenous,NA,NA,NA,NA,1/17/1997,4/17/1998,1998,prevention and treatment of secondary hyperparathyroidism encountered with chronic renal failure,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-01-17,1998-04-17,455,6.12029741895095,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,455,6.12029741895095
Xeloda,capecitabine,Roche,NDA,20896,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1997,4/30/1998,1998,"treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents",NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,1997-10-31,1998-04-30,181,5.198497031265826,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,181,5.198497031265826
Simulect,basiliximab,Novartis Pharmaceuticals,BLA,103764,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/12/1997,5/12/1998,1998,indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-11-12,1998-05-12,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Aggrastat,tirofiban hydrochloride,Merck,NDA,20912,20913,NA,Injectable,Injection,Injectable,Injection,NA,NA,10/31/1997,5/14/1998,1998,"in combination with heparin, for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-10-31,1998-05-14,195,5.272999558563747,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,195,5.272999558563747
Integrilin,eptifibatide,COR Therapeutics,NDA,20718,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/2/1996,5/18/1998,1998,"treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction;  also indicated for treatment of patients undergoing PCI. In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-04-02,1998-05-18,776,6.654152520183219,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,776,6.654152520183219
Atacand,candesartan cilexetil,Astra Merck,NDA,20838,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/30/1997,6/4/1998,1998,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-30,1998-06-04,400,5.991464547107982,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,400,5.991464547107982
Synagis,palivizumab,MedImmune,BLA,103770,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/1997,6/19/1998,1998,"prophylaxis of serious lower respiratory tract disease, caused by respiratory syncytial virus, in pediatric patients at high risk of RSV disease",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-19,1998-06-19,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Priftin,rifapentine,Hoechst Marion Roussel,NDA,21024,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/1997,6/22/1998,1998,treatment of pulmonary tuberculosis,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-22,1998-06-22,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Maxalt; Maxalt-MLT,rizatriptan benzoate,Merck,NDA,20864,20865,NA,Tablet,Oral,Tablet,Oral,NA,NA,6/30/1997,6/29/1998,1998,acute treatment of migraine headache,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-30,1998-06-29,364,5.8971538676367405,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,364,5.8971538676367405
Infasurf,calfactant,Ony,BLA,20521,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,7/31/1995,7/1/1998,1998,prevention and treatment of Respiratory Distress Syndrome (RDS) in neonates,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1995-07-31,1998-07-01,1066,6.97166860472579,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1066,6.97166860472579
Thalomid,thalidomide,Celgene,NDA,20785,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/20/1996,7/16/1998,1998,acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-20,1998-07-16,573,6.35088571671474,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,573,6.35088571671474
Celexa,citalopram hydrobromide,Forest Laboratories,NDA,20822,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/12/1997,7/17/1998,1998,treatment of depression,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-05-12,1998-07-17,431,6.066108090103747,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,431,6.066108090103747
Remicade,infliximab,Centocor,BLA,103772,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1997,8/24/1998,1998,"indicated for the treatment of moderately to severely active Crohn’s disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn’s disease for the reduction in the number of draining enterocutaneous fistula(s)",NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1998-08-24,237,5.4680601411351315,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,237,5.4680601411351315
Vitravene,fomivirsen sodium,Isis Pharm,NDA,20961,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/9/1998,8/26/1998,1998,local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant or have a contraindication to other treatments for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-04-09,1998-08-26,139,4.9344739331306915,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,139,4.9344739331306915
Arava,leflunomide,Quintiles,NDA,20905,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/10/1998,9/10/1998,1998,treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms and to retard structural damage as evidenced by X-ray erosions and joint space narrowing,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-10,1998-09-10,184,5.214935757608986,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,184,5.214935757608986
AcuTect,technetium Tc-99m apcitide,Diatide,NDA,20887,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/20/1997,9/14/1998,1998,for scintigraphic imaging of acute venous thrombosis in the lower extremities of patients who have signs and symptoms of acute venous thrombosis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-08-20,1998-09-14,390,5.966146739123692,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,390,5.966146739123692
Sustiva,efavirenz,Dupont Pharmaceuticals,NDA,20972,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/11/1998,9/17/1998,1998,provides for the use of efavirenz in combination with other antiretroviral agents for the treatment of HIV-1 infection,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-06-11,1998-09-17,98,4.584967478670572,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,98,4.584967478670572
Herceptin,trastuzumab,Genentech,BLA,103792,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/4/1998,9/25/1998,1998,treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease; also indicated in combination with paclitaxel for treatment of patients with metastatic breast cancer whose tumors overexpress HER2 protein and who have not received chemotherapy for their metastatic disease,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,1998-05-04,1998-09-25,144,4.969813299576001,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,144,4.969813299576001
Valstar,valrubicin,Anthra Pharm,NDA,20892,NA,NA,Solution,Intravesical,NA,NA,NA,NA,12/31/1997,9/25/1998,1998,indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-12-31,1998-09-25,268,5.5909869805108565,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,268,5.5909869805108565
Renagel,sevelamer hydrochloride,GelTex Pharm,NDA,20926,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/3/1997,10/30/1998,1998,indicated for the reduction of serum phosphorus in patients with end stage renal disease who are on hemodialysis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-11-03,1998-10-30,361,5.8888779583328805,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,361,5.8888779583328805
Enbrel,etanercept,Immunex,BLA,103795,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/8/1998,11/2/1998,1998,indicated for reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDS); Etanercept can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,1998-05-08,1998-11-02,178,5.181783550292085,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,178,5.181783550292085
Micardis,telmisartan,Boehringer Ingelheim Pharmaceuticals,NDA,20850,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/1997,11/10/1998,1998,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-26,1998-11-10,410,6.016157159698354,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,410,6.016157159698354
Thyrogen,thyrotropin alfa,Genzyme,BLA,20898,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1997,11/30/1998,1998,indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1997-12-15,1998-11-30,350,5.857933154483459,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,350,5.857933154483459
Ziagen,abacavir sulfate,Glaxo Wellcome,NDA,20977,20978,NA,Tablet,Oral,Solution,Oral,NA,NA,6/24/1998,12/17/1998,1998,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-06-24,1998-12-17,176,5.170483995038151,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,176,5.170483995038151
Provigil,modafinil,Cephalon,NDA,20717,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1996,12/24/1998,1998,indicated  to  improve  wakefulness  in  patients  with  excessive  daytime sleepiness associated with narcolepsy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1998-12-24,724,6.584791392385716,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,724,6.584791392385716
Celebrex,celecoxib,Searle,NDA,20998,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/30/1998,12/31/1998,1998,indicated for relief of the signs and symptoms of osteoarthritis; also indicated for relief of signs and symptoms of rheumatoid arthritis in adults,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-30,1998-12-31,184,5.214935757608986,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,184,5.214935757608986
Pletal,cilostazol,Otsuka Pharmaceutical,NDA,20863,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/19/1997,1/15/1999,1999,indicated for the reduction of symptoms of intermittent claudication,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-19,1999-01-15,483,6.180016653652572,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,483,6.180016653652572
Panretin,alitretinoin,Ligand Pharm,NDA,20886,NA,NA,Gel,Topical,NA,NA,NA,NA,5/27/1998,2/2/1999,1999,topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-05-27,1999-02-02,251,5.5254529391317835,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,251,5.5254529391317835
Ontak,denileukin diftitox,Seragen,BLA,103767,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/9/1997,2/5/1999,1999,treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-09,1999-02-05,423,6.0473721790462776,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,423,6.0473721790462776
Ferrlecit,sodium ferric gluconate complex,Makoff R&D Labs,NDA,20955,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1997,2/18/1999,1999,treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1999-02-18,415,6.028278520230698,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,415,6.028278520230698
Wellferon,interferon alfa-n1,Glaxo Wellcome,BLA,103760,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/1997,3/25/1999,1999,treatment of chronic hepatitis C in patients 18 years of age or older without decompensated liver disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-30,1999-03-25,541,6.293419278846481,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,541,6.293419278846481
Agenerase,amprenavir,Glaxo Wellcome,NDA,21007,21039,NA,Capsule,Oral,Solution,Oral,NA,NA,10/16/1998,4/15/1999,1999,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-10-16,1999-04-15,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Xenical,orlistat,Roche,NDA,20766,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/27/1996,4/23/1999,1999,indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet;  also indicated to reduce the risk for weight re-gain after prior loss,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-11-27,1999-04-23,877,6.776506992372183,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,877,6.776506992372183
Vioxx,rofecoxib,Merck Research Laboratories,NDA,21042,21052,NA,Tablet,Oral,Suspension,Oral,NA,NA,11/23/1998,5/20/1999,1999,"indicated for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain, and for the treatment of primary dysmenorrhea",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-11-23,1999-05-20,178,5.181783550292085,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,178,5.181783550292085
Avandia,rosiglitazone maleate,SKB Pharms,NDA,21071,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/25/1998,5/25/1999,1999,indicated as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes mellitus as monotherapy or in combination with metformin,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-11-25,1999-05-25,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Hectorol,doxercalciferol,Bone Care,NDA,20862,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/9/1998,6/9/1999,1999,indicated for the reduction of elevated iPTH levels in the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-09,1999-06-09,457,6.124683390894205,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,457,6.124683390894205
Zaditor,ketotifen fumarate,Ciba Vision,NDA,21066,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/4/1999,7/2/1999,1999,prevention of itching of the eye due to allergic conjunctivitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-04,1999-07-02,179,5.187385805840755,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,179,5.187385805840755
Actos,pioglitazone hydrochloride,Takeda America,NDA,21073,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/1999,7/15/1999,1999,"indicated for the improvement of glycemic control in patients with type 2 diabetes as monotherapy, or in combination with a sulfonylurea, metformin or insulin when diet and the single agent does not result in adequate glycemic control",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-15,1999-07-15,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Relenza,zanamivir,Glaxo Wellcome,NDA,21036,NA,NA,Powder,Inhalation,NA,NA,NA,NA,10/27/1998,7/26/1999,1999,treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-10-27,1999-07-26,272,5.605802066295998,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,272,5.605802066295998
Antagon,ganirelix acetate,Organon,NDA,21057,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/29/1999,7/29/1999,1999,indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-29,1999-07-29,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
NeoTect,technetium Tc 99m depreotide,Diatide,NDA,21012,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/16/1998,8/3/1999,1999,indicated as a scintigraphic imaging agent that identifies somatostatin receptor-bearing pulmonary masses in patients presenting with pulmonary lesions on computed tomography and/or chest x-ray who have known malignancy or who are highly suspect for malignancy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-16,1999-08-03,413,6.023447592961033,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,413,6.023447592961033
Temodar,temozolomide,Schering,NDA,21029,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/13/1998,8/11/1999,1999,"treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1998-08-13,1999-08-11,363,5.8944028342648505,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,363,5.8944028342648505
Sonata,zaleplon,Wyeth-Ayerst,NDA,20859,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/6/1998,8/13/1999,1999,short-term treatment of insomnia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-01-06,1999-08-13,584,6.369900982828227,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,584,6.369900982828227
Raplon,rapacuronium bromide,Organon,NDA,20984,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/1998,8/18/1999,1999,"indicated for outpatients and inpatients as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-25,1999-08-18,419,6.037870919922137,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,419,6.037870919922137
Aciphex,rabeprazole sodium,Eisai,NDA,20973,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,3/31/1998,8/19/1999,1999,"indicated for: healing of erosive or ulcerative gastroesophageal reflux disease (GERD); maintenance of healing of erosive or ulcerative GERD; healing of duodenal ulcer; treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-31,1999-08-19,506,6.226536669287466,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,506,6.226536669287466
Ellence,epirubicin hydrochloride,Pharmacia and Upjohn,NDA,50778,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1998,9/15/1999,1999,indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-15,1999-09-15,274,5.6131281063880705,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,274,5.6131281063880705
Rapamune,sirolimus,Wyeth Ayerst Research,NDA,21083,NA,NA,Solution,Oral,NA,NA,NA,NA,12/15/1998,9/15/1999,1999,prophylaxis of organ rejection in patients receiving renal transplants,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-15,1999-09-15,274,5.6131281063880705,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,274,5.6131281063880705
Synercid,"dalfopristin, quinupristin",Rhone-Poulenc Rorer,NDA,50747,50748,NA,Injectable,Injection,Injectable,Injection,NA,NA,9/5/1997,9/21/1999,1999,"[A] treatment of vancomycin resistant Enterococcus faecium
[B] treatment of complicated skin and skin structure infections",NA,Priority (indication [A] only),No,Yes (indication [A] only),N/A,No,N/A,N/A,N/A,NA,1997-09-05,1999-09-21,746,6.61472560020376,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,746,6.61472560020376
Alamast,pemirolast potassium,Santen,NDA,21079,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,3/26/1999,9/24/1999,1999,prevention of itching of the eye due to allergic conjunctivitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-03-26,1999-09-24,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Tikosyn,dofetilide,Pfizer,NDA,20931,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/9/1998,10/1/1999,1999,indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with atrial fibrillation /atrial flutter of greater than one week duration who have been converted to normal sinus rhythm,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-09,1999-10-01,571,6.3473892096560105,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,571,6.3473892096560105
Comtan,entacapone,Orion,NDA,20796,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/2/1998,10/19/1999,1999,"indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose ""wearing-off"" (so called ""fluctuating"" patients)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-01-02,1999-10-19,655,6.484635235635252,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,655,6.484635235635252
Aromasin,exemestane,Pharmacia and Upjohn,NDA,20753,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/1998,10/21/1999,1999,treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-21,1999-10-21,304,5.717027701406222,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,304,5.717027701406222
Tamiflu,oseltamivir phosphate,Roche,NDA,21087,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/29/1999,10/27/1999,1999,"treatment of uncomplicated acute illness due to influenza infections in adults who have been symptomatic for no more than
two days",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-04-29,1999-10-27,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,181,5.198497031265826
Curosurf,poractant,Dey Laboratories,BLA,20744,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,7/3/1996,11/18/1999,1999,treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1996-07-03,1999-11-18,1233,7.117205503164344,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1233,7.117205503164344
Keppra,levetiracetam,UCP Pharma,NDA,21035,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/1/1999,11/30/1999,1999,indicated as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-02-01,1999-11-30,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,302,5.71042701737487
Levulan Kerastick,aminolevulinic acid hydrochloride,Dusa,NDA,20965,NA,NA,Solution,Topical,NA,NA,NA,NA,7/1/1998,12/3/1999,1999,Levulan Kerastick plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-07-01,1999-12-03,520,6.253828811575473,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,520,6.253828811575473
Optimark,gadoversetamide,Mallinckrodt,NDA,20937,20975,20976,Injectable,Injection,Injectable,Injection,Injectable,Injection,3/2/1998,12/8/1999,1999,"indicated for the use with magnetic resonance imaging (MRI) in patients with an abnormal blood barrier or abnormal vascularity of the brain, spine and associated tissues; and with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities identified on computerized tomography",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-02,1999-12-08,646,6.470799503782602,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,646,6.470799503782602
Solage,"mequinol, tretinoin",Bristol-Myers Squibb,NDA,20922,NA,NA,Solution,Topical,NA,NA,NA,NA,12/30/1997,12/10/1999,1999,treatment of solar lentigines,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1999-12-10,710,6.565264970035361,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,710,6.565264970035361
Avelox,moxifloxacin hydrochloride,Bayer,NDA,21085,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/10/1998,12/10/1999,1999,"indicated for the treatment of adults with infections caused by susceptible strains of  designated microorganisms in the
following conditions: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-10,1999-12-10,365,5.8998973535824915,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,365,5.8998973535824915
Precedex,dexmedetomidine hydrochloride,Abbott Laboratories,NDA,21038,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/18/1998,12/17/1999,1999,indicated for the sedation of initially intubated and mechanically ventilated adult patients in an intensive care unit setting,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-18,1999-12-17,364,5.8971538676367405,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,364,5.8971538676367405
Tequin,gatifloxacin,Bristol-Myers Squibb,NDA,21061,21062,NA,Tablet,Oral,Injectable,Injection,NA,NA,12/28/1998,12/17/1999,1999,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the
following conditions: acute bacterial exacerbation of chronic bronchitis, acute sinusitis, community-acquired pneumonia, uncomplicated and complicated urinary tract infections, pyelonephritis, and uncomplicated gonorrhea",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-28,1999-12-17,354,5.869296913133774,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,354,5.869296913133774
Inomax,nitric oxide,Ino Therapeutics,NDA,20845,NA,NA,Gas,Inhalation,NA,NA,NA,NA,6/16/1997,12/23/1999,1999,"indicated in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence or pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-06-16,1999-12-23,920,6.824373670043086,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,920,6.824373670043086
Targretin,bexarotene,Ligand Pharms,NDA,21055,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/23/1999,12/29/1999,1999,treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-06-23,1999-12-29,189,5.241747015059643,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,189,5.241747015059643
Evoxac,cevimeline hydrochloride,Snowbrand Pharmaceuticals,NDA,20989,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/27/1998,1/11/2000,2000,treatment of symptoms of dry mouth in patients with Sjögren's Syndrome,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-08-27,2000-01-11,502,6.218600119691729,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,502,6.218600119691729
Trileptal,oxcarbazepine,Novartis Pharmaceuticals,NDA,21014,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/25/1998,1/14/2000,2000,indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-09-25,2000-01-14,476,6.16541785423142,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,476,6.16541785423142
Protonix,pantoprazole sodium,Wyeth-Ayerst Laboratories,NDA,20987,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,6/30/1998,2/2/2000,2000,short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-30,2000-02-02,582,6.366470447731438,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,582,6.366470447731438
Lotronex,alosetron hydrochloride,Glaxo Wellcome,NDA,21107,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1999,2/9/2000,2000,treatment of irritable bowel syndrome (IBS) in female patients whose predominant bowel symptom is diarrhea,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-06-30,2000-02-09,224,5.41164605185504,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,224,5.4116460518550396
Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA),"perfluoroalkylpolyether, polytetrafluoroethylene",US Army Medical Research and Materiel Command,NDA,21084,NA,NA,Paste,Topical,NA,NA,NA,NA,8/19/1999,2/17/2000,2000,in conjunction with Mission Oriented Protective Posture (MOPP) gear to reduce or delay the absorption of chemical warfare agents through the skin when applied prior to exposure,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-19,2000-02-17,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Zonegran,zonisamide,Elan Pharmaceuticals,NDA,20789,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/19/1997,3/27/2000,2000,indicated as an adjunctive therapy in the treatment of partial seizures in adults with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-19,2000-03-27,1104,7.00669522683704,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1104,7.00669522683704
Septocaine,"articaine hydrochloride, ephinephrine",Deproco,NDA,20971,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/1998,4/3/2000,2000,"indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental and periodontal procedures",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-30,2000-04-03,735,6.5998704992128365,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,735,6.5998704992128365
Visudyne,verteporfin,QLT Phototherapeutics,NDA,21119,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/16/1999,4/12/2000,2000,treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-16,2000-04-12,240,5.480638923341991,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,240,5.480638923341991
Mobic,meloxicam,Boehringer Ingelheim Pharmaceuticals,NDA,20938,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/1998,4/13/2000,2000,indicated for the relief of the signs and symptoms of osteoarthritis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-16,2000-04-13,484,6.182084906716632,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,484,6.182084906716632
Zyvox,linezolid,Pharmacia and Upjohn,NDA,21130,21131,21132,Tablet,Oral,Injectable,Injection,Suspension,Oral,10/18/1999,4/18/2000,2000,"treatment of adult patients with vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia, complicated and uncomplicated skin and skin structure infections, and community-acquired pneumonia",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-18,2000-04-18,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Lantus,insulin glargine,Aventis Pharmaceuticals,BLA,21081,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/23/1999,4/20/2000,2000,treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1999-04-23,2000-04-20,363,5.8944028342648505,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,363,5.8944028342648505
Exelon,rivastigmine tartrate,Novartis Pharmaceuticals,NDA,20823,21025,NA,Capsule,Oral,Solution,Oral,NA,NA,4/7/1997,4/21/2000,2000,treatment of mild to moderate dementia of the Alzheimer’s type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-07,2000-04-21,1110,7.01211529430638,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1110,7.01211529430638
Mylotarg,gemtuzumab ozogamicin,Wyeth-Ayerst,NDA,21174,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/29/1999,5/17/2000,2000,treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1999-10-29,2000-05-17,201,5.303304908059076,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,201,5.303304908059076
Welchol,colesevelam hydrochloride,GelTex,NDA,21176,21141,NA,Tablet,Oral,Capsule,Oral,NA,NA,7/30/1999,5/26/2000,2000,"alone or in combination with an HMG-CoA reductase inhibitor, for the reduction of elevated LDL-cholesterol in patients with primary hypercholesterolemia (Frederickson Type IIa)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-07-30,2000-05-26,301,5.707110264748875,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,301,5.707110264748875
TNKase,tenecteplase,Genentech,BLA,103909,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/2/1999,6/2/2000,2000,indicated for reduction of mortality associated with acute myocardial infarction (AMI),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-02,2000-06-02,305,5.720311776607412,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,305,5.720311776607412
Novolog,insulin aspart recombinant,Novo Nordisk,BLA,20986,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,9/16/1998,6/7/2000,2000,"treatment of adult patients with diabetes mellitus, for the control of hyperglycemia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1998-09-16,2000-06-07,630,6.4457198193855785,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,630,6.4457198193855785
Trelstar Depot,triptorelin pamoate,Debio Recherche,NDA,20715,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,6/26/1996,6/15/2000,2000,palliative treatment of advanced prostate cancer,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-06-26,2000-06-15,1450,7.27931883541462,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,1450,7.27931883541462
Acova,argatroban,Texas Biotechnology Corporation,NDA,20883,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/15/1997,6/30/2000,2000,indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-08-15,2000-06-30,1050,6.956545443151569,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1050,6.956545443151569
Innohep,tinzaparin sodium,Dupont Pharmaceuticals,NDA,20484,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1999,7/14/2000,2000,treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-06-30,2000-07-14,380,5.940171252720432,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,380,5.940171252720432
Colazal,balsalazide disodium,Salix Pharmaceuticals,NDA,20610,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/23/1997,7/18/2000,2000,treatment of mildly to moderate active ulcerative colitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-23,2000-07-18,1121,7.02197642307216,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1121,7.02197642307216
Abreva,docosanol,Avanir Pharmaceuticals,NDA,20941,NA,NA,Cream,Topical,NA,NA,NA,NA,12/22/1997,7/25/2000,2000,treatment of cold sores and fever blisters,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-22,2000-07-25,946,6.852242569051878,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,946,6.852242569051878
Rescula,unoprostone isopropyl,Ciba Vision,NDA,21214,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,2/15/2000,8/3/2000,2000,indicated for the lowering of intraocular pressure in patients with open-angel glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-02-15,2000-08-03,170,5.135798437050262,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,170,5.135798437050262
Cetrotide,cetrorelix acetate,Asta Medica,NDA,21197,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/29/1999,8/11/2000,2000,prevention of premature LH surges in women undergoing controlled ovarian stimulation,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-29,2000-08-11,287,5.659482215759621,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,287,5.659482215759621
Kaletra,"lopinavir, ritonavir",Abbott Laboratories,NDA,21226,21251,NA,Capsule,Oral,Solution,Oral,NA,NA,6/1/2000,9/15/2000,2000,in combination with other antiretroviral agents for the treatment of HIV-1 infections in adults and pediatric patients age six months and older,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-06-01,2000-09-15,106,4.663439094112067,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,106,4.663439094112067
Trisenox,arsenic trioxide,Cell Therapeutics,NDA,21248,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/2000,9/25/2000,2000,"indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-03-28,2000-09-25,181,5.198497031265826,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,181,5.198497031265826
Mifeprex,mifepristone,Population Council,NDA,20687,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/18/1996,9/28/2000,2000,indicated for medical termination of intrauterine pregnancy through 49 days’ pregnancy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-03-18,2000-09-28,1655,7.411556287811163,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,1655,7.411556287811163
Myobloc,botulinum toxin type B,Elan Pharmaceuticals,BLA,103846,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1998,12/8/2000,2000,treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-22,2000-12-08,717,6.57507584059962,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,717,6.57507584059962
Angiomax,bivalirudin,The Medicines Company,NDA,20873,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/23/1997,12/15/2000,2000,indicated for use as an anticoagulant in conjunction with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-23,2000-12-15,1088,6.992096427415888,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1088,6.992096427415888
Starlix,nateglinide,Novartis Pharmaceuticals,NDA,21204,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/17/1999,12/22/2000,2000,"indicated  as  monotherapy  to  lower  blood  glucose  in  patients  with  Type  2  diabetes (non-insulin   dependent   diabetes   mellitus,   NIDDM)   whose   hyperglycemia   cannot   be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents; also indicated   for   use   in   combination   with   metformin in  patients   whose hyperglycemia  is  inadequately  controlled  with  metformin,  Starlix    may  be  added  to,  but  not substituted for, metformin",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-17,2000-12-22,371,5.916202062607435,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,371,5.916202062607435
Peg-Intron,peginterferon alfa-2b,Schering,BLA,103949,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1999,1/19/2001,2001,treatment of chronic hepatitis C in patients not previously treated with interferon alfa who have compensated liver disease and are at least 18 years of age,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-23,2001-01-19,393,5.973809611869261,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,393,5.973809611869261
Cancidas,caspofungin acetate,Merck Research Laboratories,NDA,21227,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/28/2000,1/26/2001,2001,treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2000-07-28,2001-01-26,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,182,5.204006687076795
Geodon,ziprasidone hydrochloride,Pfizer Central Research,NDA,20825,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/17/1997,2/5/2001,2001,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-17,2001-02-05,1421,7.259116128097101,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1421,7.259116128097101
Foradil,formoterol fumarate,Novartis Pharmaceuticals,NDA,20831,NA,NA,Powder,Inhalation,NA,NA,NA,NA,6/26/1997,2/16/2001,2001,"indicated for the long-term, administration in the maintenance treatment of asthma and in the prevention of bronchospasm in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma; also indicated for the acute prevention of exercise-induced bronchospasm (EIB) in adults and children 12 years of age and older, when administered on an occasional, as-needed basis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-26,2001-02-16,1331,7.193685818395112,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1331,7.193685818395112
Reminyl,galantamine hydrobromide,Janssen Research Foundation,NDA,21169,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1999,2/28/2001,2001,treatment of mild to moderate dementia of the Alzheimer's type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-09-29,2001-02-28,518,6.249975242259483,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,518,6.249975242259483
Travatan,travoprost,Alcon Research,NDA,21257,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,7/7/2000,3/16/2001,2001,indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-07-07,2001-03-16,252,5.529429087511423,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,252,5.529429087511423
Lumigan,bimatoprost,Allergan,NDA,21275,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,9/18/2000,3/16/2001,2001,indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-09-18,2001-03-16,179,5.187385805840755,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,179,5.187385805840755
Campath,alemtuzumab,Millennium and ILEX Partners,BLA,103948,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1999,5/7/2001,2001,treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,1999-12-23,2001-05-07,501,6.2166061010848646,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,501,6.2166061010848646
Axert,almotriptan malate,Pharmacia and Upjohn,NDA,21001,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/1999,5/7/2001,2001,indicated for the acute treatment of migraine with or without aura in adults,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-20,2001-05-07,504,6.222576268071369,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,504,6.222576268071369
Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/27/2001,5/10/2001,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2001-02-27,2001-05-10,72,4.276666119016055,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,72,4.276666119016055
Yasmin,"drospirenone,ethinyl estradiol",Berlex Laboratories,NDA,21098,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/17/1999,5/11/2001,2001,indicated for the prevention of pregnancy in women who elect to use an oral contraceptive,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-05-17,2001-05-11,725,6.586171654854675,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,725,6.586171654854675
Definity,perflutren lipid microsphere,Dupont Pharmaceuticals,NDA,21064,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/9/1998,7/31/2001,2001,indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-09,2001-07-31,965,6.872128101338986,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,965,6.872128101338986
Natrecor,nesiritide,Scios,NDA,20920,NA,NA,For Solution,Intravenous,NA,NA,NA,NA,4/27/1998,8/10/2001,2001,treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-04-27,2001-08-10,1201,7.0909098220799835,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1201,7.0909098220799835
Zometa,zoledronic acid,Novartis Pharmaceuticals,NDA,21223,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/21/1999,8/20/2001,2001,treatment of hypercalcemia of malignancy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-12-21,2001-08-20,608,6.410174881966167,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,608,6.410174881966167
Spectracef,cefditoren pivoxil,TAP Pharmaceutical Products,NDA,21222,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/1999,8/29/2001,2001,"treatment of acute bacterial exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-29,2001-08-29,609,6.411818267709897,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,609,6.411818267709897
Aranesp,darbepoetin alfa,Amgen,BLA,103951,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1999,9/17/2001,2001,"treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-09-17,629,6.444131256700441,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,629,6.444131256700441
NuvaRing,"etonogestrel, ethinyl estradiol",Organon,NDA,21187,NA,NA,Ring,Vaginal,NA,NA,NA,NA,12/28/1999,10/3/2001,2001,indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-10-03,645,6.4692503167957724,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,645,6.4692503167957724
Viread,tenofovir disoproxil fumarate,Gilead Sciences,NDA,21356,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/1/2001,10/26/2001,2001,in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2001-05-01,2001-10-26,178,5.181783550292085,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,178,5.181783550292085
Frova,frovatriptan,Elan Pharmaceuticals,NDA,21006,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/29/1999,11/8/2001,2001,acute treatment of migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-29,2001-11-08,1014,6.921658184151129,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1014,6.921658184151129
Kineret,anakinra,Amgen,BLA,103950,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1999,11/14/2001,2001,"indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-11-14,687,6.532334292222349,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,687,6.532334292222349
Bextra,valdecoxib,GD Searle,NDA,21341,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/16/2001,11/16/2001,2001,indicated for the relief of signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-01-16,2001-11-16,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,304,5.717027701406222
Avodart,dutasteride,GlaxoSmithKline,NDA,21319,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/21/2000,11/20/2001,2001,treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-21,2001-11-20,334,5.811140992976701,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,334,5.811140992976701
Ortho Evra,"norelgestromin, ethinyl estradiol",RW Johnson Pharmaceutical Research,NDA,21180,NA,NA,"Film, Extended Release",Transdermal,NA,NA,NA,NA,12/21/2000,11/20/2001,2001,indicated for the prevention of pregnancy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-21,2001-11-20,334,5.811140992976701,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,334,5.811140992976701
Tracleer,bosentan,Actelion Pharmaceuticals,NDA,21290,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2000,11/20/2001,2001,indicated for the treatment of pulmonary arterial hypertension,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-11-17,2001-11-20,368,5.908082938168931,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,368,5.908082938168931
Invanz,ertapenem sodium,Merck,NDA,21337,NA,NA,Injectable,"Intramuscular, Intravenous",NA,NA,NA,NA,11/30/2000,11/21/2001,2001,"treatment of complicated intra-abdominal infections; complicated skin and skin structure infections; community acquired pneumonia; complicated urinary tract infections including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-11-30,2001-11-21,356,5.87493073085203,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,356,5.87493073085203
Xigris,drotrecogin alfa,Eli Lilly,BLA,125029,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/26/2001,11/21/2001,2001,indicated for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-01-26,2001-11-21,299,5.700443573390687,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,299,5.700443573390687
Arixtra,fondaparinux sodium,Fonda BV,NDA,21345,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,2/15/2001,12/7/2001,2001,"indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-02-15,2001-12-07,295,5.68697535633982,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,295,5.68697535633982
Elidel,pimecrolimus,Novartis Pharmaceuticals,NDA,21302,NA,NA,Cream,Topical,NA,NA,NA,NA,12/15/2000,12/13/2001,2001,"short-term and intermittent long-term therapy in the treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 2 years of age and older, in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-15,2001-12-13,363,5.8944028342648505,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,363,5.8944028342648505
Clarinex,desloratadine,Schering,NDA,21165,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/21/1999,12/21/2001,2001,indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-21,2001-12-21,792,6.674561391814426,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,792,6.674561391814426
Orfadin,nitisinone,Swedish Orphan,NDA,21232,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/8/2000,1/18/2002,2002,indicated as adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-09-08,2002-01-18,497,6.208590026096629,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,497,6.208590026096629
Neulasta,pegfilgrastim,Amgen,BLA,125031,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/2/2001,1/31/2002,2002,"indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-04-02,2002-01-31,304,5.717027701406222,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,304,5.717027701406222
Zevalin,ibritumomab tiuxetan,Idec Pharmaceuticals,BLA,125019,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2000,2/19/2002,2002,"as part of a specific therapeutic regimen including Rituximab, Indium-111, Ibritumomab Tiuxetan, and Yttrium-90 Ibritumomab Tiuxetan, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin’s lymphoma",NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-11-01,2002-02-19,475,6.163314804034641,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,475,6.163314804034641
Rebif,interferon beta-1a,Serono,BLA,103780,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/1998,3/7/2002,2002,treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-02-27,2002-03-07,1469,7.292337176173877,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1469,7.292337176173877
Faslodex,fulvestrant,AstraZeneca Pharmaceuticals,NDA,21344,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,3/28/2001,4/25/2002,2002,treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-03-28,2002-04-25,393,5.973809611869261,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,393,5.973809611869261
Benicar,olmesartan medoxomil,Sankyo,NDA,21286,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/25/2000,4/25/2002,2002,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-07-25,2002-04-25,639,6.459904454377535,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,639,6.459904454377535
Remodulin,treprostinil sodium,United Therapeutics,NDA,21272,NA,NA,Injectable,"Iv (Infusion), Subcutaneous",NA,NA,NA,NA,10/16/2000,5/21/2002,2002,treatment of pulmonary arterial hypertension,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,2000-10-16,2002-05-21,582,6.366470447731438,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,582,6.366470447731438
Vfend,voriconazole,Pfizer,NDA,21266,21267,NA,Tablet,Oral,Injectable,Injection,NA,NA,11/17/2000,5/24/2002,2002,"treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp., including Fusarium solani, in patients intolerant of, or refractory to, other therapy",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-11-17,2002-05-24,553,6.315358001522335,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,553,6.315358001522335
Imagent,"dimyristoylphosphatidylcholine, perflexane",Alliance Pharmaceuticals,NDA,21191,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/14/1999,5/31/2002,2002,indicated for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-14,2002-05-31,960,6.866933284461882,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,960,6.866933284461882
Elitek,rasburicase,Sanofi-Synthelabo,BLA,103946,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1999,7/12/2002,2002,"indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid",NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-12-16,2002-07-12,939,6.844815479208263,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Early-PDUFA,939,6.844815479208263
Xyrem,sodium oxybate,Orphan Medical,NDA,21196,NA,NA,Solution,Oral,NA,NA,NA,NA,10/2/2000,7/17/2002,2002,treatment of cataplexy associated with narcolepsy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-10-02,2002-07-17,653,6.481577129276431,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,653,6.481577129276431
Zelnorm,tegaserod maleate,Novartis Pharmaceuticals,NDA,21200,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/11/2000,7/24/2002,2002,short-term treatment of women with irritable bowel syndrome whose primary bowel symptom is constipation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-02-11,2002-07-24,894,6.795705775173514,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,894,6.795705775173514
Eloxatin,oxaliplatin,Sanofi-Synthelabo,NDA,21492,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,6/24/2002,8/9/2002,2002,in combination with infusional 5-FU/LV for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-06-24,2002-08-09,46,3.828641396489095,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Early-PDUFA,46,3.828641396489095
Hepsera,adefovir dipivoxil,Gilead Sciences,NDA,21449,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/21/2002,9/20/2002,2002,treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) or histologically active disease,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-03-21,2002-09-20,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,183,5.209486152841421
Inspra,eplerenone,GD Searle,NDA,21437,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/29/2001,9/27/2002,2002,"treatment of hypertension, alone or in combination with other agents",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-11-29,2002-09-27,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,302,5.71042701737487
Pegasys,peginterferon alfa-2a,Hoffmann-La Roche,BLA,103964,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/2000,10/16/2002,2002,treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-05-22,2002-10-16,877,6.776506992372183,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,877,6.776506992372183
Zetia,ezetimibe,Schering,NDA,21445,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2001,10/25/2002,2002,"indicated as adjunctive therapy to diet for reduction of elevated total-C, LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia either alone or with an HMG-Co A reductase inhibitor; treatment of homozygous familial hypercholesterolemia in combination with either atorvastatin or simvastatin, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or, if such treatments are unavailable, in combination with either atorvastatin or simvastatin alone; treatment of homozygous familial sitosterolemia as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-27,2002-10-25,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,302,5.71042701737487
Abilify,aripiprazole,Otsuka Pharmaceutical,NDA,21436,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/2001,11/15/2002,2002,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-31,2002-11-15,380,5.940171252720432,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,380,5.940171252720432
Alinia,nitazoxanide,Romark Laboratories,NDA,21498,NA,NA,For Suspension,Oral,NA,NA,NA,NA,5/29/2002,11/22/2002,2002,treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2002-05-29,2002-11-22,177,5.176149732573829,Other,high,indication_keyword_match,Priority,Other,Priority,Early-PDUFA,177,5.176149732573829
Strattera,atomoxetine hydrochloride,Eli Lilly,NDA,21411,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/12/2001,11/26/2002,2002,treatment of Attention-Deficit Hyperactivity Disorder (ADHD) for children and adolescents ages 6-18 and adults,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-12,2002-11-26,410,6.016157159698354,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,410,6.016157159698354
Extraneal,icodextrin,Baxter Healthcare,NDA,21321,NA,NA,Solution,Intraperitoneal,NA,NA,NA,NA,12/22/2000,12/20/2002,2002,indicated for a single daily exchange for the long (8-16-hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-12-22,2002-12-20,728,6.590301048196686,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,728,6.590301048196686
Relpax,eletriptan hydrobromide,Pfizer,NDA,21016,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/27/1998,12/26/2002,2002,acute treatment of migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-10-27,2002-12-26,1521,7.327123292259293,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,1521,7.327123292259293
Humira,adalimumab,Abbott Laboratories,BLA,125057,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2002,12/31/2002,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-03-29,2002-12-31,277,5.6240175061873385,Other,high,indication_keyword_match,Standard,Other,Standard,Early-PDUFA,277,5.6240175061873385
Amevive,alefacept,Biogen,BLA,125036,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/6/2001,1/30/2003,2003,treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-08-06,2003-01-30,542,6.295266001439646,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,542,6.295266001439646
Fuzeon,enfuvirtide,Hoffmann-La Roche,NDA,21481,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,9/16/2002,3/13/2003,2003,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-09-16,2003-03-13,178,5.181783550292085,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,178,5.181783550292085
Somavert,pegvisomant,Pharmacia and Upjohn,BLA,21106,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/26/2000,3/25/2003,2003,"treatment of acromegaly in patients who have an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2000-12-26,2003-03-25,819,6.70808408385307,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,819,6.70808408385307
Emend,aprepitant,Merck,NDA,21549,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2002,3/26/2003,2003,"in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-09-27,2003-03-26,180,5.19295685089021,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,180,5.19295685089021
Factive,gemifloxacin mesylate,LG Life Sciences,NDA,21158,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/1999,4/4/2003,2003,treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-16,2003-04-04,1205,7.094234845924755,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1205,7.094234845924755
Fabrazyme,agalsidase beta,Genzyme,BLA,103979,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2000,4/24/2003,2003,indicated for use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-06-23,2003-04-24,1035,6.942156705699469,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,1035,6.942156705699469
Aldurazyme,laronidase,Biomarin Pharmaceutical,BLA,125058,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/2002,4/30/2003,2003,indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2002-07-29,2003-04-30,275,5.616771097666572,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,275,5.616771097666572
Iressa,gefitinib,AstraZeneca Pharmaceuticals,NDA,21399,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/5/2002,5/5/2003,2003,indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-08-05,2003-05-05,273,5.60947179518496,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,273,5.60947179518496
Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,1/21/2003,5/13/2003,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2003-01-21,2003-05-13,112,4.718498871295094,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,112,4.718498871295094
Boniva,ibandronate sodium,Hoffmann-La Roche,NDA,21455,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/16/2002,5/16/2003,2003,treatment and prevention of postmenopausal osteoporosis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-07-16,2003-05-16,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
Uroxatral,alfuzosin hydrochloride,Sanofi-Synthelabo,NDA,21287,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/8/2000,6/12/2003,2003,treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-08,2003-06-12,916,6.82001636467413,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,916,6.82001636467413
Reyataz,atazanavir sulfate,Bristol-Myers Squibb,NDA,21567,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/20/2002,6/20/2003,2003,in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-06-20,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Xolair,omalizumab,Genentech,BLA,103976,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/5/2000,6/20/2003,2003,indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-06-05,2003-06-20,1110,7.01211529430638,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1110,7.01211529430638
Bexxar,"tositumomab, iodine I 131 tositumomab",Corixa,BLA,125011,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/2000,6/27/2003,2003,"indicated for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-09-15,2003-06-27,1015,6.922643891475888,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,1015,6.922643891475888
Emtriva,emtricitabine,Gilead Sciences,NDA,21500,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/3/2002,7/2/2003,2003,indicated for the treatment of HIV infection in adults,NA,Standard,No,No,N/A,Yes,N/A,N/A,N/A,NA,2002-09-03,2003-07-02,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,302,5.71042701737487
Aloxi,palonosetron hydrochloride,Helsinn Healthcare,NDA,21372,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,9/27/2002,7/25/2003,2003,prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy; prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-09-27,2003-07-25,301,5.707110264748875,Oncology,high,indication_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,301,5.707110264748875
Zavesca,miglustat,Actelion Pharmaceuticals,NDA,21348,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/21/2001,7/31/2003,2003,"treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)",NA,Standard,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2001-08-21,2003-07-31,709,6.5638555265321274,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,709,6.5638555265321274
Crestor,rosuvastatin calcium,AstraZeneca Pharmaceuticals,NDA,21366,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/2001,8/12/2003,2003,"indicated as an adjunct to diet to reduce elevated total-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Type IIa and IIb);  as an adjunct to diet for the treatment of patients with elevated serum TG levels (Frederickson Type IV); indicated to reduce LDL-C, total-C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-06-26,2003-08-12,777,6.655440350367647,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,777,6.655440350367647
Levitra,vardenafil hydrochloride,Bayer,NDA,21400,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/24/2001,8/19/2003,2003,treatment of erectile dysfunction,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-09-24,2003-08-19,694,6.542471960506805,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,694,6.542471960506805
Cubicin,daptomycin,Cubist Pharmaceuticals,NDA,21572,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/20/2002,9/12/2003,2003,treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-09-12,266,5.583496308781699,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,266,5.583496308781699
Radiogardase,prussian blue,Heyl Chemisch-pharmazeutische Fabrik GmbH,NDA,21626,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/13/2003,10/2/2003,2003,treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2003-03-13,2003-10-02,203,5.313205979041787,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,203,5.313205979041787
Elestat,epinastine hydrochloride,Allergan,NDA,21565,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/20/2002,10/16/2003,2003,prevention of itching associated with allergic conjunctivitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-10-16,300,5.703782474656201,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,300,5.703782474656201
Namenda,memantine hydrochloride,Forest Laboratories,NDA,21487,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2002,10/16/2003,2003,treatment of moderate to severe dementia of the Alzheimer's type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-19,2003-10-16,301,5.707110264748875,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,301,5.707110264748875
Raptiva,efalizumab,Genentech,BLA,125075,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/27/2002,10/27/2003,2003,treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-27,2003-10-27,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
Cialis,tadalafil,Lilly Icos,NDA,21368,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2001,11/21/2003,2003,treatment of erectile dysfunction,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-06-29,2003-11-21,875,6.774223886357614,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,875,6.774223886357614
Plenaxis,abarelix,Praecis Pharmaceuticals,NDA,21320,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,12/12/2000,11/25/2003,2003,"palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following:  risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-12,2003-11-25,1078,6.982862751468942,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,1078,6.982862751468942
Ertaczo,sertaconazole nitrate,Mylan Pharmaceuticals,NDA,21385,NA,NA,Cream,Topical,NA,NA,NA,NA,9/28/2001,12/10/2003,2003,"treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-09-28,2003-12-10,803,6.688354713946762,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,803,6.688354713946762
Spiriva Handihaler,tiotropium bromide,Boehringer Ingelheim Pharmaceuticals,NDA,21395,NA,NA,Powder,Inhalation,NA,NA,NA,NA,12/13/2001,1/30/2004,2004,"long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-13,2004-01-30,778,6.656726524178391,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,778,6.656726524178391
Alimta,pemetrexed disodium,Eli Lilly,NDA,21462,NA,NA,Powder,Intravenous,NA,NA,NA,NA,9/30/2003,2/4/2004,2004,treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-09-30,2004-02-04,127,4.844187086458591,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,127,4.844187086458591
Erbitux,cetuximab,ImClone Systems,BLA,125084,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/14/2003,2/12/2004,2004,"in combination with irinotecan for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy; as a single agent for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2003-08-14,2004-02-12,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Avastin,bevacizumab,Genentech,BLA,125085,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/2003,2/26/2004,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2003-09-30,2004-02-26,149,5.003946305945459,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,149,5.003946305945459
Sensipar,cinacalcet hydrochloride,Amgen,NDA,21688,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/8/2003,3/8/2004,2004,"[A] treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
[B] treatment of hypercalcemia in patients with parathyroid carcinoma",NA,Priority,Yes (indication [B] only),No,N/A,No,N/A,N/A,N/A,NA,2003-09-08,2004-03-08,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Ketek,telithromycin,Aventis Pharmaceuticals,NDA,21144,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/1/2000,4/1/2004,2004,"treatment of infections caused by susceptible strains of  designated microorganisms in the conditions listed below, for patients 18 years old and above:  acute bacterial exacerbation of chronic bronchitis,  acute bacterial sinusitis, community-acquired pneumonia (of mild to moderate severity)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-03-01,2004-04-01,1492,7.307872780763706,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1492,7.307872780763706
ChiRhoStim,human secretin,ChiRhoClin,NDA,21256,NA,NA,For Solution,Intravenous,NA,NA,NA,NA,6/14/2001,4/9/2004,2004,"indicated for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction; also indicated for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma; also indicated for stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP)",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2001-06-14,2004-04-09,1030,6.937314081223682,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,1030,6.937314081223682
Apidra,insulin glulisine,Aventis Pharmaceuticals,BLA,21629,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,6/18/2003,4/16/2004,2004,treatment of adult patients with diabetes mellitus for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-06-18,2004-04-16,303,5.713732805509369,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,303,5.713732805509369
Apokyn,apomorphine hydrochloride,Bertek Pharmaceuticals,NDA,21264,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,1/2/2003,4/20/2004,2004,"indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) associated with advanced Parkinson's disease",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-01-02,2004-04-20,474,6.161207321695077,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,474,6.161207321695077
Vitrase,hyaluronidase (ovine),Ista Pharmaceuticals,BLA,21640,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/5/2003,5/5/2004,2004,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-08-05,2004-05-05,274,5.6131281063880705,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,274,5.6131281063880705
Tindamax,tinidazole,Presutti Laboratories,NDA,21618,21681,21682,Tablet,Oral,Tablet,Oral,Tablet,Oral,7/17/2003,5/17/2004,2004,"[A] treatment of trichomoniasis
[B] treatment of giardiasis
[C] treatment of amebiasis and amebic liver abscess",NA,Standard,Yes (indication [B] and [C] only),No,N/A,No,N/A,N/A,N/A,NA,2003-07-17,2004-05-17,305,5.720311776607412,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,305,5.720311776607412
Vidaza,azacitidine,Pharmion,NDA,50794,NA,NA,Powder,"Intravenous, Subcutaneous",NA,NA,NA,NA,12/29/2003,5/19/2004,2004,"treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-12-29,2004-05-19,142,4.955827057601261,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,142,4.955827057601261
Xifaxan,rifaximin,Salix Pharmaceuticals,NDA,21361,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2001,5/25/2004,2004,treatment of patients (> 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-26,2004-05-25,881,6.78105762593618,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,881,6.78105762593618
Sanctura,trospium chloride,Indevus Pharmaceuticals,NDA,21595,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/29/2003,5/28/2004,2004,"treatment of overactive bladder associated with symptoms of urge urinary incontinence, urgency, and urinary frequency",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-04-29,2004-05-28,395,5.978885764901122,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,395,5.978885764901122
NutreStore,l-glutamine,Nutritional Restart Pharmaceutical,NDA,21667,NA,NA,For Solution,Oral,NA,NA,NA,NA,8/11/2003,6/10/2004,2004,treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth that is approved for this indication,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2003-08-11,2004-06-10,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
NeutroSpec,technetium Tc 99m fanolesomab,Palatin Technologies,BLA,103928,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/22/1999,7/2/2004,2004,indicated for scintigraphic imaging of patients with equivocal signs and symptoms of appendicitis who are five years of age or older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-11-22,2004-07-02,1684,7.428927194802272,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1684,7.428927194802272
Campral,acamprosate calcium,Lipha Pharmaceuticals,NDA,21431,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,12/27/2001,7/29/2004,2004,indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-27,2004-07-29,945,6.851184927493743,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,945,6.851184927493743
Cymbalta,duloxetine hydrochloride,Eli Lilly,NDA,21427,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,11/13/2001,8/3/2004,2004,treatment of major depressive disorder (MDD),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-11-13,2004-08-03,994,6.901737206656574,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,994,6.901737206656574
[drug marketed without a proprietary name],pentetate calcium trisodium,Hameln Pharmaceuticals GmbH,NDA,21749,NA,NA,Solution,"Inhalation, Intravenous",NA,NA,NA,NA,4/28/2004,8/11/2004,2004,"treatment of internal contamination with plutonium, americium or curium to increase the rates of elimination",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-04-28,2004-08-11,105,4.653960350157523,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,105,4.653960350157523
[drug marketed without a proprietary name],pentetate zinc trisodium,Hameln Pharmaceuticals GmbH,NDA,21751,NA,NA,Solution,"Inhalation, Intravenous",NA,NA,NA,NA,4/28/2004,8/11/2004,2004,"treatment of internal contamination with plutonium, americium or curium to increase the rates of elimination",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-04-28,2004-08-11,105,4.653960350157523,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,105,4.653960350157523
Amphadase,hyaluronidase (bovine),Amphastar Pharmaceuticals,BLA,21665,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/7/2003,10/26/2004,2004,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-07-07,2004-10-26,477,6.1675164908883415,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,477,6.1675164908883415
Fosrenol,lanthanum carbonate hydrate,Shire Pharmaceutical Development,NDA,21468,NA,NA,"Tablet, Chewable",Oral,NA,NA,NA,NA,4/30/2002,10/26/2004,2004,indicated to reduce serum phosphate in patients with end stage renal disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-04-30,2004-10-26,910,6.813444599510896,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,910,6.813444599510896
Omacor,omega-3-acid ethyl esters,Abbott Laboratories,NDA,21654,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/12/2004,11/10/2004,2004,indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with TG levels > 500 mg/dL,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-01-12,2004-11-10,303,5.713732805509369,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,303,5.713732805509369
Tarceva,erlotinib hydrochloride,OSI Pharmaceuticals,NDA,21743,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/30/2004,11/18/2004,2004,treatment of locally advanced or metastatic Non Small-Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-07-30,2004-11-18,111,4.709530201312334,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,111,4.709530201312334
Vesicare,solifenacin succinate,Yamanouchi Pharma America,NDA,21518,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2002,11/19/2004,2004,"treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-19,2004-11-19,701,6.55250788703459,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,701,6.55250788703459
Multihance,gadobenate dimeglumine,Bracco Diagnostics,NDA,21357,21358,NA,Injectable,Intravenous,Injectable,Injection,NA,NA,4/27/2001,11/23/2004,2004,"indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-04-27,2004-11-23,1306,7.174724309836376,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1306,7.174724309836376
Tysabri,natalizumab,Biogen Idec,BLA,125104,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/24/2004,11/23/2004,2004,treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations,NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,2004-05-24,2004-11-23,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Kepivance,palifermin,Amgen,BLA,125103,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/15/2004,12/15/2004,2004,indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-06-15,2004-12-15,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Lunesta,eszopiclone,Sepracor,NDA,21476,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2003,12/15/2004,2004,treatment of insomnia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-01-31,2004-12-15,684,6.52795791762255,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,684,6.52795791762255
VisionBlue,trypan blue,Dutch Ophthalmic USA,NDA,21670,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,10/27/2003,12/16/2004,2004,indicated as an aid in ophthalmic surgery by staining the anterior capsule of the lens,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2003-10-27,2004-12-16,416,6.030685260261263,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,416,6.030685260261263
Macugen,pegaptanib sodium,Eyetech Pharmaceuticals,NDA,21756,NA,NA,Injectable,Intravitreal,NA,NA,NA,NA,6/17/2004,12/17/2004,2004,treatment of neovascular (wet) age-related macular degeneration,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-06-17,2004-12-17,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Enablex,darifenacin hydrobromide,Novartis Pharmaceuticals,NDA,21513,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/3/2002,12/22/2004,2004,treatment of overactive bladder,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-03,2004-12-22,750,6.620073206530356,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,750,6.620073206530356
Prialt,ziconotide,Elan Pharmaceuticals,NDA,21060,NA,NA,Injectable,Intrathecal,NA,NA,NA,NA,12/28/1999,12/28/2004,2004,"management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2004-12-28,1827,7.510430556378006,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,1827,7.510430556378006
Clolar,clofarbine,Genzyme,NDA,21673,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/30/2004,12/28/2004,2004,treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2004-03-30,2004-12-28,273,5.60947179518496,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,273,5.60947179518496
Ventavis,iloprost,CoTherix,NDA,21779,NA,NA,Solution,Inhalation,NA,NA,NA,NA,6/30/2004,12/29/2004,2004,treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-06-30,2004-12-29,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Lyrica,pregabalin,Pfizer,NDA,21446,21723,NA,Capsule,Oral,Capsule,Oral,NA,NA,10/31/2003,12/30/2004,2004,"[A] management of neuropathic pain associated with diabetic peripheral neuropathy
[B] management of postherpetic neuralgia",NA,Priority (indication [A] only),No,No,N/A,No,N/A,N/A,N/A,NA,2003-10-31,2004-12-30,426,6.054439346269371,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,426,6.054439346269371
Symlin,pramlintide acetate,Amylin Pharmaceuticals,NDA,21332,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/8/2000,3/16/2005,2005,"indicated for type 1 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy; indicated for type 2 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy, with or without a concurrent sulfonylurea agent and/or metformin",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-08,2005-03-16,1559,7.351799869057777,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1559,7.351799869057777
Mycamine,micafungin sodium,Fujisawa Healthcare,NDA,21506,21754,NA,Injectable,Intravenous,Injectable,Injection,NA,NA,4/29/2002,3/16/2005,2005,"[A] prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
[B] treatment of esophageal candidiasis",NA,Priority (indication [A] only),No,No,N/A,No,N/A,N/A,N/A,NA,2002-04-29,2005-03-16,1052,6.9584483932976555,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,1052,6.9584483932976555
Baraclude,entecavir,Bristol-Myers Squibb,NDA,21797,21798,NA,Tablet,Oral,Solution,Oral,NA,NA,9/29/2004,3/29/2005,2005,treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2004-09-29,2005-03-29,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,181,5.198497031265826
Byetta,exenatide,Amylin Pharmaceuticals,NDA,21773,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,6/30/2004,4/28/2005,2005,"indicated to improve glycemic control in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control on metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-06-30,2005-04-28,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,302,5.71042701737487
Naglazyme,galsulfase,Biomarin Pharmaceutical,BLA,125117,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/29/2004,5/31/2005,2005,treatment of patients with Mucopolysaccharidosis VI (MPS VI),NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2004-11-29,2005-05-31,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Tygacil,tigecycline,Wyeth Pharmaceuticals,NDA,21821,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/15/2004,6/15/2005,2005,treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Complicated Intra-abdominal Infections (cIAI),NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2004-12-15,2005-06-15,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Levemir,insulin detemir,Novo Nordisk,BLA,21536,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/5/2002,6/16/2005,2005,treatment of adult patients with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2002-12-05,2005-06-16,924,6.828712071641684,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,924,6.828712071641684
Aptivus,tipranavir,Boehringer Ingelheim Pharmaceuticals,NDA,21814,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/22/2004,6/22/2005,2005,"co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors",NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,2004-12-22,2005-06-22,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Rozerem,ramelteon,Takeda Global Research & Development Center,NDA,21782,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/22/2004,7/22/2005,2005,treatment of insomnia characterized by difficulty with sleep onset,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-09-22,2005-07-22,303,5.713732805509369,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,303,5.713732805509369
Nevanac,nepafenac,Alcon,NDA,21862,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,2/28/2005,8/19/2005,2005,treatment of pain and inflammation associated with cataract surgery,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-02-28,2005-08-19,172,5.147494476813453,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,172,5.147494476813453
Increlex,mecasermin (rDNA origin),Tercica,BLA,21839,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,2/28/2005,8/30/2005,2005,long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-02-28,2005-08-30,183,5.209486152841421,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Hydase,hyaluronidase (bovine),PrimaPharm,BLA,21716,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/20/2003,10/25/2005,2005,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-10-20,2005-10-25,736,6.601230118728877,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,736,6.601230118728877
Arranon,nelarabine,GlaxoSmithKline,NDA,21877,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,4/29/2005,10/28/2005,2005,treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-04-29,2005-10-28,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Exjade,deferasirox,Novartis Pharmaceuticals,NDA,21882,NA,NA,"Tablet, For Suspension",Oral,NA,NA,NA,NA,5/2/2005,11/2/2005,2005,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-05-02,2005-11-02,184,5.214935757608986,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,184,5.214935757608986
Hylenex,hyaluronidase (human),Halozyme Therapeutics,BLA,21859,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/23/2005,12/2/2005,2005,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-03-23,2005-12-02,254,5.537334267018537,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,254,5.537334267018537
Iplex,mecasermin rinfabate (rDNA origin),Insmed,BLA,21884,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,1/3/2005,12/12/2005,2005,treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-01-03,2005-12-12,343,5.8377304471659395,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,343,5.8377304471659395
Nexavar,sorafenib tosylate,Bayer Pharmaceuticals,NDA,21923,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/8/2005,12/20/2005,2005,treatment of patients with advanced renal cell carcinoma,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-07-08,2005-12-20,165,5.10594547390058,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,165,5.10594547390058
Orencia,abatacept,Bristol-Myers Squibb,BLA,125118,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/1/2005,12/23/2005,2005,"indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti-Rheumatoid Drugs (DMARDs), such as methotrexate or TNF antagonists.  Abatacept may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists",NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2005-04-01,2005-12-23,266,5.583496308781699,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,266,5.583496308781699
Revlimid,lenalidomide,Celgene,NDA,21880,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/7/2005,12/27/2005,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-04-07,2005-12-27,264,5.575949103146316,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,264,5.575949103146316
Vaprisol,conivaptan hydrochloride,Astellas Pharma,NDA,21697,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,1/30/2004,12/29/2005,2005,treatment of euvolemic hyponatremia in hospitalized patients,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-01-30,2005-12-29,699,6.54965074223381,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,699,6.54965074223381
Sutent,sunitinib malate,Pfizer,NDA,21938,21968,NA,Capsule,Oral,Capsule,Oral,NA,NA,8/11/2005,1/26/2006,2006,"[A] treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate
[B] treatment of advanced renal cell carcinoma",NA,Priority,No,Yes (indication [B] only),N/A,Yes,N/A,N/A,N/A,NA,2005-08-11,2006-01-26,168,5.123963979403259,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,168,5.123963979403259
Ranexa,ranolazine,CV Therapeutics,NDA,21526,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/30/2002,1/27/2006,2006,treatment of chronic angina,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-30,2006-01-27,1124,7.024649030453636,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1124,7.024649030453636
Amitiza,lubiprostone,Sucampo Pharmaceuticals,NDA,21908,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2005,1/31/2006,2006,treatment of chronic idiopathic constipation in the adult population,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-03-31,2006-01-31,306,5.723585101952381,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,306,5.723585101952381
Eraxis,anidulafungin,Pfizer,NDA,21632,21948,NA,Powder,Intravenous,Injectable,Injection,NA,NA,4/25/2003,2/17/2006,2006,"[A] treatment of patients with esophageal candidiasis
[B] treatment of patients with candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis)",NA,Priority (indication [B] only),No,No,N/A,No,N/A,N/A,N/A,NA,2003-04-25,2006-02-17,1029,6.9363427358340495,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,1029,6.9363427358340495
Myozyme,alglucosidase alfa,Genzyme,BLA,125141,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/28/2005,4/28/2006,2006,treatment of Pompe disease (GAA deficiency),NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-07-28,2006-04-28,274,5.6131281063880705,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,274,5.6131281063880705
Dacogen,decitabine,MGI Pharma,NDA,21790,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,11/1/2004,5/2/2006,2006,treatment of myelodysplastic syndrome (MDS),NA,Standard,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2004-11-01,2006-05-02,547,6.304448802421981,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,547,6.304448802421981
Chantix,varenicline,Pfizer,NDA,21928,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/10/2005,5/10/2006,2006,indicated as an aid to smoking cessation treatment,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-11-10,2006-05-10,181,5.198497031265826,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,181,5.198497031265826
Azilect,rasagiline mesylate,Teva Pharmaceuticals,NDA,21641,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/5/2003,5/16/2006,2006,indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-09-05,2006-05-16,984,6.891625897052253,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,984,6.891625897052253
Prezista,darunavir,Tibotec,NDA,21976,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/2005,6/23/2006,2006,"coadministered with ritonavir, indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-12-23,2006-06-23,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Sprycel,dasatinib,Bristol-Myers Squibb,NDA,21986,22072,NA,Tablet,Oral,Tablet,Oral,NA,NA,12/28/2005,6/28/2006,2006,"[A] treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
[B] treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy",NA,Priority,Yes,Yes (indication [A] only),N/A,Yes (indication [A] only),N/A,N/A,N/A,NA,2005-12-28,2006-06-28,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Lucentis,ranibizumab,Genentech,BLA,125156,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/2005,6/30/2006,2006,treatment of patients with neovascular (wet) age-related macular degeneration,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-30,2006-06-30,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Anthelios SX,"avobenzone, ecamsule, octocrylene",L'Oreal USA Products,NDA,21502,NA,NA,Cream,Topical,NA,NA,NA,NA,5/12/2005,7/21/2006,2006,prevention of sunburn and to help provide protection from UVA and UVB rays,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-05-12,2006-07-21,435,6.075346031088684,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,435,6.075346031088684
Elaprase,idursulfase,Shire Human Genetic Therapies,BLA,125151,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/23/2005,7/24/2006,2006,"treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-11-23,2006-07-24,243,5.493061443340548,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,243,5.493061443340548
Noxafil,posaconazole,Schering,NDA,22003,NA,NA,Suspension,Oral,NA,NA,NA,NA,12/22/2005,9/15/2006,2006,"prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with Graft versus Host Disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-22,2006-09-15,267,5.58724865840025,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,267,5.58724865840025
Vectibix,panitumumab,Amgen,BLA,125147,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2006,9/27/2006,2006,"treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2006-03-29,2006-09-27,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Pylera,"biskalcitrate, metronidazole, tetracycline hydrochloride",Axcan Scandipharm,NDA,50786,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/23/2001,9/28/2006,2006,"in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-23,2006-09-28,1801,7.496097345175956,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,1801,7.496097345175956
Zolinza,vorinostat,Merck,NDA,21991,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/7/2006,10/6/2006,2006,"treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-04-07,2006-10-06,182,5.204006687076795,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Januvia,sitagliptin phosphate,Merck,NDA,21995,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/2005,10/16/2006,2006,"indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy and in combination with metformin or a PPAR? agonist (e.g., thiazolidinediones) when diet and exercise plus the single agent do not provide adequate glycemic control",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-16,2006-10-16,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
Omnaris,ciclesonide,Altana Pharma,NDA,22004,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,12/22/2005,10/20/2006,2006,treatment of seasonal and allergic rhinitis in patients 12 years of age and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-22,2006-10-20,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,302,5.71042701737487
Tyzeka,telbivudine,Idenix Pharmaceuticals,NDA,22011,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/2005,10/25/2006,2006,treatment of chronic hepatitis B (CHB) in patients with evidence of viral replication and active liver inflammation,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-30,2006-10-25,299,5.700443573390687,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,299,5.700443573390687
Veregen,kunecatechins,Medigene,NDA,21902,NA,NA,Ointment,Topical,NA,NA,NA,NA,9/30/2005,10/31/2006,2006,treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-09-30,2006-10-31,396,5.981414211254481,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,396,5.981414211254481
Invega,paliperidone,Johnson & Johnson,NDA,21999,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,11/30/2005,12/19/2006,2006,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-11-30,2006-12-19,384,5.950642552587727,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,384,5.950642552587727
Vyvanse,lisdexamfetamine dimesylate,New River Pharmaceuticals,NDA,21977,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/6/2005,2/23/2007,2007,treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-06,2007-02-23,444,6.095824562432225,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,444,6.095824562432225
Tekturna,aliskiren,Novartis Pharmaceuticals,NDA,21985,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/13/2006,3/5/2007,2007,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-02-13,2007-03-05,385,5.953243334287785,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,385,5.953243334287785
Tykerb,lapatinib,GlaxoSmithKline,NDA,22059,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/13/2006,3/13/2007,2007,"in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) and who have received prior therapy including and anthracycline, a taxane and trastuzumab",NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2006-09-13,2007-03-13,181,5.198497031265826,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,181,5.198497031265826
Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/2006,3/16/2007,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2006-09-15,2007-03-16,182,5.204006687076795,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Altabax,retapamulin,GlaxoSmithKline,NDA,22055,NA,NA,Ointment,Topical,NA,NA,NA,NA,6/12/2006,4/12/2007,2007,treatment of impetigo,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-06-12,2007-04-12,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
Neupro,rotigotine,Schwarz BioSciences,NDA,21829,NA,NA,"Film, Extended Release",Transdermal,NA,NA,NA,NA,1/28/2005,5/9/2007,2007,treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-01-28,2007-05-09,831,6.7226297948554485,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,831,6.7226297948554485
Torisel,temsirolimus,Wyeth,NDA,22088,NA,NA,Solution,Intravenous,NA,NA,NA,NA,10/5/2006,5/30/2007,2007,treatment of advanced renal cell carcinoma,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-10-05,2007-05-30,237,5.4680601411351315,Oncology,high,indication_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,237,5.4680601411351315
Letairis,ambrisentan,Gilead Sciences,NDA,22081,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/2006,6/15/2007,2007,treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-12-18,2007-06-15,179,5.187385805840755,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,179,5.187385805840755
Selzentry,maraviroc,Pfizer,NDA,22128,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2006,8/6/2007,2007,treatment of patients infected with CCR5-tropic HIV-1,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2006-12-20,2007-08-06,229,5.43372200355424,Other,high,indication_keyword_match,Priority,Other,Priority,Mid-PDUFA,229,5.43372200355424
[drug marketed without a proprietary name],ammonia N 13,Feinstein Institute for Medical Research,NDA,22119,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/25/2006,8/23/2007,2007,indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-10-25,2007-08-23,302,5.71042701737487,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,302,5.71042701737487
Somatuline Depot,lanreotide,Beaufour Ipsen Pharma,NDA,22074,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,10/30/2006,8/30/2007,2007,long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2006-10-30,2007-08-30,304,5.717027701406222,Other,high,indication_keyword_match,Standard,Other,Standard,Mid-PDUFA,304,5.717027701406222
Ixempra,ixabepilone,Bristol-Myers Squibb,NDA,22065,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,4/16/2007,10/16/2007,2007,NA,"IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting. 
IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.",Priority,No,No,N/A,No,N/A,No,No,NA,2007-04-16,2007-10-16,183,5.209486152841421,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,183,5.209486152841421
Tasigna,nilotinib,Novartis Pharmaceuticals,NDA,22068,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/29/2006,10/29/2007,2007,NA,"Tasigna (nilotinib) is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to  prior therapy that included imatinib. The effectiveness of Tasigna is based on hematologic and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.",Standard,Yes,Yes,N/A,Yes,N/A,No,No,NA,2006-09-29,2007-10-29,395,5.978885764901122,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,395,5.978885764901122
Mircera,methoxy polyethylene glycol-epoetin beta,Hoffmann-La Roche,BLA,125164,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/19/2006,11/14/2007,2007,NA,"Mircera is indicated for the treatment of anemia associated with chronic renal failure (CRF) in adults, including patients on dialysis and not on dialysis.
Mircera is not indicated for the treatment of anemia due to cancer chemotherapy.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-04-19,2007-11-14,574,6.352629396319567,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,574,6.352629396319567
Kuvan,sapropterin dihydrochloride,Biomarin Pharmaceutical,NDA,22181,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/25/2007,12/13/2007,2007,NA,Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-05-25,2007-12-13,202,5.308267697401205,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,202,5.308267697401205
Emend,fosaprepitant dimeglumine,Merck,NDA,22023,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/3/2006,1/25/2008,2008,NA,"EMEND for Injection, in combination with other antiemetic agents, is indicated for the: 
- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin 
- prevention of nausea and vomiting associated with initial and repeated courses of moderately emetogenic cancer chemotherapy.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-04-03,2008-01-25,662,6.495265555937008,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,662,6.495265555937008
Arcalyst,rilonacept,Regeneron Pharmaceuticals,BLA,125249,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/29/2007,2/27/2008,2008,NA,"ARCALYST (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndomes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-05-29,2008-02-27,274,5.6131281063880705,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,274,5.6131281063880705
Treanda,bendamustine hydrochloride,Cephalon,NDA,22249,NA,NA,Powder,Iv (Infusion),NA,NA,NA,NA,9/20/2007,3/20/2008,2008,NA,TREANDA (bendamustine hydrochloride) for Injection is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2007-09-20,2008-03-20,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Xenazine,tetrabenazine,Prestwick Pharmaceuticals,NDA,21894,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/2005,8/15/2008,2008,NA,XENAZINE is indicated for the treatment of chorea associated with Huntington's disease.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2005-09-26,2008-08-15,1054,6.960347729101308,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,1054,6.960347729101308
Nplate,romiplostim,Amgen,BLA,125268,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/23/2007,8/22/2008,2008,NA,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-10-23,2008-08-22,304,5.717027701406222,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,304,5.717027701406222
AdreView,iobenguane I 123,GE Healthcare,NDA,22290,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/21/2008,9/19/2008,2008,NA,AdreView is a radiopharmaceutical indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-03-21,2008-09-19,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Banzel,rufinamide,Eisai Medical Research,NDA,21911,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2005,11/14/2008,2008,NA,BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2005-11-17,2008-11-14,1093,6.996681488176539,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,1093,6.996681488176539
Promacta,eltrombopag,GlaxoSmithKline,NDA,22291,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2007,11/20/2008,2008,NA,"PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.",Priority,Yes,Yes,N/A,No,N/A,No,No,NA,2007-12-19,2008-11-20,337,5.820082930352362,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,337,5.820082930352362
Mozobil,plerixafor,Genzyme,NDA,22311,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,6/16/2008,12/15/2008,2008,NA,Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).,Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-06-16,2008-12-15,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Firmagon,degarelix,Ferring Pharmaceuticals,NDA,22201,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,2/28/2008,12/24/2008,2008,NA,degarelix is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.,Standard,No,No,N/A,No,N/A,No,No,NA,2008-02-28,2008-12-24,300,5.703782474656201,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,300,5.703782474656201
Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/2008,3/30/2009,2009,NA,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,N/A,No,N/A,No,No,NA,2008-06-30,2009-03-30,273,5.60947179518496,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,273,5.60947179518496
Coartem,"artemether, lumefantrine",Novartis Pharmaceuticals,NDA,22268,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/27/2008,4/7/2009,2009,NA,"Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. 
Limitations of Use: 
- Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. 
- Coartem Tablets are not approved for the prevention of malaria.",Priority,Yes,No,N/A,Yes,N/A,TD,No,NA,2008-06-27,2009-04-07,284,5.648974238161206,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,284,5.648974238161206
Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/17/2008,6/17/2009,2009,NA,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-12-17,2009-06-17,182,5.204006687076795,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Folotyn,pralatrexate,Allos Therapeutics,NDA,22468,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/24/2009,9/24/2009,2009,NA,FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.,Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-03-24,2009-09-24,184,5.214935757608986,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,184,5.214935757608986
Votrient,pazopanib,GlaxoSmithKline,NDA,22465,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2008,10/19/2009,2009,NA,VOTRIENT is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).,Standard,No,No,N/A,No,N/A,No,No,NA,2008-12-19,2009-10-19,304,5.717027701406222,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,304,5.717027701406222
Arzerra,ofatumumab,GlaxoSmithKline,BLA,125326,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/30/2009,10/26/2009,2009,NA,"ARZERRA (ofatumumab) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. 
The effectiveness of ARZERRA is based on the demonstration of durable objective responses. No data demonstrate an improvement in disease related symptoms or increased survival with ARZERRA.",Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-01-30,2009-10-26,269,5.594711379601839,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,269,5.594711379601839
Istodax,romidepsin,Gloucester Pharmaceuticals,NDA,22393,NA,NA,Powder,Intravenous,NA,NA,NA,NA,1/12/2009,11/5/2009,2009,NA,ISTODAX is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.,Standard,Yes,No,N/A,Yes,N/A,No,No,NA,2009-01-12,2009-11-05,297,5.6937321388027,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,297,5.6937321388027
Qutenza,capsaicin,Neurogesx,NDA,22395,NA,NA,Patch,Topical,NA,NA,NA,NA,10/16/2008,11/16/2009,2009,NA,Qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2008-10-16,2009-11-16,396,5.981414211254481,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,396,5.981414211254481
Kalbitor,ecallantide,Dyax,BLA,125277,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/23/2008,12/1/2009,2009,NA,KALBITOR (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-09-23,2009-12-01,434,6.073044534100405,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,434,6.073044534100405
Ampyra,dalfampridine,Acorda Therapeutics,NDA,22250,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,4/22/2009,1/22/2010,2010,NA,AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2009-04-22,2010-01-22,275,5.616771097666572,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,275,5.616771097666572
Xiaflex,clostridial collagenase histolyticum,Auxilium Pharmaceuticals,BLA,125338,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2009,2/2/2010,2010,NA,XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2009-02-27,2010-02-02,340,5.8289456176102075,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,340,5.8289456176102075
Vpriv,velaglucerase alfa,Shire Human Genetic Therapies,BLA,22575,NA,NA,Powder,Intravenous,NA,NA,NA,NA,8/31/2009,2/26/2010,2010,NA,VPRIV (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.,Priority,Yes,No,N/A,Yes,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2009-08-31,2010-02-26,179,5.187385805840755,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,179,5.187385805840755
Carbaglu,carglumic acid,Orphan Europe,NDA,22562,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/18/2009,3/18/2010,2010,NA,"Carbaglu is indicated as an adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During acute hyperammonemic episodes concomitant administration of Carbaglu with other ammonia lowering therapies such as alternate pathway medications, hemodialysis, and dietary protein restriction are recommended. 
Carbaglu is indicated for maintenance therapy in pediatric and adult patients for chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be reduced or discontinued based on plasma ammonia levels.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2009-06-18,2010-03-18,273,5.60947179518496,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,273,5.60947179518496
Lumizyme,alglucosidase alfa,Genzyme,BLA,125291,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/30/2008,5/24/2010,2010,NA,"LUMIZYME (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients 8 years and older with late (non-infantile) onset Pompe disease (acid alpha-glucosidase(GAA) deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of LUMIZYME have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-05-30,2010-05-24,724,6.584791392385716,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,724,6.584791392385716
Jevtana,cabazitaxel,Sanofi-Aventis,NDA,201023,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/31/2010,6/17/2010,2010,NA,JEVTANA is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-03-31,2010-06-17,78,4.356708826689592,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,78,4.356708826689592
Krystexxa,pegloticase,Savient Pharmaceuticals,BLA,125293,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/31/2008,9/14/2010,2010,NA,"KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment  of chronic gout in adult patients refractory to conventional therapy. 
Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. 
Important limitations of use: 
KRSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.",Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-10-31,2010-09-14,683,6.52649485957079,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,683,6.52649485957079
Halaven,eribulin mesylate,Eisai,NDA,201532,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/30/2010,11/15/2010,2010,NA,HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.  Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.,Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-03-30,2010-11-15,230,5.438079308923196,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,230,5.438079308923196
Yervoy,ipilimumab,Bristol-Myers Squibb,BLA,125377,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2010,3/25/2011,2011,NA,YERVOY (ipilimumab) is indicated for the treatment of unresectable metastatic melanoma.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-06-25,2011-03-25,273,5.60947179518496,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,273,5.60947179518496
Caprelsa,vandetanib,AstraZeneca Pharmaceuticals,NDA,22405,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/7/2010,4/6/2011,2011,NA,"Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.  
Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-07-07,2011-04-06,273,5.60947179518496,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,273,5.60947179518496
Zytiga,abiraterone acetate,Ortho Biotech Oncology Research and Development,NDA,202379,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2010,4/28/2011,2011,NA,ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.,Priority,No,No,N/A,No,N/A,No,No,NA,2010-12-20,2011-04-28,129,4.859812404361672,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,129,4.859812404361672
Nulojix,belatacept,Bristol-Myers Squibb,BLA,125288,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/1/2009,6/15/2011,2011,NA,"NULOJIX (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.  NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.  
Limitations of use:  
Use NULOJIX only in patients who are EBV seropositive.  
Use of NULOJIX for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established.",Standard,Yes,No,N/A,Yes,N/A,No,No,NA,2009-07-01,2011-06-15,714,6.570882962339584,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,714,6.570882962339584
Zelboraf,vemurafenib,Hoffmann-La Roche,NDA,202429,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/2011,8/17/2011,2011,NA,"ZELBORAF is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.  
Limitation of Use:  ZELBORAF is not recommended for use in patients with wild-type BRAF melanoma.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-04-28,2011-08-17,111,4.709530201312334,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,111,4.709530201312334
Adcetris,brentuximab vedotin,Seattle Genetics,BLA,125388,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/2011,8/19/2011,2011,NA,"These indications are based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with ADCETRIS. 
[A] ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.  
[B] ADCETRIS is indicated for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.",Priority,Yes,Yes,N/A,Yes (indication [A] only),N/A,No,No,NA,2011-02-28,2011-08-19,172,5.147494476813453,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,172,5.147494476813453
Firazyr,icatibant,Shire Orphan Therapies,NDA,22150,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/26/2007,8/25/2011,2011,NA,FIRAZYR (icatibant) is indicated for the treatment of acute attacts of hereditary angioedema (HAE) in adults 18 years of age and older.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-10-26,2011-08-25,1399,7.243512974665482,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,1399,7.243512974665482
Xalkori,crizotinib,Pfizer,NDA,202570,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2011,8/26/2011,2011,NA,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2011-03-30,2011-08-26,149,5.003946305945459,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,149,5.003946305945459
Ferriprox,deferiprone,ApoPharma,NDA,21825,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/2009,10/14/2011,2011,NA,"FERRIPROX (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. 
Approval is based on a reduction in serum ferritin levels.  There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival.  
Limitation of Use:  
- Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.",Standard,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-01-30,2011-10-14,987,6.894670039433482,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,987,6.894670039433482
Onfi,clobazam,Lundbeck,NDA,202067,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/2010,10/21/2011,2011,NA,ONFI (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2010-12-23,2011-10-21,302,5.71042701737487,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,302,5.71042701737487
Jakafi,ruxolitinib,Incyte,NDA,202192,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/3/2011,11/16/2011,2011,NA,"Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-06-03,2011-11-16,166,5.111987788356544,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,166,5.111987788356544
Erwinaze,asparaginase Erwinia chrysanthemi,EUSA Pharma,BLA,125359,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2010,11/18/2011,2011,NA,ERWINAZE (asparaginase Erwinia chrysanthemi) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-11-01,2011-11-18,382,5.945420608606575,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,382,5.945420608606575
Voraxaze,glucarpidase,BTG International,BLA,125327,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/18/2011,1/17/2012,2012,NA,"VORAXAZE (glucarpidase) is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.  
Limitation of Use:
VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-07-18,2012-01-17,183,5.209486152841421,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,183,5.209486152841421
Inlyta,axitinib,Pfizer,NDA,202324,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/14/2011,1/27/2012,2012,NA,INLYTA is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.,Standard,No,No,N/A,Yes,N/A,No,No,NA,2011-04-14,2012-01-27,288,5.662960480135946,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,288,5.662960480135946
Erivedge,vismodegib,Genentech,NDA,203388,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/8/2011,1/30/2012,2012,NA,"ERIVEDGE capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.",Priority,No,No,N/A,No,N/A,No,No,NA,2011-09-08,2012-01-30,144,4.969813299576001,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,144,4.969813299576001
Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/18/2011,1/31/2012,2012,NA,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-10-18,2012-01-31,105,4.653960350157523,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,105,4.653960350157523
Omontys,peginesatide,Affymax,NDA,202799,NA,NA,Solution,"Intravenous, Subcutaneous",NA,NA,NA,NA,5/27/2011,3/27/2012,2012,NA,"OMONTYS is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  
Limitations of Use:
OMONTYS is not indicated and is not recommended for use: 
- In patients with CKD not on dialysis because of safety concerns in this population.  
- In patients receiving treatment for cancer and whose anemia is not due to CKD, because ESAs have shown harm in some settings and the benefit-risk factors for OMONTYS in this setting have not been evaluated.  
- As a substitute for RBC transfusions in patients who require immediate correction of anemia.  
- OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life.",Standard,No,No,N/A,No,N/A,No,No,NA,2011-05-27,2012-03-27,305,5.720311776607412,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,305,5.720311776607412
Elelyso,taliglucerase alfa,Protalix,BLA,22458,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/26/2010,5/1/2012,2012,NA,ELELYSO (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.,Standard,Yes,No,N/A,Yes,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2010-04-26,2012-05-01,736,6.601230118728877,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,736,6.601230118728877
Perjeta,pertuzumab,Genentech,BLA,125409,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/8/2011,6/8/2012,2012,NA,PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,Priority,No,No,N/A,No,N/A,No,No,NA,2011-12-08,2012-06-08,183,5.209486152841421,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,183,5.209486152841421
Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,NA,NA,Powder,Intravenous,NA,NA,NA,NA,9/27/2011,7/20/2012,2012,NA,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified.",Standard,Yes,Yes,No,Yes,No,No,No,NA,2011-09-27,2012-07-20,297,5.6937321388027,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,297,5.6937321388027
Zaltrap,ziv-aflibercept,Sanofi-Aventis,BLA,125418,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/3/2012,8/3/2012,2012,NA,"ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.",Priority,No,No,No,No,N/A,No,No,NA,2012-02-03,2012-08-03,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,182,5.204006687076795
Granix,tbo-filgrastim,Sicor Biotech,BLA,125294,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/30/2009,8/29/2012,2012,NA,Tbo-filgrastim is indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Standard,No,No,No,No,N/A,No,No,NA,2009-11-30,2012-08-29,1003,6.910750787961936,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,1003,6.910750787961936
Xtandi,enzalutamide,Medivation,NDA,203415,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/22/2012,8/31/2012,2012,NA,XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.,Priority,No,No,No,Yes,No,No,No,NA,2012-05-22,2012-08-31,101,4.61512051684126,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,101,4.61512051684126
Bosulif,bosutinib,Wyeth Pharmaceuticals,NDA,203341,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2011,9/4/2012,2012,NA,"BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",Standard,Yes,No,No,No,No,No,No,NA,2011-11-17,2012-09-04,292,5.676753802268282,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,292,5.676753802268282
[drug marketed without a proprietary name],choline C 11,Mayo Clinic,NDA,203155,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/12/2011,9/12/2012,2012,NA,"Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI).  In these patients, 11C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation.  Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.  In clinical studies, images were produced with PET/CT coregistration. 
Limitation of Use: 11C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer.",Priority,No,No,No,No,No,No,No,NA,2011-12-12,2012-09-12,275,5.616771097666572,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,275,5.616771097666572
Stivarga,regorafenib,Bayer HealthCare Pharmaceuticals,NDA,203085,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/27/2012,9/27/2012,2012,NA,"Stivarga is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and anti-VEGF therapy, and, if KRAS wild type, and anti-EGFR therapy.",Priority,No,No,No,Yes,No,No,No,NA,2012-04-27,2012-09-27,153,5.030437921392435,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,153,5.030437921392435
Synribo,omacetaxine mepesuccinate,Ivax International GmbH,NDA,203585,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,3/30/2012,10/26/2012,2012,NA,SYNRIBO is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).  This indication is based upon response rate.  There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.,Standard,Yes,Yes,No,Yes,No,No,No,NA,2012-03-30,2012-10-26,210,5.3471075307174685,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Mid-PDUFA,210,5.3471075307174685
Cometriq,cabozantinib,Exelixis,NDA,203756,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/29/2012,11/29/2012,2012,NA,"COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).",Priority,Yes,No,No,Yes,No,No,No,NA,2012-05-29,2012-11-29,184,5.214935757608986,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,184,5.214935757608986
[drug marketed without a proprietary name],raxibacumab,Human Genome Sciences,BLA,125349,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/14/2009,12/14/2012,2012,NA,"Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.  Raxibacumab is also indicated for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.  
Limitations of Use:
The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax.  It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.  
Safety and pharmacokinetics (PK) of raxibacumab have been studied in healthy volunteers.  There have been no studies of safety or PK of raxibacumab in the pediatric population.  A population PK approach was used to derive dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults. 
Raxibacumab binds to the protective antigen (PA) of B. anthracis; it does not have direct antibacterial activity.  Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis.  Raxibacumab should be used in combination with appropriate antibacterial drugs.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2009-05-14,2012-12-14,1310,7.177782416195197,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,1310,7.177782416195197
Signifor,pasireotide,Novartis Pharmaceuticals,NDA,200677,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,2/17/2012,12/14/2012,2012,NA,SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.,Standard,Yes,No,No,No,No,No,No,NA,2012-02-17,2012-12-14,301,5.707110264748875,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,301,5.707110264748875
Iclusig,ponatinib,Ariad Pharmaceuticals,NDA,203469,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/27/2012,12/14/2012,2012,NA,"Iclusig (ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. 
This indication is based upon response rate.  There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2012-09-27,2012-12-14,78,4.356708826689592,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Mid-PDUFA,78,4.356708826689592
Juxtapid,lomitapide,Aegerion Pharmaceuticals,NDA,203858,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/29/2012,12/21/2012,2012,NA,"JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use: 
- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH. 
- The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.",Standard,Yes,No,No,No,No,No,No,NA,2012-02-29,2012-12-21,296,5.69035945432406,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,296,5.69035945432406
Gattex,teduglutide (rDNA origin),NPS Pharmaceuticals,NDA,203441,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,11/30/2011,12/21/2012,2012,NA,GATTEX (teduglutide [rDNA origin]) for injection is indicated for the treatment of adult patiens with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,Standard,Yes,No,No,No,No,No,No,NA,2011-11-30,2012-12-21,387,5.958424693029782,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Mid-PDUFA,387,5.958424693029782
Sirturo,bedaquiline,Janssen Research & Development,NDA,204384,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2012,12/28/2012,2012,NA,"SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>= 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).  Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.  SIRTURO should be administered by directly observed therapy (DOT). 
This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. 
Limitations of Use: 
The safety and efficacy of SIRTURO for the treatment of latent infection due to Mycobacterium tuberculosis has not been established.  The safety and efficacy of SIRTURO for the treatment of drug-sensitive TB has not been established.  In addition, there are no data on the treatment with SIRTURO of extra-pulmonary TB (e.g., central nervous system).  Therefore, use of SIRTURO in these settings is not recommended.",Priority,Yes,Yes,No,Yes,No,TD,No,NA,2012-06-29,2012-12-28,182,5.204006687076795,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Mid-PDUFA,182,5.204006687076795
Kynamro,mipomersen sodium,Genzyme,NDA,203568,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/29/2012,1/29/2013,2013,NA,"KYNAMRO is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use : 
- The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH.  
- The effect of KYNAMRO on cardiovascular morbidity has not been determined.  
- The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have not been established; therefore, the use of KYNAMRO as an adjunct to LDL apheresis is not recommended.",Standard,Yes,No,No,No,No,No,No,NA,2012-03-29,2013-01-29,306,5.723585101952381,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,306,5.723585101952381
Pomalyst,pomalidomide,Celgene,NDA,204026,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/10/2012,2/8/2013,2013,NA,"POMALYST is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified.",Standard,Yes,Yes,No,Yes,No,No,No,NA,2012-04-10,2013-02-08,304,5.717027701406222,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,304,5.717027701406222
Kadcyla,ado-trastuzumab emtansine,Genentech,BLA,125427,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/27/2012,2/22/2013,2013,NA,"KADCYLA, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.  Patients should have either: 
- received prior therapy for metastatic disease, or, 
- developed disease recurrence during or within six months of completing adjuvant therapy.",Priority,No,No,No,Yes,N/A,No,No,NA,2012-08-27,2013-02-22,179,5.187385805840755,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,179,5.187385805840755
Lymphoseek,technetium Tc 99m tilmanocept,Navidea Biopharmaceuticals,NDA,202207,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/10/2011,3/13/2013,2013,NA,Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a handheld gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.,Standard,No,No,No,No,No,No,No,NA,2011-08-10,2013-03-13,581,6.364750756851911,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,581,6.364750756851911
Xofigo,radium Ra 223 dichloride,Bayer HealthCare Pharmaceuticals,NDA,203971,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/14/2012,5/15/2013,2013,NA,"Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.",Priority,No,No,No,Yes,No,No,No,NA,2012-12-14,2013-05-15,152,5.0238805208462765,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,152,5.0238805208462765
Tafinlar,dabrafenib,GlaxoSmithKline,NDA,202806,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/30/2012,5/29/2013,2013,NA,"TAFINLAR is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. 
TAFINLAR is not indicated for the treatment of patients with wild-type BRAF melanoma. 

Unresectable or metastatic melanoma with BRAF V600E mutation as detected
by an FDA-approved test. 
Limitation of use: TAFINLAR is not indicated for treatment of patients with
wild-type BRAF melanoma.",Standard,Yes,No,No,Yes,No,No,No,NA,2012-07-30,2013-05-29,303,5.713732805509369,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,303,5.713732805509369
Mekinist,trametinib,GlaxoSmithKline,NDA,204114,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/3/2012,5/29/2013,2013,NA,"MEKINIST is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  
MEKINIST is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.",Standard,Yes,No,No,Yes,No,No,No,NA,2012-08-03,2013-05-29,299,5.700443573390687,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,299,5.700443573390687
Gilotrif,afatinib,Boehringer Ingelheim Pharmaceuticals,NDA,201292,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/2012,7/12/2013,2013,NA,"GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  
Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.",Priority,Yes,No,No,Yes,No,No,No,NA,2012-11-15,2013-07-12,239,5.476463551931511,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,239,5.476463551931511
Adempas,riociguat,Bayer HealthCare Pharmaceuticals,NDA,204819,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/8/2013,10/8/2013,2013,NA,"Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. 
Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. 
Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids.  Studies establishing effectiveness including predominantly patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue disease (25%).",Priority,Yes,No,No,No,No,No,No,NA,2013-02-08,2013-10-08,242,5.488937726156687,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,242,5.488937726156687
Opsumit,macitentan,Actelion Pharmaceuticals,NDA,204410,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/19/2012,10/18/2013,2013,NA,"OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.  Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening or PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).  OPSUMIT also reduced hospitalization for PAH. 
Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years.  Patients were treated with OPSUMIT monotherapy or in combination with phosphodieasterase-5 inhibitors or inhaled prostanoids.  Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).",Standard,Yes,No,No,No,No,No,No,NA,2012-10-19,2013-10-18,364,5.8971538676367405,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,364,5.8971538676367405
Gazyva,obinutuzumab,Genentech,BLA,125486,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/22/2013,11/1/2013,2013,NA,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).",Priority,Yes,No,Yes,No,N/A,No,No,NA,2013-04-22,2013-11-01,193,5.262690188904886,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,193,5.262690188904886
Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/28/2013,11/13/2013,2013,NA,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2013-06-28,2013-11-13,138,4.927253685157205,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,138,4.927253685157205
Sovaldi,sofosbuvir,Gilead Sciences,NDA,204671,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/8/2013,12/6/2013,2013,NA,"SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. 
- SOVALDI efficacy has been established in subjects with HCV genotype 1, 2, 3, or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.  
The following points should be considered when initiating treatment with SOVALDI: 
- Monotherapy of SOVALDI is not recommended for treatment of CHC. 
- Treatment regimen and duration are dependent on both viral genotype and patient population.  
- Treatment response varies based on baseline host and viral factors.",Priority,No,No,Yes,Yes,No,No,No,NA,2013-04-08,2013-12-06,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Hetlioz,tasimelteon,Vanda Pharmaceuticals,NDA,205677,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/31/2013,1/31/2014,2014,NA,HETLIOZ is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).,Priority,Yes,No,No,No,No,No,No,NA,2013-05-31,2014-01-31,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Vimizim,elosulfase alfa,BioMarin Pharmaceutical,BLA,125460,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2013,2/14/2014,2014,NA,Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2013-03-29,2014-02-14,322,5.7745515455444085,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,322,5.7745515455444085
Northera,droxidopa,Chelsea Therapeutics,NDA,203202,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/28/2011,2/18/2014,2014,NA,"NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system atrophy and pure autonomic failure], dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2011-09-28,2014-02-18,874,6.773080375655535,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,874,6.773080375655535
Myalept,metreleptin,Amylin Pharmaceuticals,BLA,125390,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/27/2013,2/24/2014,2014,NA,"MYALEPT (metreleptin for injection) is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.  
Limitations of Use: 
- The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established.  
- The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established.  
- MYALEPT is not indicated for use in patients with HIV-related lipodystrphy.  
- MYALEPT is not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2013-03-27,2014-02-24,334,5.811140992976701,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,334,5.811140992976701
Impavido,miltefosine,Paladin Therapeutics,NDA,204684,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/19/2013,3/19/2014,2014,NA,"IMPAVIDO (miltefosine) capsules are indicated in adults and adolescents >= 12 years of age weighing  >= 30 kg for the treatment of: 
- Visceral leishmaniasis caused by Leishmania donovani. 
- Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis. 
- Mucosal leishmaniasis caused by Leishmania braziliensis. 
Limitations of Use: 
- Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data. 
- There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO. 
- The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.",Priority,Yes,No,No,Yes,No,TD,No,NA,2013-04-19,2014-03-19,334,5.811140992976701,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,334,5.811140992976701
Cyramza,ramucirumab,Eli Lilly,BLA,125477,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/23/2013,4/21/2014,2014,NA,"Cyramza as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum- containing chemotherapy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2013-08-23,2014-04-21,241,5.484796933490655,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,241,5.484796933490655
Sylvant,siltuximab,Janssen Biotech,BLA,125496,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/30/2013,4/23/2014,2014,NA,"SYLVANT is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. 
Limitation of Use: 
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.",Priority,Yes,No,No,No,N/A,No,No,NA,2013-08-30,2014-04-23,236,5.4638318050256105,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,236,5.4638318050256105
Zykadia,ceritinib,Novartis Pharmaceuticals,NDA,205755,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/24/2013,4/29/2014,2014,NA,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,Priority,Yes,Yes,Yes,No,No,No,No,NA,2013-12-24,2014-04-29,126,4.836281906951478,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,126,4.836281906951478
Entyvio,vedolizumab,Takeda Pharmaceuticals,BLA,125476,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/20/2013,5/20/2014,2014,NA,"Entyvio (vedolizumab) is indicated for: -inducing and maintaining clinical response, 
- inducing and maintaining clinical remission, 
- improving the endoscopic appearance of the mucosa, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. 
Entyvio (vedolizumab) is indicated for: 
- achieving clinical response, 
- achieving clinical remission, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.",Priority,No,No,No,Yes,N/A,No,No,NA,2013-06-20,2014-05-20,334,5.811140992976701,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,334,5.811140992976701
Beleodaq,belinostat,Spectrum Pharmaceuticals,NDA,206256,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/9/2013,7/3/2014,2014,NA,"Beleodaq is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 
This indication is approved under accelerated approval based on tumor response rate and duration of response.  An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2013-12-09,2014-07-03,206,5.327876168789581,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,206,5.327876168789581
Zydelig,idelalisib,Gilead Sciences,NDA,206545,205858,NA,Tablet,Oral,Tablet,Oral,NA,NA,9/11/2013,7/23/2014,2014,NA,"[A] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
[B] Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on Overall Response Rate.  An improvement in patient survival or disease related symptoms has not been established. Continues approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials. 
[C] Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.  Accelerated approval was granted for this indication based on Overall Response Rate. An improvement in patient survival or disease related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.",Priority (indication [A] only),Yes,Yes (indications [B] and [C] only),Yes (indication [A] only),Yes (indication [A] only),No,No,No,NA,2013-09-11,2014-07-23,315,5.752572638825633,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,315,5.752572638825633
Cerdelga,eliglustat,Genzyme,NDA,205494,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/20/2013,8/19/2014,2014,NA,"CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. 
Limitations of Use: 
- Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.  
- A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).",Priority,Yes,No,No,No,No,No,No,NA,2013-09-20,2014-08-19,333,5.808142489980444,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,333,5.808142489980444
Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2014,9/4/2014,2014,NA,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2014-02-27,2014-09-04,189,5.241747015059643,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,189,5.241747015059643
Movantik,naloxegol,AstraZeneca Pharmaceuticals,NDA,204760,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/16/2013,9/16/2014,2014,NA,MOVANTIK (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No,No,No,No,NA,2013-09-16,2014-09-16,365,5.8998973535824915,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,365,5.8998973535824915
Akynzeo,"netupitant, palonosetron",Helsinn Healthcare,NDA,205718,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2013,10/10/2014,2014,NA,"AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2013-09-27,2014-10-10,378,5.934894195619588,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,378,5.934894195619588
Esbriet,pirfenidone,Intermune,NDA,22535,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/4/2009,10/15/2014,2014,NA,ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF),Priority,Yes,No,Yes,Yes,No,No,No,NA,2009-11-04,2014-10-15,1806,7.498869733976931,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,1806,7.498869733976931
Ofev,nintedanib,Boehringer Ingelheim Pharmaceuticals,NDA,205832,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/2/2014,10/15/2014,2014,NA,OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2014-05-02,2014-10-15,166,5.111987788356544,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,166,5.111987788356544
Blincyto,blinatumomab,Amgen,BLA,125557,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/19/2014,12/3/2014,2014,NA,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2014-09-19,2014-12-03,75,4.31748811353631,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,75,4.31748811353631
Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/3/2014,12/19/2014,2014,NA,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2014-02-03,2014-12-19,319,5.765191102784844,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,319,5.765191102784844
Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/30/2014,12/22/2014,2014,NA,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2014-07-30,2014-12-22,145,4.976733742420574,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,145,4.976733742420574
Natpara,parathyroid hormone,NPS Pharmaceuticals,BLA,125511,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2013,1/23/2015,2015,NA,"NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.  
Limitations of use: 
- Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. 
- NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations.  
- NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.",Standard,Yes,No,No,No,N/A,No,No,NA,2013-10-24,2015-01-23,456,6.1224928095143865,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,456,6.1224928095143865
Ibrance,palbociclib,Pfizer,NDA,207103,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/13/2014,2/3/2015,2015,NA,"IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. 
This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,No,No,No,No,NA,2014-08-13,2015-02-03,174,5.159055299214529,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,174,5.159055299214529
Lenvima,lenvatinib,Eisai,NDA,206947,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/14/2014,2/13/2015,2015,NA,"LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).",Priority,Yes,No,No,No,No,No,No,NA,2014-08-14,2015-02-13,183,5.209486152841421,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,183,5.209486152841421
Farydak,panobinostat,Novartis Pharmaceuticals,NDA,205353,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/24/2014,2/23/2015,2015,NA,"FARYDAK, a histone deacetylase inhibitor, in combination with bortezomin and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.  This indication is approved under accelerated approval based on progression free survival.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2014-03-24,2015-02-23,336,5.817111159963204,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,336,5.817111159963204
Cresemba,isavuconazonium sulfate,Astellas Pharma,NDA,207500,207501,NA,Capsule,Oral,Injectable,Injection,NA,NA,7/8/2014,3/6/2015,2015,NA,"CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis.
CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive mucormycosis.
Usage:
Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.",Priority,Yes,No,No,No,Yes,No,No,NA,2014-07-08,2015-03-06,241,5.484796933490655,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,241,5.484796933490655
Unituxin,dinutuximab,United Therapeutics,BLA,125516,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/11/2014,3/10/2015,2015,NA,"Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.",Priority,Yes,No,No,No,N/A,RPD,No,NA,2014-04-11,2015-03-10,333,5.808142489980444,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,333,5.808142489980444
Cholbam,cholic acid,Asklepion Pharmaceuticals,NDA,205750,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/21/2013,3/17/2015,2015,NA,"CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). 
CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption. 
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.",Priority,Yes,No,No,No,No,RPD,No,NA,2013-11-21,2015-03-17,481,6.175867270105761,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,481,6.175867270105761
Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/5/2014,7/2/2015,2015,NA,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes,No,No,No,NA,2014-11-05,2015-07-02,239,5.476463551931511,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,239,5.476463551931511
Odomzo,sonidegib,Novartis Pharmaceuticals,NDA,205266,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/26/2014,7/24/2015,2015,NA,"ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.",Standard,No,No,No,No,No,No,No,NA,2014-09-26,2015-07-24,301,5.707110264748875,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,301,5.707110264748875
Varubi,rolapitant,Tesaro,NDA,206500,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/5/2014,9/1/2015,2015,NA,"VARUBI is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2014-09-05,2015-09-01,361,5.8888779583328805,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,361,5.8888779583328805
Xuriden,uridine triacetate,Wellstat Therapeutics,NDA,208169,NA,NA,Granule,Oral,NA,NA,NA,NA,1/8/2015,9/4/2015,2015,NA,XURIDEN is indicated for the treatment of hereditary orotic aciduria.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2015-01-08,2015-09-04,239,5.476463551931511,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,239,5.476463551931511
Lonsurf,trifluridine and tipiracil,Taiho Oncology,NDA,207981,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2014,9/22/2015,2015,NA,"LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.",Standard,No,No,No,Yes,No,No,No,NA,2014-12-19,2015-09-22,277,5.6240175061873385,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,277,5.6240175061873385
Praxbind,idarucizumab,Boehringer Ingelheim Pharmaceuticals,BLA,761025,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/19/2015,10/16/2015,2015,NA,"PRAXBIND is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: 
- For emergency surgery/urgent procedures
- In life-threatening or uncontrolled bleeding
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2015-02-19,2015-10-16,239,5.476463551931511,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,239,5.476463551931511
Strensiq,asfotase alfa,Alexion Pharmaceuticals,BLA,125513,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/2014,10/23/2015,2015,NA,Strensiq is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2014-12-23,2015-10-23,304,5.717027701406222,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,304,5.717027701406222
Yondelis,trabectedin,Janssen Products,NDA,207953,NA,NA,Powder,Intravenous,NA,NA,NA,NA,11/24/2014,10/23/2015,2015,NA,YONDELIS is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.,Priority,Yes,No,No,No,No,No,No,NA,2014-11-24,2015-10-23,333,5.808142489980444,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,333,5.808142489980444
Cotellic,cobimetinib,Genentech,NDA,206192,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/2014,11/10/2015,2015,NA,"COTELLIC is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 
Limitation of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",Priority,Yes,No,No,Yes,No,No,No,NA,2014-12-11,2015-11-10,334,5.811140992976701,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,334,5.811140992976701
Tagrisso,osimertinib,AstraZeneca Pharmaceuticals,NDA,208065,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/5/2015,11/13/2015,2015,NA,"TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. 
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2015-06-05,2015-11-13,161,5.081404364984463,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,161,5.081404364984463
Darzalex,daratumumab,Janssen Biotech,BLA,761036,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/9/2015,11/16/2015,2015,NA,"DARZALEX is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2015-07-09,2015-11-16,130,4.867534450455582,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,130,4.867534450455582
Ninlaro,ixazomib,Millennium Pharmaceuticals,NDA,208462,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/10/2015,11/20/2015,2015,NA,NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.,Priority,Yes,No,No,No,No,No,No,NA,2015-07-10,2015-11-20,133,4.890349128221754,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,133,4.890349128221754
Portrazza,necitumumab,Eli Lilly,BLA,125547,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/2/2014,11/24/2015,2015,NA,"PORTRAZZA is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. 
Limitation of Use:
PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.",Standard,Yes,No,No,Yes,N/A,No,No,NA,2014-12-02,2015-11-24,357,5.877735781779639,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,357,5.877735781779639
Empliciti,elotuzumab,Bristol-Myers Squibb,BLA,761035,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/2015,11/30/2015,2015,NA,EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2015-06-29,2015-11-30,154,5.0369526024136295,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,154,5.0369526024136295
Kanuma,sebelipase alfa,Alexion Pharmaceuticals,BLA,125561,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/8/2015,12/8/2015,2015,NA,KANUMA is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2015-01-08,2015-12-08,334,5.811140992976701,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,334,5.811140992976701
Alecensa,alectinib,Hoffmann-La Roche,NDA,208434,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/6/2015,12/11/2015,2015,NA,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2015-07-06,2015-12-11,158,5.062595033026967,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,158,5.062595033026967
Uptravi,selexipag,Actelion Pharmaceuticals,NDA,207947,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/2014,12/21/2015,2015,NA,"UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).",Standard,Yes,No,No,No,No,No,No,NA,2014-12-22,2015-12-21,364,5.8971538676367405,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,364,5.8971538676367405
Anthim,obiltoxaximab,Elusys Therapeutics,BLA,125509,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/2015,3/18/2016,2016,NA,"ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. 
ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate. 
Limitations of Use:
ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis.
The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.
Safety and PK of ANTHIM have been studied in adult healthy volunteers. There have been no studies of safety or PK of ANTHIM in the pediatric population. A population PK approach was used to derive intravenous infusion dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults.
ANTHIM binds to the protective antigen (PA) component of B. anthracis toxin; it does not have direct antibacterial activity. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ANTHIM should be used in combination with appropriate antibacterial drugs.",Standard,Yes,No,No,Yes,N/A,No,No,NA,2015-03-20,2016-03-18,364,5.8971538676367405,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,364,5.8971538676367405
Defitelio,defibrotide sodium,Jazz Pharmaceuticals,NDA,208114,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/31/2015,3/30/2016,2016,NA,"DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).",Priority,Yes,No,No,Yes,No,No,No,NA,2015-07-31,2016-03-30,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Venclexta,venetoclax,AbbVie,NDA,208573,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/29/2015,4/11/2016,2016,NA,"VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2015-10-29,2016-04-11,165,5.10594547390058,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,165,5.10594547390058
Tecentriq,atezolizumab,Genentech,BLA,761034,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/12/2016,5/18/2016,2016,NA,"TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2016-01-12,2016-05-18,127,4.844187086458591,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,127,4.844187086458591
Axumin,fluciclovine F 18,Blue Earth Diagnostics,NDA,208054,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/28/2015,5/27/2016,2016,NA,Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.,Priority,No,No,No,No,No,No,No,NA,2015-09-28,2016-05-27,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Ocaliva,obeticholic acid,Intercept Pharmaceuticals,NDA,207999,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2015,5/27/2016,2016,NA,"OCALIVA is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2015-06-29,2016-05-27,333,5.808142489980444,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,333,5.808142489980444
Netspot,gallium Ga 68 dotatate,Advanced Accelerator Applications,NDA,208547,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/1/2015,6/1/2016,2016,NA,"NETSPOT, after radiolabeling with Ga 68, is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.",Priority,Yes,No,No,No,No,No,No,NA,2015-07-01,2016-06-01,336,5.817111159963204,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,336,5.817111159963204
Exondys 51,eteplirsen,Sarepta Therapeutics,NDA,206488,NA,NA,Solution,Intravenous,NA,NA,NA,NA,6/26/2015,9/19/2016,2016,NA,EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2015-06-26,2016-09-19,451,6.111467339502679,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,451,6.111467339502679
Lartruvo,olaratumab,Eli Lilly,BLA,761038,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/24/2016,10/19/2016,2016,NA,"LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2016-02-24,2016-10-19,238,5.472270673671475,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,238,5.472270673671475
Rubraca,rucaparib,Clovis Oncology,NDA,209115,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/23/2016,12/19/2016,2016,NA,"Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2016-06-23,2016-12-19,179,5.187385805840755,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,179,5.187385805840755
Spinraza,nusinersen,Biogen,NDA,209531,NA,NA,Solution,Intrathecal,NA,NA,NA,NA,9/23/2016,12/23/2016,2016,NA,SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2016-09-23,2016-12-23,91,4.51085950651685,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,91,4.51085950651685
Parsabiv,etelcalcetide,Amgen,NDA,208325,NA,NA,Solution,Intravenous,NA,NA,NA,NA,8/24/2015,2/7/2017,2017,NA,"PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Limitations of Use:
PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations.",Standard,No,No,No,No,No,No,No,NA,2015-08-24,2017-02-07,533,6.278521424165844,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,533,6.278521424165844
Emflaza,deflazacort,Marathon Pharmaceuticals,NDA,208684,208685,NA,Tablet,Oral,Solution,Oral,NA,NA,6/9/2016,2/9/2017,2017,NA,EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2016-06-09,2017-02-09,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Xermelo,telotristat ethyl,Lexicon Pharmaceuticals,NDA,208794,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/30/2016,2/28/2017,2017,NA,Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,Priority,Yes,No,No,Yes,No,No,No,NA,2016-03-30,2017-02-28,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Kisqali,ribociclib,Novartis Pharmaceuticals,NDA,209092,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/2016,3/13/2017,2017,NA,"KISQALI is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer.",Priority,No,No,Yes,No,No,No,No,NA,2016-08-29,2017-03-13,196,5.278114659230517,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,196,5.278114659230517
Bavencio,avelumab,EMD Serono,BLA,761049,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/23/2016,3/23/2017,2017,NA,"BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2016-09-23,2017-03-23,181,5.198497031265826,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,181,5.198497031265826
Symproic,naldemedine,Shionogi,NDA,208854,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/2016,3/23/2017,2017,NA,Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No,No,No,No,NA,2016-03-23,2017-03-23,365,5.8998973535824915,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,365,5.8998973535824915
Zejula,niraparib,Tesaro,NDA,208447,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/31/2016,3/27/2017,2017,NA,"ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Priority,Yes,No,Yes,Yes,No,No,No,NA,2016-10-31,2017-03-27,147,4.990432586778736,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,147,4.990432586778736
Austedo,deutetrabenazine,Teva Pharmaceuticals,NDA,208082,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/29/2015,4/3/2017,2017,NA,AUSTEDO is indicated for the treatment of chorea associated with Huntington’s disease.,Standard,Yes,No,No,No,No,No,No,NA,2015-05-29,2017-04-03,675,6.51471269087253,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,675,6.51471269087253
Brineura,cerliponase alfa,BioMarin Pharmaceutical,BLA,761052,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/27/2016,4/27/2017,2017,NA,"Brineura is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",Priority,Yes,No,Yes,No,N/A,RPD,No,NA,2016-05-27,2017-04-27,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Rydapt,midostaurin,Novartis Pharmaceuticals,NDA,207997,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/29/2016,4/28/2017,2017,NA,"[A] RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.
Limitations of Use:  RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
[B] RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).",Priority,Yes,No,Yes (indication [A] only),Yes (indication [B] only),No,No,No,NA,2016-08-29,2017-04-28,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Tymlos,abaloparatide,Radius Health,NDA,208743,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/30/2016,4/28/2017,2017,NA,"TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
Limitations of Use:
Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.",Standard,No,No,No,No,No,No,No,NA,2016-03-30,2017-04-28,394,5.976350909297934,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,394,5.976350909297934
Alunbrig,brigatinib,Ariad Pharmaceuticals,NDA,208772,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/2016,4/28/2017,2017,NA,"ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2016-08-29,2017-04-28,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Imfinzi,durvalumab,AstraZeneca UK Limited,BLA,761069,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/13/2016,5/1/2017,2017,NA,"IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2016-10-13,2017-05-01,200,5.298317366548036,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,200,5.298317366548036
Radicava,edaravone,Mitsubishi Tanabe Pharma Development,NDA,209176,NA,NA,Solution,Intravenous,NA,NA,NA,NA,6/16/2016,5/5/2017,2017,NA,RADICAVA is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,Standard,Yes,No,No,No,No,No,No,NA,2016-06-16,2017-05-05,323,5.777652323222656,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,323,5.777652323222656
Nerlynx,neratinib,Puma Biotechnology,NDA,208051,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/19/2016,7/17/2017,2017,NA,"NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.",Standard,No,No,No,No,No,No,No,NA,2016-07-19,2017-07-17,363,5.8944028342648505,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,363,5.8944028342648505
Idhifa,enasidenib,Celgene,NDA,209606,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/2016,8/1/2017,2017,NA,IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2016-12-30,2017-08-01,214,5.365976015021851,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,214,5.365976015021851
Besponsa,inotuzumab ozogamicin,Pfizer,BLA,761040,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/20/2016,8/17/2017,2017,NA,BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,Priority,Yes,No,Yes,No,N/A,No,No,NA,2016-12-20,2017-08-17,240,5.480638923341991,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,240,5.480638923341991
[drug marketed without a proprietary name],benznidazole,"Chemo Research, S.L.",NDA,209570,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/2016,8/29/2017,2017,NA,"Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.
This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,TD,No,NA,2016-12-29,2017-08-29,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Aliqopa,copanlisib,Bayer HealthCare Pharmaceuticals,NDA,209936,NA,NA,Powder,Intravenous,NA,NA,NA,NA,3/16/2017,9/14/2017,2017,NA,"ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. 
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2017-03-16,2017-09-14,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,182,5.204006687076795
Verzenio,abemaciclib,Eli Lilly,NDA,208716,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/5/2017,9/28/2017,2017,NA,"VERZENIO (abemaciclib) is indicated:
- in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",Priority,No,No,Yes,Yes,No,No,No,NA,2017-05-05,2017-09-28,146,4.983606621708336,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,146,4.983606621708336
Calquence,acalabrutinib,Acerta Pharma B.V.,NDA,210259,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/13/2017,10/31/2017,2017,NA,"CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2017-06-13,2017-10-31,140,4.941642422609304,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,140,4.941642422609304
Prevymis,letermovir,Merck,NDA,209939,209940,NA,Tablet,Oral,Injectable,Injection,NA,NA,3/8/2017,11/8/2017,2017,NA,PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2017-03-08,2017-11-08,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Mepsevii,vestronidase alfa-vjbk,Ultragenyx Pharmaceutical,BLA,761047,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/16/2017,11/15/2017,2017,NA,"MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Limitations of Use:
The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.",Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2017-03-16,2017-11-15,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Hemlibra,emicizumab-kxwh,Genentech,BLA,761083,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2017,11/16/2017,2017,NA,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2017-06-23,2017-11-16,146,4.983606621708336,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,146,4.983606621708336
Ozempic,semaglutide,Novo Nordisk,NDA,209637,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,12/5/2016,12/5/2017,2017,NA,"OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- OZEMPIC is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.",Standard,No,No,No,No,No,No,No,NA,2016-12-05,2017-12-05,365,5.8998973535824915,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,365,5.8998973535824915
Macrilen,macimorelin,Aeterna Zentaris GmBH,NDA,205598,NA,NA,For Solution,Oral,NA,NA,NA,NA,11/5/2013,12/20/2017,2017,NA,"MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Limitations of Use:
The safety and diagnostic performance of MACRILEN have not been established for subjects with a body mass index (BMI) > 40 kg/m2.",Standard,Yes,No,No,No,No,No,No,NA,2013-11-05,2017-12-20,1506,7.317212408359839,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,1506,7.317212408359839
Lutathera,lutetium Lu 177 dotatate,Advanced Accelerator Applications,NDA,208700,NA,NA,Solution,Intravenous,NA,NA,NA,NA,4/28/2016,1/26/2018,2018,NA,"LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.",Priority,Yes,No,No,Yes,No,No,No,NA,2016-04-28,2018-01-26,638,6.45833828334479,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,638,6.45833828334479
Symdeko,"tezacaftor, ivacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,210491,NA,NA,"Tablet, Tablet",Oral,NA,NA,NA,NA,6/28/2017,2/12/2018,2018,NA,"SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.",Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2017-06-28,2018-02-12,229,5.43372200355424,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,229,5.43372200355424
Erleada,apalutamide,Janssen Biotech,NDA,210951,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/10/2017,2/14/2018,2018,NA,"ERLEADA is indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).",Priority,No,No,No,Yes,No,No,No,NA,2017-10-10,2018-02-14,127,4.844187086458591,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,127,4.844187086458591
Trogarzo,ibalizumab-uiyk,TaiMed Biologics,BLA,761065,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/3/2017,3/6/2018,2018,NA,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-05-03,2018-03-06,307,5.726847747587197,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,307,5.726847747587197
Crysvita,burosumab-twza,Ultragenyx Pharmaceutical,BLA,761068,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/17/2017,4/17/2018,2018,NA,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2017-08-17,2018-04-17,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Tavalisse,fostamatinib disodium hexahydrate,Rigel Pharmaceuticals,NDA,209299,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/17/2017,4/17/2018,2018,NA,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,Standard,Yes,No,No,No,No,No,No,NA,2017-04-17,2018-04-17,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Akynzeo,fosnetupitant and palonosetron,Helsinn Healthcare,NDA,210493,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/20/2017,4/19/2018,2018,NA,"AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
AKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Limitations of Use:
AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2017-04-20,2018-04-19,364,5.8971538676367405,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,364,5.8971538676367405
Palynziq,pegvaliase-pqpz,BioMarin Pharmaceutical,BLA,761079,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/2017,5/24/2018,2018,NA,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2017-06-30,2018-05-24,328,5.793013608384144,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,328,5.793013608384144
Olumiant,baricitinib,Eli Lilly,NDA,207924,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/2016,5/31/2018,2018,NA,"OLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.",Standard,No,No,No,No,No,No,No,NA,2016-01-15,2018-05-31,867,6.7650389767805414,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,867,6.7650389767805414
[drug marketed without a proprietary name],moxidectin,Medicines Development For Global Health,NDA,210867,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/13/2017,6/13/2018,2018,NA,"Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older.
Limitations of Use:
Moxidectin Tablets do not kill adult O. volvulus. Follow-up evaluation is advised.
The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O. volvulus has not been studied.",Priority,Yes,No,No,No,No,TD,No,NA,2017-10-13,2018-06-13,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Epidiolex,cannabidiol,GW Pharmaceuticals,NDA,210365,NA,NA,Solution,Oral,NA,NA,NA,NA,10/27/2017,6/25/2018,2018,NA,EPIDIOLEX is indicated for the treatment of seizures associated with [A] Lennox-Gastaut syndrome (LGS) or [B] Dravet syndrome (DS) in patients 2 years of age and older.,Priority,Yes,No,No,Yes (indication [B] only),No,RPD,No,NA,2017-10-27,2018-06-25,241,5.484796933490655,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,241,5.484796933490655
Braftovi,encorafenib,Array Biopharma,NDA,210496,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/30/2017,6/27/2018,2018,NA,"BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.",Standard,Yes,No,No,No,No,No,No,NA,2017-06-30,2018-06-27,362,5.8916442118257715,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,362,5.8916442118257715
Mektovi,binimetinib,Array Biopharma,NDA,210498,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/2017,6/27/2018,2018,NA,"MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",Standard,Yes,No,No,No,No,No,No,NA,2017-06-30,2018-06-27,362,5.8916442118257715,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,362,5.8916442118257715
Tpoxx,tecovirimat,SIGA Technologies,NDA,208627,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/8/2017,7/13/2018,2018,NA,"TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Limitations of Use:
The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical.
TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models.",Priority,Yes,No,No,Yes,No,MTMC,No,NA,2017-12-08,2018-07-13,217,5.37989735354046,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,217,5.37989735354046
Krintafel,tafenoquine,GlaxoSmithKline,NDA,210795,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/22/2017,7/20/2018,2018,NA,"KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Limitation of Use:
KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria.",Priority,Yes,No,Yes,No,No,TD,No,NA,2017-11-22,2018-07-20,240,5.480638923341991,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,240,5.480638923341991
Tibsovo,ivosidenib,Agios Pharmaceuticals,NDA,211192,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/2017,7/20/2018,2018,NA,TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2017-12-21,2018-07-20,211,5.351858133476067,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,211,5.351858133476067
Omegaven,fish oil triglycerides,Fresenius Kabi,NDA,210589,NA,NA,Emulsion,Intravenous,NA,NA,NA,NA,12/1/2017,7/27/2018,2018,NA,"Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Limitations of Use:
- Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.
- It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product.",Priority,Yes,No,No,Yes,No,No,No,NA,2017-12-01,2018-07-27,238,5.472270673671475,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,238,5.472270673671475
Poteligeo,mogamulizumab-kpkc,Kyowa Kirin Pharmaceutical Development,BLA,761051,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/2017,8/8/2018,2018,NA,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2017-10-04,2018-08-08,308,5.730099782973574,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,308,5.730099782973574
Galafold,migalastat,Amicus Therapeutics,NDA,208623,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/13/2017,8/10/2018,2018,NA,"GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2017-12-13,2018-08-10,240,5.480638923341991,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,240,5.480638923341991
Onpattro,patisiran,Alnylam Pharmaceuticals,NDA,210922,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/11/2017,8/10/2018,2018,NA,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2017-12-11,2018-08-10,242,5.488937726156687,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,242,5.488937726156687
Diacomit,stiripentol,Biocodex SA,NDA,206709,207223,NA,Capsule,Oral,Suspension,Oral,NA,NA,12/20/2017,8/20/2018,2018,NA,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.,Priority,Yes,No,No,No,No,No,No,NA,2017-12-20,2018-08-20,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Oxervate,cenegermin-bkbj,Dompé farmaceutici S.p.A.,BLA,761094,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/22/2017,8/22/2018,2018,NA,OXERVATE (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-12-22,2018-08-22,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Takhzyro,lanadelumab-flyo,Dyax Corporation,BLA,761090,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/26/2017,8/23/2018,2018,NA,TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-12-26,2018-08-23,240,5.480638923341991,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,240,5.480638923341991
Lumoxiti,moxetumomab pasudotox-tdfk,AstraZeneca Pharmaceuticals,BLA,761104,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/29/2018,9/13/2018,2018,NA,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
Limitations of Use:
LUMOXITI is not recommended in patients with severe renal impairment (CrCl = 29 mL/min).",Priority,Yes,No,No,Yes,N/A,No,No,NA,2018-01-29,2018-09-13,227,5.424950017481403,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,227,5.424950017481403
Copiktra,duvelisib,Verastem,NDA,211155,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/5/2018,9/24/2018,2018,NA,"[A] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.
[B] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.
This indication is approved under accelerated approval based on overall response rate (ORR); continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes (indication [B] only),No,Yes,No,No,No,NA,2018-02-05,2018-09-24,231,5.442417710521793,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,231,5.442417710521793
Vizimpro,dacomitinib,Pfizer,NDA,211288,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2018,9/27/2018,2018,NA,VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.,Priority,Yes,No,No,No,No,No,No,NA,2018-01-31,2018-09-27,239,5.476463551931511,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,239,5.476463551931511
Libtayo,cemiplimab-rwlc,Regeneron Pharmaceuticals,BLA,761097,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/2018,9/28/2018,2018,NA,LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.,Priority,No,No,Yes,No,N/A,No,No,NA,2018-02-28,2018-09-28,212,5.356586274672012,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,212,5.356586274672012
Revcovi,elapegademase-lvlr,Leadiant Biosciences,BLA,761092,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2017,10/5/2018,2018,NA,REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2017-10-24,2018-10-05,346,5.846438775057725,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,346,5.846438775057725
Tegsedi,inotersen,Ionis Pharmaceuticals,NDA,211172,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,11/6/2017,10/5/2018,2018,NA,TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,No,Yes,No,No,No,NA,2017-11-06,2018-10-05,333,5.808142489980444,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,333,5.808142489980444
Talzenna,talazoparib,Pfizer,NDA,211651,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/6/2018,10/16/2018,2018,NA,TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.,Priority,No,No,No,No,No,No,No,NA,2018-04-06,2018-10-16,193,5.262690188904886,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,193,5.262690188904886
Lorbrena,lorlatinib,Pfizer,NDA,210868,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/5/2017,11/2/2018,2018,NA,"LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on
- crizotinib and at least one other ALK inhibitor for metastatic disease; or
- alectinib as the first ALK inhibitor therapy for metastatic disease; or
- ceritinib as the first ALK inhibitor therapy for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2017-12-05,2018-11-02,332,5.805134968916488,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,332,5.805134968916488
Gamifant,emapalumab-lzsg,Novimmune S.A.,BLA,761107,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/2018,11/20/2018,2018,NA,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Priority,Yes,No,Yes,No,N/A,RPD,No,NA,2018-03-20,2018-11-20,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Daurismo,glasdegib,Pfizer,NDA,210656,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/27/2018,11/21/2018,2018,NA,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: DAURISMO has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.",Priority,Yes,No,No,No,No,No,No,NA,2018-04-27,2018-11-21,208,5.337538079701318,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,208,5.337538079701318
Vitrakvi,larotrectinib,Loxo Oncology,NDA,210861,211710,NA,Capsule,Oral,Solution,Oral,NA,NA,3/26/2018,11/26/2018,2018,NA,"VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:
- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2018-03-26,2018-11-26,245,5.501258210544727,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,245,5.501258210544727
Firdapse,amifampridine,Catalyst Pharmaceuticals,NDA,208078,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/28/2018,11/28/2018,2018,NA,FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.,Priority,Yes,No,Yes,No,No,No,No,NA,2018-03-28,2018-11-28,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Xospata,gilteritinib,Astellas Pharma,NDA,211349,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/29/2018,11/28/2018,2018,NA,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2018-03-29,2018-11-28,244,5.497168225293202,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,244,5.497168225293202
Asparlas,calaspargase pegol-mknl,Servier Pharmaceuticals,BLA,761102,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/2017,12/20/2018,2018,NA,ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.,Standard,Yes,No,No,No,N/A,No,No,NA,2017-12-22,2018-12-20,363,5.8944028342648505,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,363,5.8944028342648505
Ultomiris,ravulizumab-cwvz,Alexion Pharmaceuticals,BLA,761108,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/18/2018,12/21/2018,2018,NA,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,Priority (used priority review voucher),Yes,No,No,No,N/A,No,Yes,NA,2018-06-18,2018-12-21,186,5.225746673713202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,186,5.225746673713202
Elzonris,tagraxofusp-erzs,Stemline Therapeutics,BLA,761116,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/21/2018,12/21/2018,2018,NA,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2018-06-21,2018-12-21,183,5.209486152841421,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,183,5.209486152841421
Cablivi,caplacizumab-yhdp,Ablynx NV,BLA,761112,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/6/2018,2/6/2019,2019,NA,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2018-06-06,2019-02-06,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Egaten,triclabendazole,Novartis Pharmaceuticals,NDA,208711,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/14/2018,2/13/2019,2019,NA,EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.,Priority,Yes,No,No,Yes,No,TD,No,NA,2018-06-14,2019-02-13,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Balversa,erdafitinib,Janssen Biotech,NDA,212018,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/18/2018,4/12/2019,2019,NA,"BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:
- susceptible FGFR3 or FGFR2 genetic alterations, and
- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. 
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,No,No,No,NA,2018-09-18,2019-04-12,206,5.327876168789581,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,206,5.327876168789581
Vyndaqel,tafamidis meglumine,Pfizer,NDA,211996,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/2/2018,5/3/2019,2019,NA,VYNDAQEL is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2018-11-02,2019-05-03,182,5.204006687076795,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,182,5.204006687076795
Piqray,alpelisib,Novartis Pharmaceuticals,NDA,212526,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/2018,5/24/2019,2019,NA,"PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",Priority,No,No,No,No,No,No,No,NA,2018-12-18,2019-05-24,157,5.056245805348308,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,157,5.056245805348308
Polivy,polatuzumab vedotin-piiq,Genentech,BLA,761121,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2018,6/10/2019,2019,NA,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2018-12-19,2019-06-10,173,5.153291594497779,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,173,5.153291594497779
Xpovio,selinexor,Karyopharm Therapeutics,NDA,212306,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/6/2018,7/3/2019,2019,NA,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2018-08-06,2019-07-03,331,5.802118375377063,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,331,5.802118375377063
Nubeqa,darolutamide,Bayer HealthCare Pharmaceuticals,NDA,212099,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/26/2019,7/30/2019,2019,NA,NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).,Priority,No,No,No,Yes,No,No,No,NA,2019-02-26,2019-07-30,154,5.0369526024136295,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,154,5.0369526024136295
Turalio,pexidartinib,Daiichi Sankyo,NDA,211810,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/3/2018,8/2/2019,2019,NA,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,Priority,Yes,No,Yes,No,No,No,No,NA,2018-12-03,2019-08-02,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Wakix,pitolisant,Bioprojet Pharma,NDA,211150,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2018,8/14/2019,2019,NA,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.,Priority,Yes,No,No,Yes,No,No,No,NA,2018-12-14,2019-08-14,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
[drug marketed without a proprietary name],pretomanid,Global Alliance for TB Drug Development,NDA,212862,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2018,8/14/2019,2019,NA,"Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use:
- Pretomanid Tablets are not indicated in patients with the following conditions:
-- Drug-sensitive (DS) tuberculosis
-- Latent infection due to Mycobacterium tuberculosis.
-- Extra-pulmonary infection due to Mycobacterium tuberculosis.
-- MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy.
- Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen.",Priority,Yes,No,No,Yes,Yes,TD,No,NA,2018-12-14,2019-08-14,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Rozlytrek,entrectinib,Genentech,NDA,212725,212726,NA,Capsule,Oral,Capsule,Oral,NA,NA,12/18/2018,8/15/2019,2019,NA,"[A] ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
[B] ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:
- have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have either progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes (indication [B] only),Yes (indication [B] only),No,No,No,No,NA,2018-12-18,2019-08-15,240,5.480638923341991,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,240,5.480638923341991
Inrebic,fedratinib,Celgene,NDA,212327,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/3/2019,8/16/2019,2019,NA,INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,Priority,Yes,No,No,No,No,No,No,NA,2019-01-03,2019-08-16,225,5.41610040220442,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,225,5.41610040220442
[drug marketed without a proprietary name],Ga 68 DOTATOC,University of Iowa Health Care,NDA,210828,NA,NA,Solution,Intravenous,NA,NA,NA,NA,5/23/2018,8/21/2019,2019,NA,Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,Standard,Yes,No,No,No,No,No,No,NA,2018-05-23,2019-08-21,455,6.12029741895095,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,455,6.12029741895095
Scenesse,afamelanotide,Clinuvel,NDA,210797,NA,NA,Implant,Subcutaneous,NA,NA,NA,NA,11/8/2018,10/8/2019,2019,NA,SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).,Priority,Yes,No,No,Yes,No,No,No,NA,2018-11-08,2019-10-08,334,5.811140992976701,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,334,5.811140992976701
Trikafta,"elexacaftor, ivacaftor, tezacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,212273,NA,NA,"Tablet, Tablet",Oral,NA,NA,NA,NA,7/19/2019,10/21/2019,2019,NA,"TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.",Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2019-07-19,2019-10-21,94,4.543294782270004,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,94,4.543294782270004
Reblozyl,luspatercept-aamt,Celgene,BLA,761136,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/4/2019,11/8/2019,2019,NA,"REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2019-04-04,2019-11-08,218,5.384495062789089,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,218,5.384495062789089
Brukinsa,zanubrutinib,BeiGene USA,NDA,213217,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/27/2019,11/14/2019,2019,NA,"BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-06-27,2019-11-14,140,4.941642422609304,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,140,4.941642422609304
Adakveo,crizanlizumab-tmca,Novartis Pharmaceuticals,BLA,761128,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/16/2019,11/15/2019,2019,NA,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2019-05-16,2019-11-15,183,5.209486152841421,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,183,5.209486152841421
Givlaari,givosiran,Alnylam Pharmaceuticals,NDA,212194,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,6/4/2019,11/20/2019,2019,NA,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,Priority,Yes,No,Yes,No,No,No,No,NA,2019-06-04,2019-11-20,169,5.1298987149230735,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,169,5.1298987149230735
Oxbryta,voxelotor,Global Blood Therapeutics,NDA,213137,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/2019,11/25/2019,2019,NA,"OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2019-06-26,2019-11-25,152,5.0238805208462765,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,152,5.0238805208462765
Vyondys 53,golodirsen,Sarepta Therapeutics,NDA,211970,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/19/2018,12/12/2019,2019,NA,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2018-12-19,2019-12-12,358,5.8805329864007,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,358,5.8805329864007
Padcev,enfortumab vedotin-ejfv,Astellas Pharma,BLA,761137,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/15/2019,12/18/2019,2019,NA,"PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2019-07-15,2019-12-18,156,5.049856007249537,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,156,5.049856007249537
Enhertu,fam-trastuzumab deruxtecan-nxki,Daiichi Sankyo,BLA,761139,NA,NA,Powder,Intravenous,NA,NA,NA,NA,8/29/2019,12/20/2019,2019,NA,"ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,Yes,N/A,No,No,NA,2019-08-29,2019-12-20,113,4.727387818712341,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,113,4.727387818712341
TissueBlue,Brilliant Blue G,D.O.R.C International b.v,NDA,209569,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,4/29/2019,12/20/2019,2019,NA,TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).,Priority,Yes,No,No,No,No,No,No,NA,2019-04-29,2019-12-20,235,5.459585514144159,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,235,5.459585514144159
Ayvakit,avapritinib,Blueprint Medicines Corporation,NDA,212608,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/14/2019,1/9/2020,2020,NA,"Ayvakit is indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-06-14,2020-01-09,209,5.342334251964811,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,209,5.342334251964811
Tepezza,teprotumumab-trbw,Horizon Therapeutics Ireland DAC,BLA,761143,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/8/2019,1/21/2020,2020,NA,Tepezza is indicated for the treatment of thyroid eye disease,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2019-07-08,2020-01-21,197,5.2832037287379885,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,197,5.2832037287379885
Tazverik,tazemetostat,"Epizyme, Inc.",NDA,211723,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/23/2019,1/23/2020,2020,NA,Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection,Priority,Yes,Yes,No,No,No,No,No,NA,2019-05-23,2020-01-23,245,5.501258210544727,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,245,5.501258210544727
Sarclisa,isatuximab-irfc,Sanofi Aventis US LLC,BLA,761113,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/2019,3/2/2020,2020,NA,"Sarclisa is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor",Standard,Yes,No,No,No,N/A,No,No,NA,2019-04-30,2020-03-02,307,5.726847747587197,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,307,5.726847747587197
Isturisa,osilodrostat,Novartis Pharmaceuticals Corporation,NDA,212801,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/7/2019,3/6/2020,2020,NA,Isturisa is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,Standard,Yes,No,No,No,No,No,No,NA,2019-03-07,2020-03-06,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Koselugo,selumetinib,AstraZeneca Pharmaceuticals LP,NDA,213756,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/13/2019,4/10/2020,2020,NA,"Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",Priority,Yes,No,Yes,No,No,RPD,No,NA,2019-09-13,2020-04-10,210,5.3471075307174685,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,210,5.3471075307174685
Pemazyre,pemigatinib,Incyte Corporation,NDA,213736,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/30/2019,4/17/2020,2020,NA,"Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-09-30,2020-04-17,200,5.298317366548036,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,200,5.298317366548036
Tukysa,tucatinib,"Seattle Genetics, Inc.",NDA,213411,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2019,4/17/2020,2020,NA,"Tukysa is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-12-20,2020-04-17,119,4.77912349311153,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,119,4.77912349311153
Trodelvy,sacituzumab govitecan-hziy,"Immunomedics, Inc",BLA,761115,NA,NA,Powder,Intravenous,NA,NA,NA,NA,5/18/2018,4/22/2020,2020,NA,Trodelvy is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease,Priority,No,Yes,Yes,Yes,N/A,No,No,NA,2018-05-18,2020-04-22,705,6.558197802812269,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,705,6.558197802812269
Tabrecta,capmatinib,Novartis Pharmaceuticals Corporation,NDA,213591,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/10/2019,5/6/2020,2020,NA,Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test,Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-12-10,2020-05-06,148,4.997212273764115,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,148,4.997212273764115
Retevmo,selpercatinib,"Loxo Oncology, Inc.",NDA,213246,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/4/2019,5/8/2020,2020,NA,Retevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) .Is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-12-04,2020-05-08,156,5.049856007249537,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,156,5.049856007249537
Qinlock,ripretinib,"Deciphera Pharmaceuticals, LLC",NDA,213973,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/13/2019,5/15/2020,2020,NA,"Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-12-13,2020-05-15,154,5.0369526024136295,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,154,5.0369526024136295
Cerianna,fluoroestradiol F 18,Zionexa-US Corporation,NDA,212155,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2019,5/20/2020,2020,NA,Cerianna is indicated for positron emission tomography (PET) imaging for detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer,Standard,No,No,No,No,No,No,No,NA,2019-02-27,2020-05-20,448,6.104793232414985,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,448,6.104793232414985
[drug marketed without a proprietary name],artesunate,"Amivas, LLC",NDA,213036,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/26/2019,5/26/2020,2020,NA,Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients,Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-09-26,2020-05-26,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Uplizna,inebilizumab-cdon,"Viela Bio, Inc.",BLA,761142,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/11/2019,6/11/2020,2020,NA,Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,No,N/A,No,No,NA,2019-06-11,2020-06-11,366,5.902633333401366,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,366,5.902633333401366
Zepzelca,lurbinectedin,"Pharma Mar USA, Inc.",NDA,213702,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/2019,6/15/2020,2020,NA,Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy,Priority,Yes,Yes,No,No,No,No,No,NA,2019-12-16,2020-06-15,182,5.204006687076795,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,182,5.204006687076795
Dojolvi,triheptanoin,Ultragenyx Pharmaceutical Inc.,NDA,213687,NA,NA,Liquid,Oral,NA,NA,NA,NA,7/31/2019,6/30/2020,2020,NA,Dojolvi is indicated for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD),Standard,Yes,No,No,Yes,No,No,No,NA,2019-07-31,2020-06-30,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,335,5.814130531825066
Inqovi,decitabine and cedazuridine,"Astex Pharmaceuticals, Inc.",NDA,212576,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/2019,7/7/2020,2020,NA,"Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups",Priority,Yes,No,No,No,No,No,No,NA,2019-12-11,2020-07-07,209,5.342334251964811,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,209,5.342334251964811
Monjuvi,tafasitamab-cxix,"MorphoSys US, Inc.",BLA,761163,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/2019,7/31/2020,2020,NA,"Monjuvi is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2019-12-30,2020-07-31,214,5.365976015021851,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,214,5.365976015021851
Blenrep,belantamab mafodotin-blmf,GlaxoSmithKline Intellectual Property Development Ltd. England,BLA,761158,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/5/2019,8/5/2020,2020,NA,"Blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2019-12-05,2020-08-05,244,5.497168225293202,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,244,5.497168225293202
Lampit,nifurtimox,"Bayer HealthCare Pharmaceuticals, Inc.",NDA,213464,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/6/2019,8/6/2020,2020,NA,Lampit is indicated for the treatment of Chagas disease in pediatric patients birth to less than 18 years of age and weighing at least 2.5 kg,Priority,Yes,Yes,No,No,No,TD,No,NA,2019-12-06,2020-08-06,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Evrysdi,risdiplam,"Genentech, Inc.",NDA,213535,NA,NA,Powder,Oral,NA,NA,NA,NA,9/24/2019,8/7/2020,2020,NA,Evrysdi is indicated for the treatment of later-onset spinal muscular atrophy (SMA) in patients 2 months of age and older. Is indicated for the treatment of infantile-onset spinal muscular atrophy (SMA) in patients 2 months of age and older,Priority,Yes,No,No,Yes,No,RPD,No,NA,2019-09-24,2020-08-07,318,5.762051382780177,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,318,5.762051382780177
Viltepso,viltolarsen,"Nippon Shinyaku Co., Ltd.",NDA,212154,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/2019,8/12/2020,2020,NA,Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2019-12-12,2020-08-12,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Enspryng,satralizumab-mwge,"Genentech, Inc.",BLA,761149,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/15/2019,8/14/2020,2020,NA,Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,Yes,N/A,No,No,NA,2019-08-15,2020-08-14,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Detectnet,copper Cu 64 dotatate,"RadioMedix, Inc.",NDA,213227,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/3/2020,9/3/2020,2020,NA,Detectnet is indicated for positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults,Priority,Yes,No,No,Yes,No,No,No,NA,2020-01-03,2020-09-03,244,5.497168225293202,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,244,5.497168225293202
Gavreto,pralsetinib,Blueprint Medicines Corporation,NDA,213721,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/23/2020,9/4/2020,2020,NA,Gavreto is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,Priority,Yes,Yes,Yes,No,No,No,No,NA,2020-03-23,2020-09-04,165,5.10594547390058,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,165,5.10594547390058
Inmazeb,"atoltivimab, maftivimab, and odesivimab-ebgn","Regeneron Pharmaceuticals, Inc.",BLA,761169,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/25/2020,10/14/2020,2020,NA,"Inmazeb is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Priority,Yes,No,Yes,No,N/A,MTMC,No,NA,2020-02-25,2020-10-14,232,5.44673737166631,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,232,5.44673737166631
Zokinvy,lonafarnib,"Eiger BioPharmaceuticals, Inc.",NDA,213969,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/20/2020,11/20/2020,2020,NA,Zokinvy is indicated for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations in patients 12 months of age and older. Is indicated to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS),Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-03-20,2020-11-20,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Oxlumo,lumasiran,"Alnylam Pharmaceuticals, Inc.",NDA,214103,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/3/2020,11/23/2020,2020,NA,Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-04-03,2020-11-23,234,5.455321115357702,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,234,5.455321115357702
Imcivree,setmelanotide,"Rhythm Pharmaceuticals, Inc.",NDA,213793,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/27/2020,11/25/2020,2020,NA,"Imcivree is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency confirmed by genetic testing demonstrating variants in POMC or PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)",Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-03-27,2020-11-25,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Danyelza,naxitamab-gqgk,"Y-mAbs Therapeutics, Inc.",BLA,761171,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/31/2020,11/25/2020,2020,NA,"Danyelza is indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy",Priority,Yes,Yes,Yes,No,N/A,RPD,No,NA,2020-03-31,2020-11-25,239,5.476463551931511,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,239,5.476463551931511
[drug marketed without a proprietary name],gallium Ga 68 PSMA-11,University of California Los Angeles,NDA,212642,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/6/2019,12/1/2020,2020,NA,gallium Ga 68 PSMA-11 Is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy,Standard,No,No,No,No,No,No,No,NA,2019-09-06,2020-12-01,452,6.113682179832232,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,452,6.113682179832232
Orladeyo,berotralstat,"BioCryst Pharmaceuticals, Inc.",NDA,214094,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/3/2019,12/3/2020,2020,NA,Orladeyo is indicated as prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older,Standard,Yes,No,No,Yes,No,No,No,NA,2019-12-03,2020-12-03,366,5.902633333401366,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,366,5.902633333401366
Margenza,margetuximab-cmkb,"MacroGenics, Inc.",BLA,761150,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/18/2019,12/16/2020,2020,NA,"Margenza is indicated in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease",Standard,No,No,No,Yes,N/A,No,No,NA,2019-12-18,2020-12-16,364,5.8971538676367405,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,364,5.8971538676367405
Orgovyx,relugolix,Myovant Sciences GmbH,NDA,214621,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/20/2020,12/18/2020,2020,NA,Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer,Priority,No,No,No,No,No,No,No,NA,2020-04-20,2020-12-18,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Ebanga,ansuvimab-zykl,"Ridgeback Biotherapeutics, LP",BLA,761172,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/29/2020,12/21/2020,2020,NA,"Ebanga is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Priority,Yes,No,Yes,No,N/A,MTMC,No,NA,2020-05-29,2020-12-21,206,5.327876168789581,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,206,5.327876168789581
Tepmetko,tepotinib,"EMD Serono, Inc.",NDA,214096,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2020,2/3/2021,2021,NA,"TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,No,No,No,No,No,NA,2020-06-29,2021-02-03,219,5.389071729816501,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,219,5.389071729816501
Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/15/2020,2/5/2021,2021,NA,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No,No,No,No,NA,2020-06-15,2021-02-05,235,5.459585514144159,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,235,5.459585514144159
Evkeeza,evinacumab-dgnb,"Regeneron Pharmaceuticals, Inc.",BLA,761181,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/11/2020,2/11/2021,2021,NA,"EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
- The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2020-06-11,2021-02-11,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Cosela,trilaciclib,"G1 Therapeutics, Inc.",NDA,214200,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/15/2020,2/12/2021,2021,NA,COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).,Priority,No,No,Yes,No,No,No,No,NA,2020-06-15,2021-02-12,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Amondys 45,casimersen,"Sarepta Therapeutics, Inc.",NDA,213026,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2020,2/25/2021,2021,NA,AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2020-06-25,2021-02-25,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Nulibry,fosdenopterin,"Origin Biosciences, Inc.",NDA,214018,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/2020,2/26/2021,2021,NA,NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-06-29,2021-02-26,242,5.488937726156687,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,242,5.488937726156687
Pepaxto,melphalan flufenamide,Oncopeptides AB,NDA,214383,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/2020,2/26/2021,2021,NA,"PEPAXTO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
PEPAXTO is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2020-06-30,2021-02-26,241,5.484796933490655,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,241,5.484796933490655
Fotivda,tivozanib,"Aveo Pharmaceuticals, Inc.",NDA,212904,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2020,3/10/2021,2021,NA,FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.,Standard,No,No,No,No,No,No,No,NA,2020-03-31,2021-03-10,344,5.840641657373398,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,344,5.840641657373398
Jemperli,dostarlimab-gxly,"GlaxoSmithKline, LLC",BLA,761174,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2019,4/22/2021,2021,NA,"JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,Yes,No,N/A,No,No,NA,2019-12-19,2021-04-22,490,6.194405391104672,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,490,6.194405391104672
Zynlonta,loncastuximab tesirine-lpyl,ADC Therapeutics S.A.,BLA,761196,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/21/2020,4/23/2021,2021,NA,"ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,No,N/A,No,No,NA,2020-09-21,2021-04-23,214,5.365976015021851,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,214,5.365976015021851
Empaveli,pegcetacoplan,"Apellis Pharmaceuticals, Inc.",NDA,215014,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/14/2020,5/14/2021,2021,NA,EMPAVELI is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,Priority,Yes,No,No,Yes,No,No,No,NA,2020-09-14,2021-05-14,242,5.488937726156687,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,242,5.488937726156687
Rybrevant,amivantamab-vmjw,"Janssen Biotech, Inc.",BLA,761210,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/2020,5/21/2021,2021,NA,"RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2020-11-24,2021-05-21,178,5.181783550292085,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,178,5.181783550292085
Pylarify,piflufolastat F 18,"Progenics Pharmaceuticals, Inc.",NDA,214793,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/29/2020,5/26/2021,2021,NA,"PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",Priority,No,No,No,No,No,No,No,NA,2020-09-29,2021-05-26,239,5.476463551931511,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,239,5.476463551931511
Lumakras,sotorasib,"Amgen, Inc.",NDA,214665,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/2020,5/28/2021,2021,NA,"LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2020-12-16,2021-05-28,163,5.093750200806762,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,163,5.093750200806762
Truseltiq,infigratinib,"QED Therapeutics, Inc.",NDA,214622,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/29/2020,5/28/2021,2021,NA,"TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,Yes,No,No,No,NA,2020-09-29,2021-05-28,241,5.484796933490655,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,241,5.484796933490655
Rylaze,asparaginase erwinia chrysanthemi (recombinant)-rywn,Jazz Pharmaceuticals Ireland Limited,BLA,761179,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/2021,6/30/2021,2021,NA,RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.,Standard,Yes,No,No,Yes,N/A,No,No,NA,2021-04-30,2021-06-30,61,4.110873864173311,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,61,4.110873864173311
[drug marketed without a proprietary name],fexinidazole,Drugs for Neglected Diseases initiative,NDA,214429,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/12/2020,7/16/2021,2021,NA,"Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.
Limitations of Use:
Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options.",Priority,Yes,No,No,No,No,TD,No,NA,2020-03-12,2021-07-16,491,6.19644412779452,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,491,6.19644412779452
Rezurock,belumosudil,"Kadmon Pharmaceuticals, LLC",NDA,214783,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/30/2020,7/16/2021,2021,NA,REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.,Priority,Yes,No,Yes,No,No,No,No,NA,2020-09-30,2021-07-16,289,5.666426688112432,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,289,5.666426688112432
Bylvay,odevixibat,Albireo AB,NDA,215498,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/20/2020,7/20/2021,2021,NA,"BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Limitations of Use:
-BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3).",Priority,Yes,No,No,Yes,No,RPD,No,NA,2020-11-20,2021-07-20,242,5.488937726156687,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,242,5.488937726156687
Nexviazyme,avalglucosidase alfa-ngpt,Genzyme Corporation,BLA,761194,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/18/2020,8/6/2021,2021,NA,NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2020-09-18,2021-08-06,322,5.7745515455444085,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,322,5.7745515455444085
Welireg,belzutifan,Merck Sharp and Dohme Corp.,NDA,215383,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/2021,8/13/2021,2021,NA,"WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.",Priority,Yes,No,No,No,No,No,No,NA,2021-01-15,2021-08-13,210,5.3471075307174685,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,210,5.3471075307174685
Skytrofa,lonapegsomatropin-tcgd,Ascendis Pharma Endocrinology Division A/S,BLA,761177,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2020,8/25/2021,2021,NA,SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).,Standard,Yes,No,No,No,N/A,No,No,NA,2020-06-25,2021-08-25,426,6.054439346269371,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,426,6.054439346269371
Exkivity,mobocertinib,"Takeda Pharmaceuticals U.S.A., Inc.",NDA,215310,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/26/2021,9/15/2021,2021,NA,"EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2021-02-26,2021-09-15,201,5.303304908059076,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,201,5.303304908059076
Tivdak,tisotumab vedotin-tftv,"Seagen, Inc.",BLA,761208,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/10/2021,9/20/2021,2021,NA,"TIVDAK is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,No,No,N/A,No,No,NA,2021-02-10,2021-09-20,222,5.402677381872279,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,222,5.402677381872279
Livmarli,maralixibat,"Mirum Pharmaceuticals, Inc.",NDA,214662,NA,NA,Solution,Oral,NA,NA,NA,NA,1/29/2021,9/29/2021,2021,NA,LIVMARLI is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2021-01-29,2021-09-29,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Tavneos,avacopan,"ChemoCentryx, Inc.",NDA,214487,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/7/2020,10/7/2021,2021,NA,TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.,Standard,Yes,No,No,No,No,No,No,NA,2020-07-07,2021-10-07,457,6.124683390894205,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,457,6.124683390894205
Scemblix,asciminib,Novartis Pharmaceuticals Corporation,NDA,215358,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/24/2021,10/29/2021,2021,NA,"SCEMBLIX is indicated for the treatment of adult patients with:
[A]Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
[B] Treatment of adult patients with Ph+ CML in CP with the T315I mutation.",Priority,Yes,Yes (indication [A] only),Yes,Yes,No,No,No,NA,2021-06-24,2021-10-29,127,4.844187086458591,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,127,4.844187086458591
Besremi,ropeginterferon alfa-2b-njft,PharmaEssentia Corporation,BLA,761166,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/13/2020,11/12/2021,2021,NA,BESREMi is indicated for the treatment of adults with polycythemia vera.,Standard,Yes,No,No,No,N/A,No,No,NA,2020-03-13,2021-11-12,609,6.411818267709897,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,609,6.411818267709897
Voxzogo,vosoritide,"BioMarin Pharmaceutical, Inc.",NDA,214938,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/20/2020,11/19/2021,2021,NA,VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,No,No,RPD,No,NA,2020-08-20,2021-11-19,456,6.1224928095143865,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,456,6.1224928095143865
Livtencity,maribavir,"Takeda Pharmaceuticals U.S.A., Inc.",NDA,215596,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/2021,11/23/2021,2021,NA,"LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.",Priority,Yes,No,Yes,No,No,No,No,NA,2021-03-23,2021-11-23,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Cytalux,pafolacianine,"On Target Laboratories, Inc.",NDA,214907,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/2020,11/29/2021,2021,NA,CYTALUX is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.,Priority,Yes,No,No,Yes,No,No,No,NA,2020-12-29,2021-11-29,335,5.814130531825066,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,335,5.814130531825066
Vyvgart,efgartigimod alfa-fcab,argenx BV,BLA,761195,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/17/2020,12/17/2021,2021,NA,VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.,Standard,Yes,No,No,Yes,N/A,No,No,NA,2020-12-17,2021-12-17,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Kimmtrak,tebentafusp-tebn,Immunocore Limited,BLA,761228,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2021,1/25/2022,2022,NA,KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-06-23,2022-01-25,216,5.375278407684165,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,216,5.375278407684165
Enjaymo,sutimlimab-jome,"Bioverativ USA, Inc.",BLA,761164,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/13/2020,2/4/2022,2022,NA,ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Priority,Yes,No,Yes,No,N/A,No,No,NA,2020-03-13,2022-02-04,693,6.541029999189903,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,693,6.541029999189903
Pyrukynd,mitapivat,"Agios Pharmaceuticals, Inc.",NDA,216196,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/2021,2/17/2022,2022,NA,PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.,Priority,Yes,No,No,Yes,No,No,No,NA,2021-06-17,2022-02-17,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Vonjo,pacritinib,CTI BioPharma Corporation,NDA,208712,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2021,2/28/2022,2022,NA,VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10^9/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,Priority,Yes,Yes,No,Yes,No,No,No,NA,2021-03-30,2022-02-28,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Opdualag,nivolumab and relatlimab-rmbw,Bristol-Myers Squibb Company,BLA,761234,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/19/2021,3/18/2022,2022,NA,OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2021-07-19,2022-03-18,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Ztalmy,ganaxolone,"Marinus Pharmaceuticals, Inc.",NDA,215904,NA,NA,Suspension,Oral,NA,NA,NA,NA,7/20/2021,3/18/2022,2022,NA,ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.,Priority,Yes,No,No,No,No,RPD,No,NA,2021-07-20,2022-03-18,241,5.484796933490655,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,241,5.484796933490655
Pluvicto,lutetium Lu 177 vipivotide tetraxetan,"Advanced Accelerator Applications USA, Inc.",NDA,215833,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/29/2021,3/23/2022,2022,NA,PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.,Priority,No,No,Yes,No,No,No,No,NA,2021-07-29,2022-03-23,237,5.4680601411351315,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,237,5.4680601411351315
Camzyos,mavacamten,"MyoKardia, Inc.",NDA,214998,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/28/2021,4/28/2022,2022,NA,CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.,Standard,Yes,No,Yes,No,No,No,No,NA,2021-01-28,2022-04-28,455,6.12029741895095,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,455,6.12029741895095
Amvuttra,vutrisiran,"Alnylam Pharmaceuticals, Inc.",NDA,215515,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,4/14/2021,6/13/2022,2022,NA,AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Standard,Yes,No,No,Yes,No,No,No,NA,2021-04-14,2022-06-13,425,6.052089168924417,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,425,6.052089168924417
Xenpozyme,olipudase alfa-rpcp,Genzyme Corporation,BLA,761261,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/3/2021,8/31/2022,2022,NA,XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2021-11-03,2022-08-31,301,5.707110264748875,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,301,5.707110264748875
Spevigo,spesolimab-sbzo,"Boehringer Ingelheim Pharmaceuticals, Inc.",BLA,761244,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/1/2021,9/1/2022,2022,NA,SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-10-01,2022-09-01,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Rolvedon,eflapegrastim-xnst,"Spectrum Pharmaceuticals, Inc.",BLA,761148,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/24/2019,9/9/2022,2022,NA,"ROLVEDON is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Limitations of Use:
Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.",Standard,No,No,No,No,N/A,No,No,NA,2019-10-24,2022-09-09,1051,6.957497370876951,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,1051,6.957497370876951
Relyvrio,sodium phenylbutyrate and taurursodiol,"Amylyx Pharmaceuticals, Inc.",NDA,216660,NA,NA,For Suspension,Oral,NA,NA,NA,NA,10/29/2021,9/29/2022,2022,NA,RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.,Priority,Yes,No,No,No,No,No,No,NA,2021-10-29,2022-09-29,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Lytgobi,futibatinib,"Taiho Oncology, Inc.",NDA,214801,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2022,9/30/2022,2022,NA,"LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2022-01-31,2022-09-30,242,5.488937726156687,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,242,5.488937726156687
Imjudo,tremelimumab-actl,AstraZeneca AB,BLA,761289,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,2/23/2022,10/21/2022,2022,NA,IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).,Priority (used priority review voucher),Yes,No,No,No,N/A,No,Yes,NA,2022-02-23,2022-10-21,240,5.480638923341991,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,240,5.480638923341991
Tecvayli,teclistamab-cqyv,"Janssen Biotech, Inc.",BLA,761291,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/2021,10/25/2022,2022,NA,"TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2021-12-28,2022-10-25,301,5.707110264748875,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,301,5.707110264748875
Elahere,mirvetuximab soravtansine-gynx,"ImmunoGen, Inc.",BLA,761310,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/2022,11/14/2022,2022,NA,"ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRalpha) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,N/A,No,No,NA,2022-03-28,2022-11-14,231,5.442417710521793,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,231,5.442417710521793
Rezlidhia,olutasidenib,"Forma Therapeutics, Inc.",NDA,215814,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/15/2022,12/1/2022,2022,NA,REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,Standard,Yes,No,No,No,No,No,No,NA,2022-02-15,2022-12-01,289,5.666426688112432,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,289,5.666426688112432
Krazati,adagrasib,"Mirati Therapeutics, Inc.",NDA,216340,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2021,12/12/2022,2022,NA,"KRAZATI is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",Standard,Yes,Yes,Yes,Yes,No,No,No,NA,2021-12-14,2022-12-12,363,5.8944028342648505,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,363,5.8944028342648505
Lunsumio,mosunetuzumab-axgb,"Genentech, Inc.",BLA,761263,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/29/2022,12/22/2022,2022,NA,"LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2022-04-29,2022-12-22,237,5.4680601411351315,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,237,5.4680601411351315
NexoBrid,anacaulase-bcdb,"MediWound, Ltd.",BLA,761192,NA,NA,Gel,Topical,NA,NA,NA,NA,6/29/2020,12/28/2022,2022,NA,"NEXOBRID is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. 
Limitations of Use:
The safety and effectiveness of NEXOBRID have not been established for treatment of:
-Chemical or electrical burns
-Burns on the face, perineum, or genitalia
-Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
-Circumferential burns
-Burns in patients with significant cardiopulmonary disease, including inhalation injury
NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.",Standard,Yes,No,No,No,N/A,No,No,NA,2020-06-29,2022-12-28,912,6.815639990074331,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,912,6.815639990074331
Jaypirca,pirtobrutinib,"Loxo Oncology, Inc.",NDA,216059,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/27/2022,1/27/2023,2023,NA,"JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2022-05-27,2023-01-27,245,5.501258210544727,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,245,5.501258210544727
Orserdu,elacestrant,"Stemline Therapeutics, Inc.",NDA,217639,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/2022,1/27/2023,2023,NA,"ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",Priority,No,No,No,Yes,No,No,No,NA,2022-06-17,2023-01-27,224,5.41164605185504,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,224,5.4116460518550396
Lamzede,velmanase alfa-tycv,Chiesi Farmaceutici SpA,BLA,761278,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/17/2022,2/16/2023,2023,NA,LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2022-06-17,2023-02-16,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Filspari,sparsentan,"Travere Therapeutics, Inc.",NDA,216403,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/17/2022,2/17/2023,2023,NA,"FILSPARI is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) >=1.5 g/g.
This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether FILSPARI slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.",Priority,Yes,Yes,No,No,No,No,No,NA,2022-03-17,2023-02-17,337,5.820082930352362,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,337,5.820082930352362
Skyclarys,omaveloxolone,"Reata Pharmaceuticals, Inc.",NDA,216718,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2022,2/28/2023,2023,NA,SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2022-03-30,2023-02-28,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Daybue,trofinetide,"Acadia Pharmaceuticals, Inc.",NDA,217026,NA,NA,Solution,Oral,NA,NA,NA,NA,7/12/2022,3/10/2023,2023,NA,DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2022-07-12,2023-03-10,241,5.484796933490655,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,241,5.484796933490655
Rezzayo,rezafungin,"Cidara Therapeutics, Inc.",NDA,217417,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/22/2022,3/22/2023,2023,NA,"REZZAYO is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO.
Limitations of Use:
REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.",Priority,Yes,No,No,Yes,Yes,No,No,NA,2022-07-22,2023-03-22,243,5.493061443340548,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,243,5.493061443340548
Zynyz,retifanlimab-dlwr,Incyte Corporation,BLA,761334,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/8/2022,3/22/2023,2023,NA,"ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,N/A,No,No,NA,2022-08-08,2023-03-22,226,5.420534999272286,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,226,5.420534999272286
Joenja,leniolisib,Pharming Technologies B.V.,NDA,217759,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/29/2022,3/24/2023,2023,NA,JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older.,Priority,Yes,No,No,No,No,RPD,No,NA,2022-07-29,2023-03-24,238,5.472270673671475,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,238,5.472270673671475
Qalsody,tofersen,"Biogen, Inc.",NDA,215887,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/25/2022,4/25/2023,2023,NA,QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,Yes,No,No,No,NA,2022-05-25,2023-04-25,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Epkinly,epcoritamab-bysp,"Genmab US, Inc.",BLA,761324,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/21/2022,5/19/2023,2023,NA,"EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of
response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,No,No,N/A,No,No,NA,2022-09-21,2023-05-19,240,5.480638923341991,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,240,5.480638923341991
Posluma,flotufolastat F 18,"Blue Earth Diagnostics, Ltd.",NDA,216023,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/25/2022,5/25/2023,2023,NA,"POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",Standard,No,No,No,No,No,No,No,NA,2022-05-25,2023-05-25,365,5.8998973535824915,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,365,5.8998973535824915
Columvi,glofitamab-gxbm,"Genentech, Inc.",BLA,761309,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2022,6/15/2023,2023,NA,"COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,No,Yes,N/A,No,No,NA,2022-11-01,2023-06-15,226,5.420534999272286,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,226,5.420534999272286
Rystiggo,rozanolixizumab-noli,"UCB, Inc.",BLA,761286,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2022,6/26/2023,2023,NA,RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.,Priority,Yes,No,No,No,N/A,No,No,NA,2022-10-24,2023-06-26,245,5.501258210544727,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,245,5.501258210544727
Ngenla,somatrogon-ghla,Pfizer Ireland Pharmaceuticals,BLA,761184,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/22/2020,6/27/2023,2023,NA,NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.,Standard,Yes,No,No,No,N/A,No,No,NA,2020-10-22,2023-06-27,978,6.885509670034818,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,978,6.885509670034818
Vanflyta,quizartinib,"Daiichi Sankyo, Inc.",NDA,216993,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/24/2022,7/20/2023,2023,NA,"VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Limitations of Use:
VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.",Priority,Yes,No,No,Yes,No,No,No,NA,2022-08-24,2023-07-20,330,5.799092654460526,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,330,5.799092654460526
Talvey,talquetamab-tgvs,"Janssen Biotech, Inc.",BLA,761342,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/9/2022,8/9/2023,2023,NA,"TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2022-12-09,2023-08-09,243,5.493061443340548,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,243,5.493061443340548
Elrexfio,elranatamab-bcmm,"Pfizer, Inc.",BLA,761345,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2022,8/14/2023,2023,NA,"ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2022-12-19,2023-08-14,238,5.472270673671475,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,238,5.472270673671475
Sohonos,palovarotene,"Ipsen Biopharmaceuticals, Inc.",NDA,215559,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2021,8/16/2023,2023,NA,SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).,Priority,Yes,No,No,No,No,RPD,No,NA,2021-03-31,2023-08-16,868,6.7661917146603505,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,868,6.7661917146603505
Veopoz,pozelimab-bbfg,"Regeneron Pharmaceuticals, Inc.",BLA,761339,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/20/2022,8/18/2023,2023,NA,"VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.",Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2022-12-20,2023-08-18,241,5.484796933490655,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,241,5.484796933490655
Aphexda,motixafortide,"BioLineRx, Ltd.",NDA,217159,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/9/2022,9/8/2023,2023,NA,APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.,Standard,Yes,No,No,No,No,No,No,NA,2022-09-09,2023-09-08,364,5.8971538676367405,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,364,5.8971538676367405
Ojjaara,momelotinib,"GlaxoSmithKline, LLC",NDA,216873,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/16/2022,9/15/2023,2023,NA,"OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.",Standard,Yes,No,No,No,No,No,No,NA,2022-06-16,2023-09-15,456,6.1224928095143865,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,456,6.1224928095143865
Pombiliti,cipaglucosidase alfa-atga,"Amicus Therapeutics US, LLC",BLA,761204,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/2021,9/28/2023,2023,NA,"POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing >=40 kg and who are not improving on their current enzyme replacement therapy (ERT).",Standard,Yes,No,Yes,No,N/A,No,No,NA,2021-07-29,2023-09-28,791,6.673297967767654,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,791,6.673297967767654
Rivfloza,nedosiran,"Novo Nordisk, Inc.",NDA,215842,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/2022,9/29/2023,2023,NA,"RIVFLOZA is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR >= 30 mL/min/1.73 m^2",Standard,Yes,No,Yes,No,No,No,No,NA,2022-09-30,2023-09-29,364,5.8971538676367405,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,364,5.8971538676367405
Zilbrysq,zilucoplan,"UCB, Inc.",NDA,216834,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/2022,10/17/2023,2023,NA,ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.,Standard,Yes,No,No,No,No,No,No,NA,2022-08-31,2023-10-17,412,6.021023349349527,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,412,6.021023349349527
Agamree,vamorolone,Santhera Pharmaceuticals (Switzerland) Ltd.,NDA,215239,NA,NA,Suspension,Oral,NA,NA,NA,NA,10/26/2022,10/26/2023,2023,NA,AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.,Standard,Yes,No,No,Yes,No,No,No,NA,2022-10-26,2023-10-26,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Loqtorzi,toripalimab-tpzi,"Coherus BioSciences, Inc.",BLA,761240,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/2021,10/27/2023,2023,NA,"LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-08-31,2023-10-27,787,6.668228248417403,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,787,6.668228248417403
Fruzaqla,fruquintinib,"Takeda Pharmaceuticals USA, Inc.",NDA,217564,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2023,11/8/2023,2023,NA,"FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.",Priority,No,No,No,Yes,No,No,No,NA,2023-03-30,2023-11-08,223,5.407171771460119,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,223,5.407171771460119
Augtyro,repotrectinib,Bristol-Myers Squibb Company,NDA,218213,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/27/2023,11/15/2023,2023,NA,AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,Priority,Yes,No,No,No,No,No,No,NA,2023-03-27,2023-11-15,233,5.4510384535657,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,233,5.4510384535657
Truqap,capivasertib,AstraZeneca Pharmaceuticals LP,NDA,218197,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/28/2023,11/16/2023,2023,NA,"TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Priority,No,No,No,Yes,No,No,No,NA,2023-03-28,2023-11-16,233,5.4510384535657,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,233,5.4510384535657
Ryzneuta,efbemalenograstim alfa-vuxw,Evive Biotechnology Singapore PTE. Ltd.,BLA,761134,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/2021,11/16/2023,2023,NA,"RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use:
RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.",Standard,No,No,No,No,N/A,No,No,NA,2021-03-30,2023-11-16,961,6.8679744089702925,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,961,6.8679744089702925
Ogsiveo,nirogacestat,"SpringWorks Therapeutics, Inc.",NDA,217677,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2022,11/27/2023,2023,NA,OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2022-12-27,2023-11-27,335,5.814130531825066,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,335,5.814130531825066
Fabhalta,iptacopan,Novartis Pharmaceuticals Corporation,NDA,218276,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/5/2023,12/5/2023,2023,NA,FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).,Priority (used priority review voucher),Yes,No,Yes,No,No,No,Yes,NA,2023-04-05,2023-12-05,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Filsuvez,birch triterpenes,Amryt Pharmaceuticals DAC,NDA,215064,NA,NA,Gel,Topical,NA,NA,NA,NA,3/30/2021,12/18/2023,2023,NA,FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2021-03-30,2023-12-18,993,6.900730664045173,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,993,6.900730664045173
Wainua,eplontersen,"Ionis Pharmaceuticals, Inc.",NDA,217388,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/2022,12/21/2023,2023,NA,WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Standard,Yes,No,No,No,No,No,No,NA,2022-12-22,2023-12-21,364,5.8971538676367405,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,364,5.8971538676367405
Tevimbra,tislelizumab-jsgr,"BeiGene U.S.A., Inc.",BLA,761232,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,7/12/2021,3/13/2024,2024,NA,"TEVIMBRA (tislelizumab-jsgr), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.",Standard,Yes,No,No,No,N/A,No,No,NA,2021-07-12,2024-03-13,975,6.882437470997847,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,975,6.882437470997847
Duvyzat,givinostat,Italfarmaco SpA,NDA,217865,NA,NA,Suspension,Oral,NA,NA,NA,NA,4/21/2023,3/21/2024,2024,NA,DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2023-04-21,2024-03-21,335,5.814130531825066,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,335,5.814130531825066
Winrevair,sotatercept-csrk,"Merck Sharp and Dohme, LLC",BLA,761363,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,7/26/2023,3/26/2024,2024,NA,"WINREVAIR is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2023-07-26,2024-03-26,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Voydeya,danicopan,"Alexion Pharmaceuticals, Inc.",NDA,218037,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/30/2023,3/29/2024,2024,NA,"VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Limitations of Use:
VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.",Standard,Yes,No,Yes,No,No,No,No,NA,2023-03-30,2024-03-29,365,5.8998973535824915,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,365,5.8998973535824915
Lumisight,pegulicianine,"Lumicell, Inc.",NDA,214511,NA,NA,Powder,Intravenous,NA,NA,NA,NA,3/17/2023,4/17/2024,2024,NA,LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.,Priority,No,No,No,Yes,No,No,No,NA,2023-03-17,2024-04-17,397,5.983936280687191,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,397,5.983936280687191
Anktiva,nogapendekin alfa inbakicept-pmln,"Altor BioScience, LLC",BLA,761336,NA,NA,Solution,Intravesical,NA,NA,NA,NA,5/23/2022,4/22/2024,2024,NA,ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.,Standard,No,No,Yes,Yes,N/A,No,No,NA,2022-05-23,2024-04-22,700,6.551080335043404,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,700,6.551080335043404
Ojemda,tovorafenib,"Day One Biopharmaceuticals, Inc.",NDA,217700,218033,NA,Suspension,Oral,Tablet,Oral,NA,NA,8/31/2023,4/23/2024,2024,NA,"OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,No,RPD,No,NA,2023-08-31,2024-04-23,236,5.4638318050256105,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,236,5.4638318050256105
Xolremdi,mavorixafor,"X4 Pharmaceuticals, Inc.",NDA,218709,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/31/2023,4/26/2024,2024,NA,"XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.",Priority,Yes,No,No,Yes,No,RPD,No,NA,2023-08-31,2024-04-26,239,5.476463551931511,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,239,5.476463551931511
Imdelltra,tarlatamab-dlle,"Amgen, Inc.",BLA,761344,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/12/2023,5/16/2024,2024,NA,"IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2023-10-12,2024-05-16,217,5.37989735354046,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,217,5.37989735354046
Rytelo,imetelstat,Geron Corporation,NDA,217779,NA,NA,Powder,Intravenous,NA,NA,NA,NA,6/16/2023,6/6/2024,2024,NA,RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents (ESA).,Standard,Yes,No,No,Yes,No,No,No,NA,2023-06-16,2024-06-06,356,5.87493073085203,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,356,5.87493073085203
Iqirvo,elafibranor,"Ipsen Biopharmaceuticals, Inc.",NDA,218860,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/10/2023,6/10/2024,2024,NA,"IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).",Priority,Yes,Yes,Yes,No,No,No,No,NA,2023-10-10,2024-06-10,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Piasky,crovalimab-akkz,"Genentech, Inc.",BLA,761388,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,6/20/2023,6/20/2024,2024,NA,PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.,Standard,Yes,No,No,No,N/A,No,No,NA,2023-06-20,2024-06-20,366,5.902633333401366,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,366,5.902633333401366
Voranigo,vorasidenib,"Servier Pharmaceuticals, LLC",NDA,218784,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2023,8/6/2024,2024,NA,"VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection",Priority,Yes,No,Yes,Yes,No,No,No,NA,2023-12-20,2024-08-06,230,5.438079308923196,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,230,5.438079308923196
Yorvipath,palopegteriparatide,Ascendis Pharma Bone Diseases A/S,NDA,216490,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,8/31/2022,8/9/2024,2024,NA,"YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.
Limitations of Use:
- YORVIPATH was not studied for acute post-surgical hypoparathyroidism.
- YORVIPATH’s titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.",Priority,Yes,No,No,No,No,No,No,NA,2022-08-31,2024-08-09,709,6.5638555265321274,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,709,6.5638555265321274
Livdelzi,seladelpar,"CymaBay Therapeutics, Inc.",NDA,217899,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/14/2023,8/14/2024,2024,NA,"LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
Use of LIVDELZI is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).",Priority,Yes,Yes,Yes,No,No,No,No,NA,2023-12-14,2024-08-14,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Niktimvo,axatilimab-csfr,Incyte Corporation,BLA,761411,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/28/2023,8/14/2024,2024,NA,NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2023-12-28,2024-08-14,230,5.438079308923196,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,230,5.438079308923196
Lazcluze,lazertinib,"Janssen Biotech, Inc.",NDA,219008,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2023,8/19/2024,2024,NA,"LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",Priority,No,No,No,No,No,No,No,NA,2023-12-20,2024-08-19,243,5.493061443340548,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,243,5.493061443340548
Miplyffa,arimoclomol,Zevra Denmark A/S,NDA,214927,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/17/2020,9/20/2024,2024,NA,MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.,Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2020-07-17,2024-09-20,1526,7.330405211844402,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,1526,7.330405211844402
Aqneursa,levacetylleucine,"IntraBio, Inc.",NDA,219132,NA,NA,Suspension,Oral,NA,NA,NA,NA,1/24/2024,9/24/2024,2024,NA,AQNEURSA is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing >=15 kg.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2024-01-24,2024-09-24,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Itovebi,inavolisib,"Genentech, Inc.",NDA,219249,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/27/2024,10/10/2024,2024,NA,"ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",Priority,No,No,Yes,No,No,No,No,NA,2024-03-27,2024-10-10,197,5.2832037287379885,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,197,5.2832037287379885
Hympavzi,marstacimab-hncq,"Pfizer, Inc.",BLA,761369,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/11/2023,10/11/2024,2024,NA,"HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
- hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.",Standard,Yes,No,No,No,N/A,No,No,NA,2023-10-11,2024-10-11,366,5.902633333401366,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,366,5.902633333401366
Vyloy,zolbetuximab-clzb,"Astellas Pharma US, Inc.",BLA,761365,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,5/12/2023,10/18/2024,2024,NA,"VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2023-05-12,2024-10-18,525,6.263398262591624,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,525,6.263398262591624
Revuforj,revumenib,"Syndax Pharmaceuticals, Inc.",NDA,218944,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/26/2024,11/15/2024,2024,NA,REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2024-01-26,2024-11-15,294,5.683579767338681,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,294,5.683579767338681
Ziihera,zanidatamab-hrii,"Jazz Pharmaceuticals Ireland, Limited",BLA,761416,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,3/29/2024,11/20/2024,2024,NA,"ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2024-03-29,2024-11-20,236,5.4638318050256105,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,236,5.4638318050256105
Attruby,acoramidis,"BridgeBio Pharma, Inc.",NDA,216540,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/29/2023,11/22/2024,2024,NA,ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.,Standard,Yes,No,No,No,No,No,No,NA,2023-11-29,2024-11-22,359,5.883322388488279,Other,medium,orphan_drug_keyword_match,Standard,Other,Standard,Post-FDASIA,359,5.883322388488279
Bizengri,zenocutuzumab-zbco,Merus N.V.,BLA,761352,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,3/4/2024,12/4/2024,2024,NA,"BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 
BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2024-03-04,2024-12-04,275,5.616771097666572,Oncology,medium,approved_use_keyword_match,Priority,Oncology,Priority,Post-FDASIA,275,5.616771097666572
Crenessity,crinecerfont,"Neurocrine Biosciences, Inc.",NDA,218808,218820,NA,Capsule,Oral,Solution,Oral,NA,NA,4/29/2024,12/13/2024,2024,NA,CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).,Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2024-04-29,2024-12-13,228,5.429345628954441,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,228,5.429345628954441
Unloxcyt,cosibelimab-ipdl,"Checkpoint Therapeutics, Inc.",BLA,761297,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,1/3/2023,12/13/2024,2024,NA,UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.,Standard,No,No,No,No,N/A,No,No,NA,2023-01-03,2024-12-13,710,6.565264970035361,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,710,6.565264970035361
Ensacove,ensartinib,"Xcovery Holdings, Inc.",NDA,218171,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/2023,12/18/2024,2024,NA,ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.,Standard,No,No,No,No,No,No,No,NA,2023-12-28,2024-12-18,356,5.87493073085203,Oncology,medium,approved_use_keyword_match,Standard,Oncology,Standard,Post-FDASIA,356,5.87493073085203
Tryngolza,olezarsen,"Ionis Pharmaceuticals, Inc.",NDA,218614,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,4/19/2024,12/19/2024,2024,NA,TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2024-04-19,2024-12-19,244,5.497168225293202,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,244,5.497168225293202
Alhemo,concizumab-mtci,"Novo Nordisk, Inc.",BLA,761315,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,8/24/2022,12/20/2024,2024,NA,"Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors
- hemophilia B (congenital factor IX deficiency) with FIX inhibitors",Priority,Yes,No,No,No,N/A,RPD,No,NA,2022-08-24,2024-12-20,849,6.744059186311348,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,849,6.744059186311348
Alyftrek,"vanzacaftor, tezacaftor and deutivacaftor","Vertex Pharmaceuticals, Inc.",NDA,218730,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/2/2024,12/20/2024,2024,NA,"ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see Table 5).
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.",Priority (used priority review voucher),Yes,No,No,No,No,No,Yes,NA,2024-05-02,2024-12-20,232,5.44673737166631,Other,medium,orphan_drug_keyword_match,Priority,Other,Priority,Post-FDASIA,232,5.44673737166631
